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Mitochondrial proteins are encoded by both the nuclear and mitochondrial genome (mtDNA). 
Thus, alterations in mtDNA affect mitochondrial function and are involved in a plethora of 
diseases associated with mitochondrial dysfunction. Although role of nuclear DNA methylation 
in regulating gene expression is fairly well understood, the very existence of mtDNA 
methylation has been debated for the past four decades. In spite of the controversies revolving 
mtDNA methylation, differences in mtDNA methylation have been reported in a number of 
pathological conditions. However, role of mtDNA methylation in regulating transcription of 
mtDNA and consequently, mitochondrial function remains unexplored. Besides, whether 
mtDNA methylation can be altered experimentally has not been investigated. The goal of this 
dissertation is to establish a method to quantitate mtDNA methylation and evaluate its presence 
in SH-SY5Y neuroblastoma cells; examine if mtDNA methylation can be altered and if there are 
any associated changes in mitochondrial transcription and function; and further, determine if 
mtDNA methylation is altered in a model associated with mitochondrial dysfunction. 
In Chapter II, we aimed to investigate the presence of mtDNA methylation in SH-SY5Y 
neuroblastoma cells at global and site-specific levels. In order to investigate the presence of 
methylation at global levels in SH-SY5Y mtDNA, we established a direct, sensitive and highly 
specific method using HPLC-ESI-MS/MS by addressing limitations such as differential or 
incomplete enzymatic digestion of DNA and also, potential nuclear DNA contamination. 
Differential enzymatic digestion of DNA was addressed by incorporation of one-step digestion 
for DNA and using oligonucleotides harboring known amounts of dC and 5m-dC as calibrators. 
5m-dC was detected in a linear and proportional manner in SH-SY5Y mtDNA. Around 3% 
methylation was found in mtDNA obtained from crude mitochondrial isolates, which was 
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comparable to whole-cell DNA methylation levels. Interestingly, similar percentages of 
methylation were observed even in mtDNA obtained from gradient-purified mitochondria. 
Further, purity of mtDNA was characterized, indicating elimination of 99.95 % of nuclear DNA 
contamination with 115 fold-enrichment of mtDNA in gradient-purified mitochondria. Presence 
of methylation in SH-SY5Y mtDNA was further substantiated using methylation-specific PCR 
for a specific site in 12S rRNA. Thus, we established a direct method to quantify global 
methylation in mtDNA using HPLC-MS/MS and also, reported presence of methylated DNA in 
purified SH-SY5Y mitochondria. 
In Chapter III, we investigated if mtDNA methylation can be altered by experimental 
interventions and whether altered mtDNA methylation has any concomitant effects on 
mitochondrial transcription and mitochondrial function. Global mtDNA methylation was 
assessed by HPLC-ESI-MS/MS and site-specific methylation of 12S rRNA was studied by 
methylation-specific PCR assay. DNMT1 is known to localize in mitochondria but its role in 
mtDNA methylation is unknown. We reported that transient over-expression of DNMT1 in SH-
SY5Y increased mtDNA methylation, decreased transcription of mtDNA-encoded genes and 
reduced total and basal-mitochondrial oxygen consumption rates. Likewise, treatment of SH-
SY5Y by DNA methylation inhibitor (5-aza-dC) reduced levels of mtDNA methylation, 
increased transcription of mtDNA-encoded genes and altered mitochondrial oxygen consumption 
rate. Thus, we found that that mtDNA methylation is an alterable phenomenon, which is affected 
by DNMT1 levels and 5-aza-dC treatment and is associated with changes in mtDNA 
transcription and mitochondrial function.  
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In chapter IV, we investigated the direct role of mtDNA in aging-associated mitochondrial 
dysfunction using cytoplasmic hybrid cell lines that were created by transferring mitochondria 
from platelets of healthy young and aged human subjects to mtDNA-depleted SH-SY5Y ρ0cells. 
Bioenergetic fluxes, their regulators and DNA methylation-associated parameters were 
characterized in these resulting cytoplasmic hybrids. Relative to the cybrids generated from 
young donors, mitochondrial oxygen consumption parameters and COX activity were reduced in 
the cybrids made from aged subjects. Interestingly, there was a compensatory increase of 
Complex I activity in the cybrids generated from aged subjects.  However, no alterations were 
found in ATP levels, redox states and glycolysis fluxes. Although the mitochondrial mass was 
not different, mRNA levels of some of the mtDNA-encoded OXPHOS genes and nuclear-
encoded genes that promote mitochondrial biogenesis were induced in the cybrids created from 
aged subjects. Although total DNA methylation remained unaltered, levels of DNMT1 protein, 
mtDNMT1 mRNA and methylation in the mtDNA were higher in the cybrids generated from 
aged subjects. Thus, we found that mtDNA have a direct role in age-associated mitochondrial 
dysfunction and mtDNA methylation is altered in age-dependent manner in cybrid model.  
In summary, this dissertation work established a method to detect global mtDNA methylation 
and quantified methylation levels in isolated mitochondria of characterized purity. Also, it 
established that mtDNA methylation is an alterable phenomenon, which is affected by DNMT1 
levels and 5-aza-dC treatment and is associated with mitochondrial transcription and 
mitochondrial function. Further, it established a direct role of mtDNA in age-associated 
mitochondrial dysfunction and alteration in mtDNA methylation as one of the age-dependent 
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1.1 MITOCHONDRIAL DNA AND ITS FUNCTION 
1.1.1 MITOCHONDRIA AND MITOCHONDRIAL DNA 
Mitochondria are double membraned organelles where fats and carbohydrates are oxidized and 
converted to the reducing power of NADH (Nicotinamide adenine dinucleotide) and FADH2 
(Flavin adenine dinucleotide). This reducing power is utilized by series of electrogenic proton 
pumps called the electron transport chain (ETC) to create an electrochemical proton gradient that 
drives the ATP synthase pump to synthesize ATP (Adenosine triphosphate). The process by 
which this proton gradient is created and ATP is synthesized is called the oxidative 
phosphorylation (OXPHOS) (Maley and Plaut 1954, Jacobs and Sanadi 1955).  
Mitochondrial proteins are bi-genomically encoded i.e. they are encoded by both the nuclear and 
mitochondrial genome (mtDNA) (Beattie, Battie et al. 1980, de Jong, Holtrop et al. 1980, Attardi 
and Schatz 1988). MtDNA is double-stranded and circular in nature as depicted in Figure 1 
(Nass and Nass 1963). MtDNA is present compacted in the nucleoids and located in the 
mitochondrial matrix interacting with the inner membrane (Nass and Nass 1963, Nass 1969, 
Albring, Griffith et al. 1977).  With a size of 16,569 base pair (bp), mtDNA encodes for 13 
mRNAs, 2 rRNAs and 22 tRNAs, which are required for forming functional Electron transport 
chain (ETC) in the mitochondria(Anderson, Bankier et al. 1981, Andrews, Kubacka et al. 1999). 
Depending upon the metabolic capacity and energy demand of the cell, hundreds to thousands of 
mitochondria can be present (Fernandez-Vizarra, Enriquez et al. 2011), with each mitochondrion 
having 2-10 copies of the mtDNA (De Giorgi, D'Alessandro et al. 1992, Wiesner, Ruegg et al. 
1992). Unlike the nuclear genome, mitochondrial genome is maternally inherited, as 
mitochondria in sperm get actively eliminated by ubiquitin dependent mechanism (Sutovsky, 
Moreno et al. 1999, Sutovsky, Moreno et al. 2000). 
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1.1.2 TRANSCRIPTION OF MTDNA-ENCODED GENES  
MtDNA-encoded genes are asymmetrically arranged between the Heavy strand (H-strand) and 
Light strand (L-strand) and encode for all the complexes of electron transport chain, except 
Complex II. H strand encodes 12 of the 13 mRNAs, 14 of the 22 tRNAs and 2 rRNAs, whereas 
the L strand codes for single mRNA - ND6 (subunit of Complex I) and the remaining 8 of the 22 
tRNAs as depicted in Figure 1 (Anderson, Bankier et al. 1981, Attardi and Schatz 1988, 
Andrews, Kubacka et al. 1999). There are only two non-coding regions (NCR) in the mtDNA 
that house the regulatory elements for mtDNA replication and transcription. The major non-
coding region is 900 bp long and is called the D-loop. D-loop is the region of mtDNA where the 
promoters for H-strand and L-strand as well as the origin of replication for H-strand (OH) are 
located and thus, serves as the major site for transcriptional regulation as represented in Figure 1 





, within a cluster of tRNA genes. OL serves as the site of 
initiation for lagging-strand synthesis of mtDNA (Shadel and Clayton 1997).  
For mitochondrial transcription to be initiated and activated, a complex of proteins such as 
POLRMT, TFAM and TF2BM form the transcriptional machinery, that bind at the promoters 
located in the D-Loop (Figure 2). POLRMT is the RNA polymerase of mitochondria, whereas 
TFB2BM and TFAM stand for Transcription factor 2B of mitochondria and Transcription factor 
A of mitochondria, respectively. There are two promoters for the transcription from the H-strand 
– HSP1 (H-strand promoter 1) and HSP2 (H-strand promoter 2) that are located within 100 bp of 
each other and transcribed in the same direction (Montoya, Christianson et al. 1982, Montoya, 




) and 2 rRNAs 
(12S and 16S rRNA) and gets terminated just downstream of 16S rRNA by the binding of 
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TERMF1 (Termination factor 1) at tRNA
Leu 
(Kruse, Narasimhan et al. 1989, Roberti, Polosa et 
al. 2009) (Figure 2). But the HSP-2 transcript codes for all the genes present on  H-strand (2 
rRNAs, 13 tRNAs and 12 mRNAs) and gets terminated at A/T rich area called H2, which is 
located upstream of tRNA
Phe 
 (Camasamudram, Fang et al. 2003).  Similar to the HSPs, LSP or 
L-strand promoter is located within the D-loop but transcription occurs in the opposite direction 
than that of HSPs. The transcript generated from LSP codes for the genes present on L-strand 
(ND6 and 8 tRNAs) and gets terminated at a region 160-185 bp downstream of LSP within the 
D-loop where OH is located(Bonawitz, Clayton et al. 2006, Scarpulla 2008). Thus, bidirectional 
transcription of mtDNA results in poly-cistronic transcription units, which are subsequently 
processed to excise tRNAs, mRNAs and rRNAs.  Termination  codons  are  not  encoded  in  
mtDNA  but  are  generated  by  post-transcriptional polyadenylation of corresponding mRNAs 
(Peralta, Wang et al. 2012).  tRNAs are equally interspersed among other genes playing an 
important role in RNA processing (Ojala, Merkel et al. 1980, Ojala, Montoya et al. 1981). 
MtDNA-encoded genes are translated using a genetic code that differs from the universal genetic 
code, as  reflected from their  initiation  and termination  codons along with a simplified  codon-
anticodon pairing system that allows translation to proceed with only 22 tRNAs (Attardi and 
Schatz 1988). 
1.1.3 HOW RETROGRADE SIGNALING CAN DETERMINE MTDNA TRANSCRIPTION  
Although mitochondria are bi-genomically encoded where majority of mitochondrial proteins are 
encoded by the nucleus and only 13 are encoded by mtDNA, mitochondrial function can be 
governed by regulating the expression of both nuclear-encoded and mitochondrial-encoded 
mitochondrial proteins. Nuclear-encoded mitochondrial proteins comprise of various subunits of 
different complexes in the ETC, structural proteins, transcription factors governing 
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mitochondrial transcription (TFAM, PORMT, TFB2M, TERMF1) and proteins involved in 
mitochondrial DNA replication (Polymerase γ, Twinkle, mtSSB), all of which are required for 
mitochondrial maintenance and biogenesis (Scarpulla 2008).  
Interestingly, mitochondrial function can also determine the mitochondrial biogenesis via the 
retrograde signaling pathway, which regulates the transcription of nuclear DNA-encoded 
proteins that ultimately regulates mitochondrial transcription (Finley and Haigis 2009). The  
OXPHOS  activity  of  mitochondria  determines  the  levels  of  ROS (reactive oxygen species),  
ratios of ATP/ADP  and NADH/ NAD
+
 in the cells  and mitochondria’s  ability to store calcium 
ions determines the cytosolic levels of calcium ions [Ca
2+
].  Each of these parameters- ROS, 
ATP/ADP, NADH/NAD
+
 and cytosolic [Ca
2+
] - reflect the metabolic status of the cell. ROS can 
cause redox signaling through p53, ERK, PI(3)K, JNK, p38 MAPK and AKT; ATP levels can 
trigger the kinase activity of  AMPK;  NAD
+
 can activate SIRT1’s de-acetylase activity  whereas 
the  [Ca
2+
] can trigger Calcium signaling and activate  CREB  by phosphorylating it.  
Phosphorylated CREB promotes transcription of PGC1α, whereas SIRT1-mediated de-
acetylation and AMPK-mediated phosphorylation of PGC1α can stimulate PGC1α activity. 
Activated PGC1α is a nuclear coactivator of various nuclear transcription factors, such as NRF1, 
NRF2, ERR-αand PPAR-γ, that are responsible for the transcription of nuclear-encoded 
mitochondrial proteins including transcription factors required for mitochondrial transcription. 
(Finley and Haigis 2009)                                                                                              
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1.1.4 MTDNA MUTATIONS, HETEROPLASMY AND IMPLICATIONS OF POSSIBLE 
ROLE IN AGING AND NEURODEGENERATIVE DISEASES 
Importance of mtDNA can be emphasized by citing the example of Rho-zero cells (ρ0). ρ0 cells 
are created by selective depletion of mtDNA.  Thus, these cells lack functional ETC and are 
incapable of oxygen consumption. Normal respiratory function can be restored in the ρ0 cells by 
introducing exogenous functional mtDNA. (Miller, Trimmer et al. 1996, Inoue, Takai et al. 
1997) 
In a given individual, when all mtDNA copies are identical, such a state is referred to as 
homoplasmy. As mitochondria serve as the prime site for ROS generation, coupled with error-
prone Polymerase γ (DNA polymerase of the mitochondria), mutations in mtDNA can arise, be 
maintained or amplified to different levels. These mutations co-exist with the wild type-mtDNA 
giving rise to a condition called heteroplasmy. Random  distribution of mitochondria occurs  
during  mitosis  giving rise to varying degrees of  heteroplasmy  in  different  cells  or  tissues. 
When this varying degree of heteroplasmy cross the threshold level, start manifesting in the form 
of mitochondrial dysfunction and thus, results in mtDNA disease (Lightowlers, Chinnery et al. 
1997, Rossignol, Malgat et al. 1999). Several mtDNA mutations are known to be pathogenic in 
nature causing multiple disorders such as LHON, MELAS, MERFF, NARP and MILS as 
depicted in Table 1. Multiple studies have reported positive correlations between mtDNA 
mutations and aging-associated mitochondrial dysfunction observed in various disorders such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyolateral sclerosis (ALS), cancer and 
hypertension (Fujita, Yamauchi et al. 1996, Polyak, Li et al. 1998, Lin, Simon et al. 2002, 
Simon, Lin et al. 2004). However, a large fraction of mitochondrial diseases cannot be explained 
by the alteration observed in the genetic sequence of mtDNA (Dimauro and Davidzon 2005). 
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Understanding how alterations apart from the genetic sequence of mtDNA can affect 
mitochondrial function is critical and can be of therapeutic value, which remains largely 
unexplored. 
1.2. DNA METHYLATION  
1.2.1 FUNCTIONS OF DNA METHYLATION  
Addition of methyl group to the C5 position of the cytosine in DNA yields 5-methyl 2’-deoxy-
cytosine (5-mC), which is known as DNA methylation. DNA methylation is one of the 
epigenetic marks that control gene-expression without any alteration in the DNA sequence itself. 
Epigenetic marks such as histone modifications and DNA methylation control the chromatin 
architecture by regulating the access of DNA-binding proteins to DNA, which are involved in 
chromatin remodeling. Chromatin comprises of the genomic DNA associated with the 
nucleosome core histone proteins (H2A, H2B, H3 and H4) and the linker histone (H1) where 
nucleosome is the fundamental subunit of chromatin. Nucleosome is made up of DNA coiled 
twice around a histone octamer. The core histone proteins have modifications such as acetylation 
at lysine residues and methylation at arginine or lysine residues. Histone acetyl transferase 
(HAT) and histone deacetylase (HDAC) are responsible for regulating histone acetylation 
whereas Histone methyl transferase (HMT) and Histone demethylase (HDM) regulate histone 
methylation. Repressor complexes such as HDAC and HMT are recruited by methyl-DNA-
binding proteins (MBP) that are known to bind methylated CpG sites in the DNA. This 
recruitment of HDAC and HMT by MBP bound at a methylated CpG site, leads to creation of 
repressive marks on histone (de-acetylation and methylation) and establishes a chromatin 
architecture where gene expression is repressed.  (Ndlovu, Denis et al. 2011, Jones 2012) 
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Most  work  in  animals  regarding DNA methylation have  been focused  on  5-methyl  cytosine  
(5-mC)  occurring in  CpG islands (CGI) at transcriptional start sites (TSS), but it’s the position 
of the 5-mC in the transcriptional unit that exerts its  effects  on  gene expression  (Jones 2012).  
If  5-mC  occurs  in  TSS  then  it  blocks  the initiation  of  transcription  (Kass, Landsberger et 
al. 1997, Hashimshony, Zhang et al. 2003, Kelly, Miranda et al. 2010), whereas if it occurs 
within the gene body (Wolf, Jolly et al. 1984),  it might stimulate transcription elongation  
(Hellman and Chess 2007, Feng, Cokus et al. 2010) or might impact splicing  (Schwartz, 
Meshorer et al. 2009, Shukla, Kavak et al. 2011).  5-mC  is  also observed  in  repeat  regions  or  
transposable  elements  where  it  is  known  to  suppress  their transcription and thus, play a role 
in genome stability (Yoder, Walsh et al. 1997).   
Non-CpG  methylation  can  be  defined  as  methylation  of  cytosines  that  occur  outside of 
CpG sites, within  CpC,  CpT  and  CpA  or CCWGG (W=A/T) or CpNpG (N=A/T/C/G). Non-
CpG methylation is found in plants (Vanyushin and Ashapkin 2011), bacteria (Militello, Simon 
et al. 2012), fungi (Goyon, Barry et al. 1996, Goyon, Rossignol et al. 1996) and has been 
recently reported in mammals (Tomizawa, Kobayashi et al. 2011, Ziller, Muller et al. 2011, 
Ichiyanagi, Ichiyanagi et al. 2013, Varley, Gertz et al. 2013). Non-CpG methylation in mammals 
was first seen in murine embryonic stem cells (ESC) (Ramsahoye, Biniszkiewicz et al. 2000). 
Although levels of non-CpG methylation are low in somatic tissues, it has been extensively 
found in postnatal human and mouse brain (Varley, Gertz et al. 2013). In ESC, non-CpG 
methylation has been found to correlate with gene expression (Ramsahoye, Biniszkiewicz et al. 
2000). However, an inverse correlation was seen with transcription in neurons (Varley, Gertz et 
al. 2013). Thus, the function of mammalian non-CpG methylation is not clear and appears to be 
context dependent in nature.  
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1.2.2 DNA METHYL TRANSFERASES  
DNA methyl transferases (DNMTs) transfer the methyl group from a cofactor molecule S-
Adenosyl-L-methionine (SAM) to the C5 position of the cytosine in DNA yielding 5-methyl 2’-
deoxy-cytosine (5-mC) and S-Adenosyl-L-homocysteine (SAH). The four members of 
mammalian DNMT family are DNMT1, DNMT3A, DNMT3B and the catalytically inactive 
regulatory factor DNMT3L. All the DNMTs are comprised of a large N terminal domain of 
variable size (containing regulatory domains involved in interaction with DNA, chromatin or 
other proteins) and a C-terminal catalytic domain, which is responsible for the methyl transferase 
activity (Bestor 2000, Jurkowska, Jurkowski et al. 2011). Unlike DNMT1 that has a strong 
preference for hemi-methylated sites in DNA (Goyal, Reinhardt et al. 2006), DNMT3A and 
DNMT3B does not have a preference between hemi-methylated and un-methylated DNA 
(Okano, Xie et al. 1998). Methylation patterns are established in the developing embryo by de 
novo DNA methyl transferases- DNMT3A and DNMT3B  (Okano, Bell et al. 1999). For 
maintenance, these methylation marks are predominantly copied onto the nascent strand by 
DNMT1, along with cooperation of DNMT3A and DNMT3B  (Jones and Liang 2009). 
Physiological importance of DNMTs can be emphasized by the fact that  deletion of  either of  
Dnmt1  or  Dnmt3b is embryonically  lethal,  while  Dnmt3a  null  mice  survive  for  3-4  weeks 
only after birth (Li, Bestor et al. 1992, Okano, Bell et al. 1999) . Mice knocked out for any of 
these above-mentioned Dnmts have severe developmental defects.  
Until very recently, DNMTs were known to be involved in methylation of only CpG sites in the 
mammalian genome. Recent reports suggest that DNMTs can also methylate non-CpG sites. 
DNMT3A and DNMT3B are responsible for CpC, CpT and CpA methylation exclusively in 
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embryonic stem cells (ESC) (Ramsahoye, Biniszkiewicz et al. 2000, Ziller, Muller et al. 2011, 
Arand, Spieler et al. 2012), whereas DNMT1 was found to methylate 5’ Cytosine in CpC, CpT 
and CpA in haploid sperm and somatic tissues (Grandjean, Yaman et al. 2007).   
1.2.3 DISEASE RELEVANCE OF DNA METHYLATION 
Abnormalities in DNA methylation has been found in a wide range of diseases.  DNA 
methylation is essential for genomic imprinting where paternal or maternal allele gets silenced 
by the dint of methylation. Defects in genomic imprinting are involved in Prader-Wili syndrome, 
Angleman syndrome, Beckmith-Widerman syndrome and some cancers (Paulsen and Ferguson-
Smith 2001). DNA methylation profiles of genes involved in Alzheimer’s disease (AD) such as 
Apo lipoprotein E (APOE) and presenelin 1 (PSEN1) differ distinctly in bio-specimens between 
that of AD patients and age-matched control subjects (Wang, Oelze et al. 2008). Similarly, 
decreased levels of methylation were found in α-synuclein (SNCA) gene in bio-specimens 
derived from patients with idiopathic Parkinson’s disease (Jowaed, Schmitt et al. 2010, 
Matsumoto, Takuma et al. 2010). Even during aging, global hypo-methylation and gene-specific 
hyper-methylation are observed and are increasingly reported to be associated with age-related 
diseases (Vanyushin, Nemirovsky et al. 1973, Romanov and Vanyushin 1981, Gonzalo 2010, 
D'Aquila, Rose et al. 2013).  Hypo-methylation due to mutations in the DNMT3B causes the 
autosomal dominant recessive Immunodeficiency Centromere instability and Facial anomalies 
(ICF) syndrome (Hansen, Wijmenga et al. 1999, Ehrlich, Buchanan et al. 2001). Thus, the 
correct establishment and maintenance of DNA methylation patterns are critical for mammalian 




1.3. MITOCHONDRIAL DNA METHYLATION 
1.3.1 EARLY STUDIES OF MTDNA METHYLATION 
MtDNA methylation and DNA methylase activity in mitochondria was first reported in loach 
embryos using Thin Layer Chromatography (TLC)-radiography in 1971 (Vanyushin, Kiryanov 
et al. 1971). By using similar approaches, a subsequent study found mtDNA to have low but a 
significant percentage of methylation of 0.2-0.6% in cultured mouse fibroblasts and baby 
hamster kidney cells (Nass 1973). Another study used spectrophotometric determination after 
resolving hydrolyzed DNA by TLC to determine the levels of 5-mC and reported that mtDNA 
from livers of sheath-fish r, duck, chicken, rat, ox and ox heart have mtDNA methylation at mole 
percent of 3.03, 1.52, 1.63, 2.0, 3.03 and 3.15, respectively (Vanyushin and Kirnos 1977). 
However, a single study reported mtDNA methylation levels to be below their detection limit in 
frog ovary and HeLa cells using TLC, thus claiming mtDNA methylation to be absent (Dawid 
1974).   
Later, Waalwijk and Flavell adapted usage of restriction endonucleases– MspI and HpaII – to 
determine the presence of methylation at CCGG, which is now commonly called the 
methylation-sensitive restriction enzyme (MSRE) analysis (Waalwijk and Flavell 1978). 
Coupling MSRE analysis with Sothern blot and radiography, two independent studies reported 





mouse cells (Shmookler Reis and Goldstein 1983, Pollack, Kasir et al. 
1984). However, a single study claimed mtDNA methylation to be absent when they did not 
observe a difference in digestion pattern using semi-quantitative ethidium bromide staining after 
MSRE-hydrolyzed mtDNA was resolved in an agarose gel (Groot and Kroon 1979).  
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Thus, using both the approaches – TLC and MSRE analysis, seven independent studies were 
carried out to test the presence and levels of mtDNA methylation. For both the approaches, five 
studies reported mtDNA methylation to be present (albeit at varying amounts) whereas two 
asserted its absence. Due to all these inconsistent reports about the level of mtDNA methylation 
and also two studies claiming its absence, mtDNA methylation remained controversial since its 
inception.  
 1.3.2 RESURGENCE IN THE FIELD OF MTDNA METHYLATION  
Even though significant advances were made in understanding how DNA methylation and 
histone-modifications control nuclear gene expression, mtDNA methylation remained ignored 
for almost four decades, primarily because of dearth of sensitive methods for studying mtDNA 
methylation. Although, DNA methylase activity was known to occur in mitochondrial fractions 
(Vanyushin, Kiryanov et al. 1971, Nass 1973, Vanyushin and Kirnos 1977), but no DNA methyl 
transferases were known to be present in mitochondria. Neither were “histones-like” proteins or 
structures known in mitochondria.   
Localization of DNMTs in mitochondria: 
Recently, existence of mitochondrial isoform of DNMT1 (mtDNMT1) was demonstrated by 
Shock et. al. in HCT116 human carcinoma cell line and mouse embryonic fibroblast (MEF) 
(Shock, Thakkar et al. 2011), revitalizing interest in studying mtDNA methylation. MtDNMT1 
was found to be transcribed from two possible start sites located upstream of the canonical one.  
Moreover, mtDNMT1 was found to translocate into the mitochondrial matrix and bind mtDNA. 
MtDNMT1 expression was found to be sensitive to the transcription factors that control 
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mitochondrial biogenesis- PGC1-α and NRF1 - during oxidative stress. After this initial study 
(Shock, Thakkar et al. 2011), several in vivo and in vitro studies have independently reported the 
presence of DNMTs in mitochondria as discussed below. 
DNMT1 in mitochondria: DNMT1 localization in mitochondria has been found in both human 
cell lines (HeLa (Bellizzi, D'Aquila et al. 2013) and HCT116 colon carcinoma (Shock, Thakkar 
et al. 2011)) and bio-specimens derived from motor cortex of ALS patients (Chestnut, Chang et 
al. 2011). In murine model, mitochondrial localization of DNMT1 was detected in vitro (NSC34 
mouse motor neuron cell line, MEF (Shock, Thakkar et al. 2011) and 3T3-L1 fibroblast-like cells 
(Bellizzi, D'Aquila et al. 2013)), but not in vivo, in the adult organs such as brain, spinal cord 
(Chestnut, Chang et al. 2011) and skeletal muscle (Wong, Gertz et al. 2013). 
DNMT3A in mitochondria: DNMT3A localization in mitochondria is reported in post-mortem 
bio-specimens of cerebral cortex and specifically the motor cortex of ALS patients (Chestnut, 
Chang et al. 2011). However, DNMT3A was not detected in mitochondria of cell lines - HeLa 
(Bellizzi, D'Aquila et al. 2013) and HCT116 colon carcinoma (Shock, Thakkar et al. 2011). In 
the mouse mitochondria, DNMT3A has been detected in NSC-34 motor neuron cell line 
(Chestnut, Chang et al. 2011) as well as in several adult tissues (brain, synapses and spinal cord 
(Chestnut, Chang et al. 2011, Wong, Gertz et al. 2013), heart, testes, skeletal muscle (Wong, 
Gertz et al. 2013)). However, mitochondrial DNMT3A was not found in 3T3-L1 fibroblast-like 
cells (Bellizzi, D'Aquila et al. 2013),  mouse embryonic fibroblasts (MEF) (Shock, Thakkar et al. 
2011) and various organs in mouse (spleen, liver, lung) (Wong, Gertz et al. 2013). 
DNMT3B in mitochondria: So far, mitochondrial localization of DNMT3B has been investigated 
only in vitro conditions. DNMT3B was detected in mitochondria of HeLa and 3T3-L1 cells 
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(Bellizzi, D'Aquila et al. 2013), but not in mitochondria of HCT116 colon carcinoma and MEF 
(Shock, Thakkar et al. 2011).  
Thus, the expression of DNMTs in mitochondria is emerging to be cell-line specific as well as 
tissue and species-specific in nature. Even though all these studies have reported presence of 
DNMTs in mitochondria, whether DNMTs are involved in mtDNA methylation is not known.  
Emerging histone-like role for TFAM:  
TFAM belongs to the family of High Mobility Group (HMG) proteins and contains two HMG-
Box domains which are known to bind DNA and are characteristic of proteins that regulate 
DNA-dependent processes such as transcription and replication (Zhang and Wang 2010). TFAM 
binds mtDNA in both sequence-specific and non-specific manner. TFAM binds at HSP-1 and 
LSP in a sequence-specific manner and is responsible for bending DNA, allowing interaction 
with transcription machinery, and thus, initiate transcription (Ngo, Kaiser et al. 2011). Also, non-
specific binding of TFAM in mtDNA, is reported to be responsible for looping and finally 
compaction of mtDNA into nucleoids. Thus, TFAM determines the “ON” state of mtDNA 
during transcription from HSP-1 and LSP; and also can lead to compacted mtDNA as observed 
during “OFF” state in the nucleus. (Ngo, Lovely et al. 2014) 
Post-translational modifications of TFAM can alter its binding affinity for mtDNA and thus, 
regulate transcription. One group reported that ERK1/2-mediated phosphorylation of TFAM 
decreased the binding affinity of TFAM at LSP and thus mitochondrial transcription (Wang, Zhu 
et al. 2014).  Another study reported that ubiquitination of TFAM impedes its transport to the 
mitochondria resulting in subnormal mtDNA transcription (Santos, Mishra et al. 2014). In line 
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with above studies, phosphorylation of TFAM in HMG box 1 (HMG1) by cAMP-dependent 
protein kinase in mitochondria impaired TFAM’s ability to bind mtDNA and to activate 
transcription (Lu, Lee et al. 2013). Thus, similar to histones, TFAM can get post-translationally 
modified and affects mtDNA transcription.  
In short, a histone-like role of TFAM has been emerging which raises speculations about the 
possibility of epigenetic control of mtDNA.  
1.3.3 POSSIBLE FUNCTIONAL RELEVANCE OF MTDNA METHYLATION 
Since the discovery of DNMTs in mitochondria (Chestnut, Chang et al. 2011, Bellizzi, D'Aquila 
et al. 2013, Wong, Gertz et al. 2013) (Shock, Thakkar et al. 2011), several studies have reported 
alterations of mtDNA methylation at D-loop as well as within genes in multiple pathological and 
physiological conditions as explained below.  
Variations in mtDNA methylation in pathological conditions:  
Alteration in mtDNA methylation has been correlated with a multitude of diseases. Recently, a 
study reported decrease in global mtDNA methylation in the mtDNA isolated from EBV-
immortalized lymphoblastoid cells of children with Down’s syndrome in comparison to that of 
healthy age-matched subjects (Infantino, Castegna et al. 2011). Another study conducted using 
bio-specimens of human motor cortex found that localization of both DNMT1 and DNMT3A in 
mitochondria were increased along with an increase in mitochondrial staining of 5-methyl 
cytosine in ALS patients (Chestnut, Chang et al. 2011). Another group reported elevated levels 
of MT-ND2 in colon and rectal cancer bio-specimens, which was correlated with decreased D-
loop methylation in comparison to their corresponding non-cancerous tissues (Feng, Xiong et al. 
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2012). Additionally, MT-ND6 methylation was found to be elevated in mtDNA from liver of 
patients having non-alcoholic steatohepatitis (NASH) in comparison to simple steatosis, which 
was accompanied by significantly reduced transcription of MT-ND6 and increased DNMT1 
mRNA levels in liver of NASH subjects (Pirola, Gianotti et al. 2013). Further, platelet mtDNA 
methylation was significantly higher in cardiovascular disease patients than healthy control 
subjects at MT-CO1, MT-CO2, MT-CO3 and MT-TL1 (Baccarelli and Byun 2015).  Moreover, 
D-loop methylation has also been reported to be significantly increased in the mtDNA derived 
from buffy coat of obese subjects in comparison to lean subjects and in insulin-resistant subjects 
when compared to insulin-sensitive subjects (Zheng, Linarelli et al. 2015). In a single study 
conducted in mouse model for pre-symptomatic ALS, mitochondrial DNMT3A were 
significantly reduced in skeletal muscle and spinal cord, which was accompanied by increased in 
MT-RNR2 methylation in the spinal cord (Wong, Gertz et al. 2013).    
Variations in mtDNA methylation with physiological and environmental conditions:  
Several studies have also investigated if mtDNA methylation levels change during various 
developmental stages.  Significant reduction of mtDNA methylation was observed in MT-ND6 
and MT-ATP6 with progressing developmental stages in human brain (Ghosh, Sengupta et al. 
2014). Further, mtDNA methylation at D-loop and MT-RNR1 was significantly different 
between the bio-specimens of cord blood and placental tissue (Janssen, Byun et al. 2014).  
Similar developmental-stage specific changes in mtDNA methylation have been reported in 
mouse studies. For instance, significantly lower levels of mtDNA methylation were observed in 
mouse somatic tissues in comparison to murine ESC at various regions in the mtDNA- D-loop, 
tRNA/COXI and CytB (Kelly, Mahmud et al. 2012). 
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Few studies have also correlated mtDNA methylation with exposure levels of airborne- 
environmental toxicants. MtDNA methylation was studied in buffy coat of human subjects with 
low and high exposure of metal-rich particulate matter. MT-TF and MT-RNR1 regions in 
mtDNA were found to have significantly higher methylation in subjects with higher metal 
exposure (Byun, Panni et al. 2013). In a separate study, placental mtDNA methylation at MT-
RNR1 and D-loop was found to be positively-associated with higher levels of exposure to metal-
rich particulate matter (Janssen, Byun et al. 2015).  
In summary, several recent studies reported changes in mtDNA methylation in bio-specimens 
obtained from several physiological states and pathophysiological conditions. A few of these 
studies have also reported concomitant changes in expression levels of some of the mtDNA-
encoded genes. However, any causal significance of these changes in mtDNA methylation with 
regard to mitochondrial gene expression and function remains to be explored.   
1.3.4 IS MITOCHONDRIAL DNA METHYLATION STILL DUBIOUS?  
Several recent studies have claimed the presence of mtDNA methylation in different model 
systems and reported changes in mtDNA methylation in multiple pathological and physiological 
conditions as described above.  However, few other studies asserted mtDNA methylation to be 
absent or present at non-significant levels (Dawid 1974, Groot and Kroon 1979, Maekawa, 
Taniguchi et al. 2004, Hong, Okitsu et al. 2013). Thus, the debate revolving presence of mtDNA 
methylation still has not ended completely.  All the methods that have been used to study 
mtDNA methylation have some technical limitations that have led to reproducibility issues and 
risk of generating artifacts. Further, majority of the studies have not considered the possibilities 
of nuclear DNA contamination for studying mtDNA methylation and thus not used mtDNA 
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extracted from purified mitochondria for determining the presence of mtDNA methylation or 
characterized mtDNA purity extensively. Thus, a major limitation common for all the methods 
that have been used to study mtDNA methylation is the possibility of nuclear DNA 
contamination, which need to be addressed in order to accurately predict the levels of mtDNA 
methylation (van der Wijst and Rots 2015). 
In 1970’s, mtDNA methylation studies was studied primarily by growing cells in medium 






P, followed by 
hydrolysis of DNA and subsequent resolution by thin-layer chromatography and radiographic or 
spectrophotometric detection (Vanyushin, Kiryanov et al. 1971, Nass 1973, Dawid 1974, 
Vanyushin and Kirnos 1974, Vanyushin and Kirnos 1977). Incomplete DNA hydrolysis, inability 
to resolve relatively small fraction of modified cytosines from the parent cytosine, detection limit 
being higher than the actual amount present in test-sample and possibility of losing the 
radioactive signal were the limitations of this approach, which led to reproducibility issues.  
In 1978, Waalwijk and Flavell demonstrated the use of restriction endonucleases – MspI and 
HpaII – by exploiting the differential preference of cleaving at the internal cytosine in the 
recognition sequence – CCGG, to determine the presence of methylation (Groot and Kroon 
1979, Shmookler Reis and Goldstein 1983, Pollack, Kasir et al. 1984). Digestion products of the 
mtDNA by MspI and HpaII were run on an agarose gel, transferred on a nitrocellulose 
membrane and radiolabeled oligonucleotide probes were used to detect the presence of fragment 
of desired size depending upon the presence or absence of 5-methyl cytosine at CCGG. Using 
this approach, both Schmookler et. al 1983 and Pollack et. al 1984 have reported 2-5% 






mouse cells. On the other hand, in another study when the digested products of rat and calf 
liver mtDNA were just run on an agarose gel, no differences were found, possibly due to the 
“semi-quantitative” nature of agarose gel. The major limitations of this approach are that study 
of mtDNA methylation is restricted to a particular site CCGG only and also that the presence of 
incompletely digested or indigestible mtDNA cannot be ruled out.  
With advances in technology for studying DNA methylation since 1980’s, mtDNA methylation 
has been pursued by multiple approaches such as methylation-specific PCR and bisulfite-
sequencing post bisulfite-conversion and various antibody-based methods such as 
immunohistochemistry, methylated DNA-IP (Me DIP) and ELISA (Enzyme-linked 
Immunosorbent assay)).   
Antibody-based methods require binding of antibody at target sites, but as it is difficult to 
determine the efficiency of binding of antibodies to their target sites, percentage pulldown of the 
input DNA cannot be predicted accurately using Me DIP. Further, in 5-mC-ELISA, the 
frequency of methylation is quantitated using a control standard of unknown proprietary 
sequence available in the 5-mC-ELISA commercial kits and hence, does not provide the real 
frequency of methylation.  Additionally, chances of non-specific binding of the antibody cannot 
be eliminated completely, which holds true for all the antibody-based methods that have been 
used to study mtDNA methylation. (Shock, Thakkar et al. 2011, Dzitoyeva, Chen et al. 2012, 
Kelly, Mahmud et al. 2012, Bellizzi, D'Aquila et al. 2013, Wong, Gertz et al. 2013) 
Multiple technical limitations are present even for bisulfite-conversion based methods. The 
process of bisulfite-conversion is harsh and causes DNA degradation. Also, the efficiency of 
bisulfite-conversion needs to be addressed for accurate quantification. Moreover, multiple 
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studies have reported the presence of 5-hydroxymethy cytosine (5-hmC) in mtDNA (Shock, 
Thakkar et al. 2011, Dzitoyeva, Chen et al. 2012, Bellizzi, D'Aquila et al. 2013). Thus, detection 
of 5-mC in mtDNA is probably confounded with the presence of 5-hmC as bisulfite-conversion 
cannot distinguish between modified cytosines such as 5-methyl cytosine and 5-hydoxymethyl 
cytosine. Additionally, low-coverage issues during next-generation sequencing and Polymerase 
Chain Reaction (PCR)-jackpot effect that might occur during PCR amplification before 
sequencing are additional limitations that need to be carefully considered for accurate 
quantification of mtDNA methylation. (Maekawa, Taniguchi et al. 2004, Feng, Xiong et al. 
2012, Byun, Panni et al. 2013, Hong, Okitsu et al. 2013, Pirola, Gianotti et al. 2013, Ghosh, 
Sengupta et al. 2014, Janssen, Byun et al. 2014, Baccarelli and Byun 2015, Janssen, Byun et al. 
2015) 
A single study has investigated mtDNA methylation using high pressure liquid chromatography 
in tandem with mass spectrophotometric quantification (HPLC-MS/MS) after digesting DNA 
into nucleosides and detected 5mC in mtDNA (Infantino, Castegna et al. 2011). Although 
HPLC-MS/MS does not provide the information for site specific methylation, it is the most-
direct, specific and very sensitive method to detect global methylation (Dahl and Guldberg 
2003). Unlike methylation-specific PCR and bisulfite sequencing that require bisulfite 
conversion of the DNA or various antibody-based methods that require binding of the antibody, 
the digested DNA can be directly used for quantification of 5-mC. Unlike methods dependent on 
bisulfite-conversion, HPLC-MS/MS can distinguish between modified cytosines (5-mC or 5-
hmC) in the mtDNA, thus making HPLC-MS/MS the most specific method. However, 
incomplete DNA digestion, inter-sample variation in digestion efficiency, multiple-steps 
involved in digesting DNA and the likelihood of nuclear DNA contamination can introduce 
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variabilities and thus lead to inaccurate prediction of 5-mC in mtDNA (van der Wijst and Rots 
2015). Thus, these limitations need to be addressed for accurate quantification of global levels of 
mtDNA methylation using HPLC-MS/MS. 
1.4. AGING-ASSOCIATED MITOCHONDRIAL DYSFUNCTION - ROLE OF MTDNA, 
DNA METHYLATION AND MTDNA METHYLATION IN AGING 
1.4.1 MTDNA IS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION DURING 
AGING 
Aging-associated  mitochondrial  dysfunction such as decline in respiration and appearance of 
abnormal mitochondria and  alterations  in  mtDNA such as deletions, point-mutations and 
tandem duplications  have  been  observed  in various organs in animal models (Vermulst, 
Wanagat et al. 2008) and clinical samples (Short, Bigelow et al. 2005). During aging, mtDNA 
mutations are  known  to  accumulate  (Trifunovic 2006),  which  are  attributed  to  oxidative  
damage  caused  by  elevated levels  of  reactive  oxygen  species  (ROS)  (Harman 1956, 
Harman 1981),  the  poor  proof-reading  efficiency  of polymerase-ɤ  (Kaguni 2004, Trifunovic, 
Wredenberg et al. 2004, Pursell, McDonald et al. 2008, Vermulst, Wanagat et al. 2008)  and also 
to the limited efficiency of the mtDNA repair machinery  (Druzhyna, Wilson et al. 2008, Santos, 
Correia et al. 2013).   Further, mitochondrial dysfunction that occurs during aging is also well 
established. However, as mitochondrial function is regulated by both the nuclear and 
mitochondrial genome, whether alterations in nuclear genome or mtDNA are responsible for 
age-associated mitochondrial dysfunction, cannot be concluded. Although, several  studies  have  
reported  strong  correlation  of  mtDNA  mutations  with  age-associated decline  in oxygen 
consumption and tissue-dependent  decrease in enzymatic activities of ETC, there  is  lack  of  
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evidence  that support a  direct  role  of  mtDNA  in  aging-associated  mitochondrial dysfunction  
(Bratic and Larsson 2013).  
1.4.2 CYTOPLASMIC HYBRID SYSTEM AND STUDIES ON DIRECT ROLE OF MTDNA 
IN MITOCHONDRIAL DYSFUNCTION  
Cytoplasmic hybrid (cybrid) cell lines are created by transferring subject’s mitochondria in an 
mtDNA-depleted cell line and thus, perpetuate mitochondrial DNA (mtDNA)-encoded 
components of the subject. Since the  nuclear  background  of  different  cybrid  lines  is  kept  
constant with only difference being the source of mtDNA,  this  technique  allows investigators  
to  study  the  influence  of  mtDNA  on  various  cellular  functions.  Prior  usage  of cybrids  has  
elucidated  the  contribution  of  mtDNA  to  various  parameters  associated  with mitochondrial  
function  such  as  electron  transport  chain  activities,  bioenergetic  fluxes,  free radical 
production and mitophagy in various disease models (Swerdlow, Parks et al. 1997, Esteves, 
Domingues et al. 2008, Esteves, Lu et al. 2010, Swerdlow 2012, Silva, Selfridge et al. 2013).  
Very few studies have interrogated the direct role of human mtDNA in aging-associated 
mitochondrial dysfunction using cytoplasmic or nuclear hybrid model and have arrived at 
conclusions contradictory to each other (Hayashi, Ohta et al. 1994, Laderman, Penny et al. 1996, 
Isobe, Ito et al. 1998). All these studies used human mtDNA from skin fibroblasts, but used 
different mtDNA-depleted cell lines and different model systems. While one group concluded 
that damage in the mtDNA was responsible for the  observed  differences  in  aging-dependent  
functional  alterations  of  mitochondria  (Laderman, Penny et al. 1996),  the other group inferred 
that the nuclear genome is  responsible for age-related respiration deficiency (Hayashi, Ohta et 
al. 1994, Isobe, Ito et al. 1998). The cybrid  study that reported the role of mtDNA, was 
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conducted using clones obtained  after  generating  the  transformed  cybrid  cell  line from  
individuals of varied age and found only 5%  of  the  clones obtained  from the old individuals  
were respiration-deficient (Laderman, Penny et al. 1996). The studies which showed role of 
nuclear genome worked with clones of a very small group of individuals (Hayashi, Ohta et al. 
1994, Isobe, Ito et al. 1998). Further, very limited parameters pertinent to mitochondrial 
dysfunction were investigated in all these studies.   Hence, a direct role of human mtDNA in age-
associated mitochondrial dysfunction has not been established yet and further comprehensive 
studies are required in this regard.   
1.4.3 DNA METHYLATION AND MTDNA METHYLATION IN AGING 
Global  hypo-methylation  and  local  hyper-methylation  is  known  to  occur  upon  aging  in  
the nuclear  genome (Gonzalo 2010, D'Aquila, Rose et al. 2013).  The first study that reported a 
global loss of DNA methylation during aging was conducted using rat brain and heart 
(Vanyushin, Nemirovsky et al. 1973). Loss of DNA methylation was subsequently corroborated 
by multiple studies in different tissues (Romanov and Vanyushin 1981) from rat, mouse and 
cow, in primary fibroblasts (Wilson and Jones 1983) derived from mice, hamsters and human 
and bio-specimens such as human lymphocytes (Drinkwater, Blake et al. 1989) and peripheral 
blood cells (Fuke, Shimabukuro et al. 2004). Also, an age-associated decrease of DNA 
methylation in inactive X chromosome was seen in peripheral blood cells (Busque, Mio et al. 
1996). Such hypo-methylation predominantly affects non-island CpGs (Christensen, Houseman 
et al. 2009) and interspersed repetitive sequences (IRSs) (Jintaridth and Mutirangura 2010) 
during aging.  
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Paradoxically, significant hyper-methylation is observed at the promoters of specific genes upon 
aging (Christensen, Houseman et al. 2009, Winnefeld and Lyko 2012, Gentilini, Mari et al. 
2013).  Such age-associated hyper-methylation has been seen in the promoters for tumor 
suppressor genes such as COX7A1, LOX, RUNX3, RASSF1 and DUSP22. Multiple genes 
involved in development and growth (IGF2, c-FOS), cell adhesion (CDH1), metabolism 
(SLC38A4, SLC22A18, ECRG4, ATP13A4, LEP) and DNA repair (MLH1) also reported to 
have age-associated increase in DNA methylation (Gonzalo 2010, D'Aquila, Rose et al. 2013).  
Recently few  studies have  found  total  DNA  methylation  to  be  different  in cybrids  created  
from  different  haplogroups  of  human  mtDNA,  thus  implying  that  mtDNA-specific 
interactions between mitochondria and the nucleus can regulate epigenetic marks such as DNA 
methylation. Cybrids created from J haplogroup donors were found to have higher global 
methylation and lower ATP and ROS levels in comparison to cybrids generated from non-J 
haplogroup donor (Bellizzi, D'Aquila et al. 2012). Another study also reported differences in 
global DNA methylation when cybrids created from J and H haplogroup donors were compared 
(Atilano, Malik et al. 2015). However, whether aging-associated alterations in mtDNA can affect 
the levels of nuclear DNA methylation is not known.  
As discussed above, nuclear DNA methylation has been extensively studied during aging. 
However, very limited data is available about age-dependent changes in the mtDNA methylation. 
Dzitoyeva et. al. compared global levels of mtDNA methylation between young and old mice 
using 5-mC-ELISA in different parts of the brain (frontal cortex and cerebellum) and found them 
to be comparable (Dzitoyeva, Chen et al. 2012). However, another study analyzed mtDNA 
methylation using real-time PCR on bisulfite-treated DNA from human blood sample and found 
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a correlation between 12S rRNA methylation and aging (Iacobazzi, Castegna et al. 2013). Thus, 
further studies are required to investigate alteration in mtDNA methylation during aging.  
1.5. KNOWLEDGE GAPS, SIGNIFICANCE AND PURPOSE OF THE STUDY  
How nuclear DNA methylation determines gene-expression of nuclear DNA-encoded genes is 
fairly known (Jones 2012). However, existence of mtDNA methylation is still debated (van der 
Wijst and Rots 2015). Moreover, the role of mtDNA methylation in regulating expression of 
mtDNA-encoded genes and ultimately mitochondrial function remains unexplored. Studying 
mtDNA methylation can prove to be useful in understanding mitochondrial diseases as alteration 
in the genetic sequence of mtDNA accounts for only a small fraction of these diseases (Dimauro 
and Davidzon 2005). The purpose of this dissertation was to establish a method to quantitate 
mtDNA methylation globally and evaluate the presence of mtDNA methylation in SH-SY5Y 
neuroblastoma cells; further, to examine whether mtDNA methylation can be altered 
experimentally and also if there are any associated changes in mitochondrial transcription and 
function; and finally, to investigate  direct role of mtDNA in mitochondrial dysfunction during 
aging using cybrid model and if mtDNA methylation is also altered in this model. 
Although numerous studies investigating mtDNA methylation claimed its presence (Vanyushin, 
Kiryanov et al. 1971, Nass 1973, Vanyushin and Kirnos 1977, Shmookler Reis and Goldstein 
1983, Pollack, Kasir et al. 1984, Chestnut, Chang et al. 2011, Infantino, Castegna et al. 2011, 
Shock, Thakkar et al. 2011, Dzitoyeva, Chen et al. 2012, Feng, Xiong et al. 2012, Kelly, 
Mahmud et al. 2012, Bellizzi, D'Aquila et al. 2013, Byun, Panni et al. 2013, Jia, Li et al. 2013, 
Pirola, Gianotti et al. 2013, Wong, Gertz et al. 2013, Ghosh, Sengupta et al. 2014, Baccarelli and 
Byun 2015, Janssen, Byun et al. 2015, Mishra and Kowluru 2015, Zheng, Linarelli et al. 2015), a 
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few have asserted it to be absent or present at non-significant levels (Dawid 1974, Groot and 
Kroon 1979, Maekawa, Taniguchi et al. 2004, Hong, Okitsu et al. 2013). Methods used to study 
mtDNA methylation have multiple technical limitations which have led to issues of 
reproducibility (van der Wijst and Rots 2015). Moreover, majority of these studies have not 
addressed the possibility of nuclear DNA contamination while assessing the presence of mtDNA 
methylation and neither did majority of the studies use purified mitochondria (van der Wijst and 
Rots 2015). Hence, critical evaluation for presence of mtDNA methylation, by addressing the 
limitations of the method used and issues of nuclear DNA contamination, is required.  Here, we 
aim to establish a direct and specific HPLC-MS/MS based method to quantify global mtDNA 
methylation and to investigate the occurrence of mtDNA methylation in SH-SY5Y 
neuroblastoma along with purity characterization of mtDNA.   
Recent studies have demonstrated localization of DNMTs in mitochondria (Chestnut, Chang et 
al. 2011, Shock, Thakkar et al. 2011, Bellizzi, D'Aquila et al. 2013, Wong, Gertz et al. 2013). 
However, direct role of DNMTs in altering mtDNA methylation is yet to be established. Further, 
several studies have reported changes in levels of mtDNA methylation in various pathological 
and physiological conditions. Few of these studies have also reported correlative changes in 
expression levels of mtDNA-encoded genes (Feng, Xiong et al. 2012, Pirola, Gianotti et al. 
2013). However, any role of mtDNA methylation in controlling gene expression of mtDNA-
encoded genes and mitochondrial function is not yet tested. In order to test this, experimental 
approaches to alter mtDNA methylation need to be developed first, as it is not yet known 
whether mtDNA methylation can be altered experimentally. Hence, we investigated if mtDNA 
methylation can be altered by different experimental approaches and whether there are any 
associated changes in mtDNA transcription and mitochondrial function.  
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Global hypo-methylation (Vanyushin, Nemirovsky et al. 1973, Romanov and Vanyushin 1981, 
Wilson and Jones 1983, Drinkwater, Blake et al. 1989, Busque, Mio et al. 1996, Fuke, 
Shimabukuro et al. 2004, Christensen, Houseman et al. 2009, Jintaridth and Mutirangura 2010) 
and gene-specific hyper-methylation (Christensen, Houseman et al. 2009, Winnefeld and Lyko 
2012, Gentilini, Mari et al. 2013) are known to occur during aging. However, whether mtDNA 
methylation gets altered upon aging is not well known. Although, positive correlations between 
mtDNA mutations and aging-associated decline in mitochondrial dysfunction exist (Bratic and 
Larsson 2013), direct role of mtDNA in aging-associated mitochondrial dysfunction is also 
unclear (Hayashi, Ohta et al. 1994, Laderman, Penny et al. 1996, Isobe, Ito et al. 1998). Hence, 
we studied whether a direct role of mtDNA exists in aging-associated mitochondrial dysfunction 
using cybrid model of aging and also how global methylation and mtDNA methylation are 




Figure 1:  Human mitochondrial DNA and its structural arrangement: MtDNA is double-
stranded and circular with as size of 16,569 bp.  Blue strand represent the Heavy strand (H 
strand) whereas the black strand represents the light strand (L strand) with their asymmetric gene 
arrangement. Genes coding for protein and rRNA are interspersed with 22 tRNAs (red bars 
represented with amino acid code). Genes encoded by the H strand are marked outside whereas 
genes encoded by the L strand are marked inside by their gene symbols. OH : origin of replication 
for H-strand; OL: Origin of replication of L strand; HSP1: H-strand promoter 1; HSP2: H-strand 












Figure 2: Initiation of Mitochondrial transcription from D-loop: Bidirectional transcription 
occurs from the H-strand promoters (HSP-1 and HSP-2) and L-strand promoter (LSP) that are 
located in the D-Loop. HSPs and LSP are bound by TFAM, POLRMT and TFB2M for initiation 
of transcription. Transcription is terminated by the binding of mitochondrial Termination factors 
(MTERF1, MTERF2 and MTERF3) to mtDNA (see text for details). OH: origin of replication 
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Nuclear DNA methylation plays an important role in regulating gene expression. However, 
presence of mitochondrial DNA (mtDNA) methylation has been debatable for the past four 
decades due to limitation of the approaches used. In the current study, we used a direct, sensitive 
and highly specific method using HPLC-ESI-MS/MS to investigate the presence of methylation 
at global levels in mtDNA in SH-SY5Y neuroblastoma cell line. Differential or incomplete 
enzymatic digestion of DNA is the pitfall of quantifying DNA methylation by HPLC-ESI-
MS/MS. To address this issue, oligonucleotides harboring known amounts of 2’-deoxy-Cytosine 
(dC) and 5-methyl-2’-deoxy-Cytosine (5mdC) were used as calibrators. 5mdC was detected in a 
linear and quantifiable manner, along with other nucleosides, using 0.04 μg to 0.8 μg of SH-
SY5Y mtDNA with one-step digestion process. Around 3% methylation was found to be present 
in mtDNA obtained from crude mitochondrial isolates. Similar percentages of methylation were 
observed even in mtDNA obtained from gradient-purified mitochondria. Purity of mtDNA was 
characterized indicating elimination of 99.12% nuclear DNA contamination with 115 fold 
enrichment of mtDNA in gradient-purified mitochondria. Further, linear regression analysis 
between estimated percentage of mtDNA in various mitochondrial preparations and the 
corresponding percentage methylation revealed that mtDNA methylation occurs at levels at least 
as much as that of the nucleus. Presence of methylation in SH-SY5Y mtDNA was further 
substantiated using methylation-specific PCR for a specific site in 12S rRNA. In conclusion, we 
established a direct method to quantify global methylation in mtDNA using HPLC-ESI-MS/MS 
along with addressing issues of variable DNA digestion and the possible chances of nuclear 
DNA contamination. Further, we reported for the first time, presence of methylated DNA in 




Mitochondria contain their own genetic information in the form of mitochondrial DNA 
(mtDNA), which coupled with nuclear genome encode the proteins that form the mitochondria. 
Alterations in expression of mtDNA-encoded genes can regulate mitochondrial protein 
expression and eventually affect mitochondrial function. Methylation is known to occur in 
nuclear DNA, which is catalyzed by a group of enzymes called DNA Methyl-Transferases 
(DNMTs) (Bestor 2000, Jones 2012). While nuclear DNA methylation and its role in regulating 
nuclear gene expression are well established (Jones 2012), presence of mtDNA methylation has 
remained debatable (Maekawa, Taniguchi et al. 2004, Ferreira, Serafim et al. 2015).  Although 
mtDNA methylation was seen as early as 1970s (Vanyushin, Kiryanov et al. 1971, Nass 1973, 
Vanyushin and Kirnos 1974, Vanyushin and Kirnos 1977, Shmookler Reis and Goldstein 1983, 
Pollack, Kasir et al. 1984), possible role of mtDNA methylation in regulating the expression of 
mtDNA-encoded genes was overlooked as no DNA methyl transferases were known to be 
present in mitochondria and considering the fact that mtDNA lack histones. Recent reports of 
presence of DNMTs in mitochondria (Chestnut, Chang et al. 2011, Shock, Thakkar et al. 2011, 
Bellizzi, D'Aquila et al. 2013, Wong, Gertz et al. 2013)and the possible histone-like role of 
TFAM (Kanki, Nakayama et al. 2004, Shutt, Lodeiro et al. 2010, Lodeiro, Uchida et al. 2012) 
has rejuvenated interest in studying mtDNA methylation and its potential epigenetic role 
(Iacobazzi, Castegna et al. 2013, Maresca, Zaffagnini et al. 2015, van der Wijst and Rots 2015). 
Although numerous studies have been conducted recently to study mtDNA methylation, 
conclusions regarding the existence of methylation in mtDNA are dubious with many reports 
claiming presence of mtDNA methylation (Nass 1973, Chestnut, Chang et al. 2011, Infantino, 
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Castegna et al. 2011, Shock, Thakkar et al. 2011, Chen, Dzitoyeva et al. 2012, Dzitoyeva, Chen 
et al. 2012, Feng, Xiong et al. 2012, Bellizzi, D'Aquila et al. 2013, Byun, Panni et al. 2013, Jia, 
Li et al. 2013, Pirola, Gianotti et al. 2013, Wong, Gertz et al. 2013, Ghosh, Sengupta et al. 2014, 
Baccarelli and Byun 2015, Janssen, Byun et al. 2015, Zheng, Linarelli et al. 2015) while few 
other studies reporting it to be absent (Dawid 1974, Groot and Kroon 1979, Maekawa, Taniguchi 
et al. 2004, Hong, Okitsu et al. 2013).  Technical limitations and inability to reproduce results by 
various approaches used for studying mtDNA methylation have hindered in dispelling the doubts 
about occurrence of mtDNA methylation (Dahl and Guldberg 2003, van der Wijst and Rots 
2015). MtDNA methylation has been detected by Methylation Sensitive Restriction Enzyme 
Analysis (MSRE) followed by Southern-Blot hybridization using radio-labelled probes (Nass 
1973, Vanyushin and Kirnos 1974, Vanyushin and Kirnos 1977, Shmookler Reis and Goldstein 
1983, Pollack, Kasir et al. 1984), Methylated-DNA-IP (Shock, Thakkar et al. 2011, Bellizzi, 
D'Aquila et al. 2013, Ghosh, Sengupta et al. 2014), 5mC-ELISA (Dzitoyeva, Chen et al. 2012), 
methylation-specific PCR (Pirola, Gianotti et al. 2013) and Bisulfite-sequencing (Bellizzi, 
D'Aquila et al. 2013, Wong, Gertz et al. 2013, Ghosh, Sengupta et al. 2014). Nuclear DNA 
contamination is the common pitfall for all these approaches and needs to be taken into account. 
MSRE limits the study of mtDNA methylation at sequence-specific sites whereas reproducibility 
using different antibodies for methylated-DNA-IP and 5-mC-ELISA has been questioned 
(Maresca, Zaffagnini et al. 2015). Even though bisulfite-sequencing is considered the gold-
standard for measuring DNA methylation and  has been the most utilized approach for 
determining DNA methylation, incomplete bisulfite-conversion, bias in PCR-amplification, 
preferential cloning, low coverage considered for analysis and the inability to distinguish 5-mdC 
from other modified cytosines (5-hydroxyl-methyl-deoxy-cytosine  - another epigenetic 
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modification present in  mtDNA (Shock, Thakkar et al. 2011, Dzitoyeva, Chen et al. 2012)) have 
plagued the results. 
HPLC-MS/MS is by far the most-direct, specific and sensitive method to quantify global 
levels of 5-mdC in the nuclear DNA but does not provide site-specific information. Variability in 
DNA digestion efficiency and nuclear DNA contamination can affect accuracy and 
reproducibility of detection of DNA methylation in mitochondria using this approach  (van der 
Wijst and Rots 2015). Although a previous study reported use of HPLC-MS/MS for detection of 
mtDNA methylation (Infantino, Castegna et al. 2011), these issues regarding DNA digestion and 
nuclear contamination were either overlooked or not addressed at depth that should be accounted 
for reliable quantification. 
In the current study, we established a direct and specific method to quantify global 
methylation in mtDNA using HPLC-MS/MS.  We addressed the issue of variability during 
digestion of DNA by using custom oligonucleotides as controls. We further reported presence of 
methylated DNA in percoll-gradient purified SH-SY5Y mitochondria. To address the issue of 
nuclear DNA contamination, we have characterized purity of our mtDNA preparations.  
Additionally, we have assayed mtDNA methylation at a specific site in 12S rRNA by 
methylation-specific primer.  
2.3 MATERIALS AND METHODS 
Cell Culture and its harvest 
SH-SY5Y neuroblastoma cells were cultured in DMEM containing 25 mM glucose, 10% heat-
inactivated fetal bovine serum (FBS), 1% Pen-strep and maintained at 37°C, 5% CO2. Cell lines 
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growing in the culture flasks or petri-dishes were rinsed with 1X Phosphate Buffered Saline 
(PBS), trypsinized and then harvested using the growth media. The harvested cells were then 
pelleted at 800g for 5 minutes at 4°C and subsequently washed with 1X PBS at 4°C for 
subsequent downstream procedure. 
Isolation of crude and percoll-gradient purified mitochondria    
Crude preparation of mitochondria: Mitochondria were isolated as described previously 
(Kristian, Hopkins et al. 2006) with some modifications. Briefly, cells growing in a confluent 
T180 flask were harvested as described above. The washed cell pellets were then re-suspended in 
Mannitol-Sucrose-HEPES-EGTA (MSHE) buffer, collected in a pre-cooled cavitation chamber 
(nitrogen bomb; Parr Instrument Company, Moline, IL) and subjected to 900 psi for 15 minutes. 
The cell suspension is collected by releasing the pressure instantaneously and centrifuged at 
1000g for 5 minutes at 4°C to pellet the cell debris. The supernatant was collected and spun at 
high speed of 20000g for 10 minutes at 4°C. The pellet obtained was re-suspended in MSHE and 
is the crude preparation of mitochondria. 
Percoll gradient-purified mitochondria: Gradient-purified mitochondria were isolated in a 
modified version as described previously (Kristian, Hopkins et al. 2006). Percoll was purchased 
from GE-Healthcare (catalogue # 28-9038-48) and 100% percoll was prepared by mixing 9 parts 
of Percoll with 1 part of 1.5M NaCl. The crude pellet of mitochondria obtained is re-suspended 
in 800 µL of 15% percoll and layered on to a gradient of 50% and 21% percoll. The resulting 
percoll-gradient underwent ultra-centrifugation in a swing-bucket rotor system (SW 28.1 rotor) 
at 30,700 g for 15 minutes at 4°C. The pure mitochondria separated between 50 and 21% percoll, 
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was collected, diluted with MSHE and then washed at 20,000 g for 15 minutes at 4°C twice. The 
pellet obtained is the percoll-gradient purified mitochondria.  
Mitochondrial lysate of crude and gradient-purified mitochondria were prepared using M-PER 
Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA). Protein concentrations for 
the lysates were determined using a BCA Protein Assay kit (BioRad).  
DNA extraction 
DNA extraction was done by the method based on organic-solvent extraction of DNA as 
described previously (Guo, Jiang et al. 2009). Briefly, the sample in ice-cold lysis buffer 
underwent dounce homogenization, followed by Proteinase K digestion at 55°C for 3h in a water 
bath. The mixture was spun to remove the non-soluble fractions and the DNA in the supernatant 
was extracted by standard Phenol-Chloroform-Isoamyl alcohol method. DNA was precipitated 
using 3M Sodium Acetate and isopropanol at -20°C. The DNA pellet was washed twice with 
70% ethanol. Finally, the extracted DNA pellet is then air-dried, re-suspended in nuclease-free 
water and then quantitated using Infinite M200 (Tecan, San Jose, USA).  
SH-SY5Y mtDNA extraction: The mitochondrial DNA was extracted from both the crude and 
gradient-purified mitochondria for determining the amount of mtDNA methylation. Twenty 
million cells in a T180 flask were seeded and harvested 48 hours later for extraction of 
mitochondria as described above. The isolated mitochondria were suspended in ice-cold Lysis 
buffer for DNA extraction as described above.  
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Total DNA extraction: SH-SY5Y cells were harvested 48 hours after seeding as described above 
and the washed cell pellets were suspended in ice-cold Lysis buffer for DNA extraction as 
described above.  
Long PCR of human mtDNA 
SH-SY5Y mtDNA was extracted and used as template to generate a PCR product of 15.745 Kb 
long  to represent the un-methylated version of human mtDNA as described previously (Binder, 
Dunn et al. 2005) using Expand Long Range, dNTPack (Roche Diagnostics).  The PCR product 
thus obtained was purified using Qiaquick PCR purification kit (Qiagen) before using it for 
HPLC-ESI-MS/MS assay, following digestion and for methylation-specific PCR assay, 
following bisulfite-conversion.  
Digestion of DNA 
Oligo-deoxy-nucleotides, mtDNA, total DNA, Long PCR were digested as described previously 
(Quinlivan and Gregory 2008).  Briefly, known amount of the DNA of interest was digested in 
100 µL reaction volume, using the enzymes- 2.5 U Benzonase (Sigma E1014), 3 mU 
Phosphodieasterase I (Sigma P3243) and 2U Alkaline Phosphatase (Sigma P7923) in Tris-HCl 
(20 mM. pH 7.9) containing 1 mM NaCl and 0.2 mM MgCl2 at 37°C for 20-24 hours.   
HPLC-ESI-MS/MS  
Reagents: 5-Methyl-2'-deoxycytidine (5MdC) was purchased from Berry & Associates, Dexter, 
MI (Catalogue# PY7635). The four other deoxyribonucleosides- 2’-deoxycytosine (dC), 2’-
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deoxyguanosine (dG), 2’-deoxyadenosine (dA), and 2’-deoxythymidine (dT), were purchased 
from Sigma Chemical Co. (St. Louis, MO).  
Apparatus: Waters Acquity “Classic” (Waters Corp. Milford, MA) UPLC system was used with 
an Altima C18 column that had internal diameter of 2.1 mm and length of 50 mm, with sorbent 
particles of size 3.5 µm (Grace, Columbia, MD). Triple quadrupole mass-spectrometer (Quattro 
Ultima Micromass Ltd. Manchester, UK) was coupled with the UPLC system through electron-
spray probe for detection and quantification of nucleosides.  
LC-ESI-MS/MS Procedure: Released nucleosides in the digestion buffer of a particular sample of 
interest were separated by UPLC for MS/MS detection, adapting a general strategy used for 
separating a complex mixture of nucleosides. The injection volume used was 20 µL. LC 
separation was performed at a flow rate of 300 µL/minute. Two buffers, A: 10 mM ammonium 
acetate (NH4OAc) and B: 10% Methanol comprised the mobile phase that was used for elution 
of the nucleosides using the following gradient:  
Time    A%  B% 
(min)    
0.0  99  1  
1  99  1  
2  90  10  
9  20  80  
11  99  1  
The mobile phase effluent were passed through the electrospray probe (source block 
temperature: 110
○
C, de-solvation temperature: 200
○
C and cone voltage: 50V) and tandem mass 
spectra was acquired on triple quadrupole in multiple reaction monitoring (MRM) mode. The 
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first quadrupole (Q1) that acts as a mass-filter, allowed a parent ion of a specific mass-to-charge 
ratio to enter the second quadrupole. The second quadrupole (Q2) is the collision cell, where 
Argon gas at a pressure of 2e-3 mbar was used to fragment the ions through the process of 
collision-activated disassociation (collision energy: 15 eV). The resulting fragment ions were 
transmitted to the third quadrupole (Q3), where only the daughter ions of a desired mass-to-
charge ratio were allowed to pass and reach the detector for further quantification to compose the 
tandem mass spectra.   Selected ion recordings for 5-Methyl-2'-deoxycytidine (5MdC) was 242.1 
(parent ion) >126.1 (daughter ion) and for the other nucleosides were dC: 229.1>112.1, dT: 
244.1>127.1, dA: 253.1>136.1, dG: 269.1>152.1 with dwell time of 0.1 second. To monitor 
instrument performance, every batch of samples were punctuated with duplicate preparations of 
5MdC standard curve, ranging from 1 to 20 pmoles in a mixture of 40 pmoles of each of the 
nucleosides dA, dT, dG and dC in 10 mM NH4OAc as well as only 10mM NH4OAc as the blank. 
Determination of mtDNA purity using qPCR 
Whole-cell DNA, mtDNA from crude and gradient-purified mtDNA were extracted from equal 
number of cells and the DNA was re-suspended in equal volume of nuclease-free water. Equal 
amount of DNA from each of them were used to determine the amount of nuclear-encoded and 
mitochondrial-encoded genes -18S rRNA and 16S rRNA, respectively- by real-time PCR.  Fold-
enrichment of mtDNA was calculated by comparing ratio of 16S rRNA to 18S rRNA in crude and 
gradient-purified mtDNA with respect to whole-cell DNA. 18S rRNA /16S rRNA was then used 
to determine the percentage of nuclear DNA eliminated in crude and gradient-purified mtDNA 
with respect to whole-cell DNA similar to as reported previously (Wilkins, Carl et al. 2015) and 
corrected to account for change in proportion of mtDNA with purification.   
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An estimate of fraction of bases of mtDNA present in each sample of DNA preparation with 
respect to nuclear bases was derived from the percentage of nuclear DNA eliminated and 
mtDNA enrichment, wherein the ratio of number of bases in the mtDNA to nuclear DNA (33138 
bases in one copy of mtDNA and 1.28 X 10
10 
bases in one copy of nuclear DNA) and also the 
mtDNA copy number per copy of nuclear DNA has been accounted for. The estimated amount 
of mtDNA in each sample thus calculated was represented as a percentage of mtDNA present 
with respect to total DNA (sum of nuclear and mtDNA).  
Linear regression analysis of percentage methylation and percentage mtDNA 
Simple linear regression analysis was performed between percentages of mtDNA in whole-cell 
DNA and mtDNA extracted from mitochondrial preparations (with increasing purity levels) with 
its respective percentage methylation in order to investigate whether there is a statistically 
significant relationship between the two parameters – percentage mtDNA and percentage 
methylation. Following linear regression model was used, where β is the coefficient that 
specifies the increase in methylation based on the increase in percent mtDNA, and ε is an error 
term: Methylation = (Percent mtDNA)*β + ε 
Bisulfite conversion and Methylation-specific-PCR assay  
Bisulfite conversion: The extracted mtDNA of interest and ‘Long PCR’ was treated with bisulfite 
using EZ DNA methylation-Gold kit (Zymoresearch, Irvine, CA, USA). Bisulfite sulphonates 
and then deaminates the un-methylated Cytosine to produce uracil in DNA. Thus methylated 
cytosines are protected from the conversion to uracil, allowing the use of site-specfic PCR 
amplification i.e. methylation-specific PCR. Briefly, 350 ng of mtDNA in 20 µL nuclease-free 
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water was mixed with 130 µL of CT Conversion reagent and was placed in the thermal cycler 
where the program consisted of initial denaturation at 98°C for 10 minutes, followed by 
conversion at 64°C for 2.5 hours. The converted solution of mtDNA was mixed with binding 
buffer to allow its binding to the column. A high speed spin was followed by washes, 
desulphonation for 20 minutes at room temperature and then finally eluted using the Elution 
buffer to obtain the bisulfite-treated DNA.  
After obtaining the converted mtDNA, the following primers were used to amplify a region of 
12S rRNA using the following PCR program. The primers were designed using the bisulfite 




PCR set up: .4 µM of the forward and reverse primer was used to amplify to obtain a 320 bp 
amplicon using ZymoTaq Premix (Zymoresearch, Irvine, CA, USA).  
PCR program: Initial denaturation of 10 mins at 95°C was followed by 30 cycles of denaturation 
at 95 °C for 30 secs, annealing at 51.5°C for 45 secs and synthesis at 72°C at 45 secs, with a final 
elongation step of 7 mins at 72°C. 
Agarose-gel-electrophoresis: The subsequent PCR products obtained were electrophoresed 
through 1% agarose gel containing 0.5 µg/ml ethidium-bromide and visualized under ultraviolet 




Whole cell lysates were prepared by M-PER Mammalian Protein Extraction Reagent (Pierce, 
Rockford, IL, USA). Protein concentrations for all the lysates were determined using a BCA 
Protein Assay kit (BioRad).  
Equal amount of proteins from the protein lysates were resolved by electrophoresis in pre-cast 4–
12% gels (BioRad), and then transferred to polyvinyl di-fluoride (PVDF) membranes. Non-
specific binding was blocked by gently agitating the membranes in 5% non-fat milk and 0.1% 
Tween in PBS (PBST) for 1 hour at room temperature. Blots were subsequently incubated in 5% 
bovine serum albumin (BSA) containing 0.1% Tween with the designated primary antibody 
overnight at 4°C with gentle agitation. After PBST washes, the blot was then incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature with gentle agitation. After PBST washes, the blots were incubated with 
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Chemiluminescence signals 
were detected using a Bio-Rad ChemiDoc Imager.  
Primary antibodies for, VDAC, ß-Tubulin, GAPDH were purchased from Cell Signaling 
Technology (Beverly, MA, USA) and that of HDAC1 was purchased from Pierce (Thermo 
Scientific, Eugene, OR, USA). All of the antibodies were used at a 1:1000 dilution.   
Data analysis 
Data are expressed as means ± standard error of the means (SEM). To compare means between 
two groups we used two-way, unpaired Student’s t-tests, with p-values of <0.05 considered 




Characterization of 5mdC along with dA, dG, dT and dC by HPLC-ESI-MS/MS 
HPLC-ESI-MS/MS was used to characterize and quantify 5mdC along with dA, dG, dT and dC. 
Standards of each nucleoside were used for initial characterization by mass spectrometry. 
Electron-spray-ionization (ESI) generated ions obtained at m/z 253.1, 244.1, 269.1, 229.1 and 
242.1 corresponded to protonated nucleosides for dA, dG, dT, dC and 5mdC, respectively. The 
collision-assisted dissociation (CAD) of these ions resulted in generation of daughter fragments. 
Most abundant daughter ions were obtained at m/z 136.1, 127.1, 152.1, 112.1 and 126.1 
corresponding to the protonated bases (A, G, T, C, 5mC) resulting from glyosidic-bond cleavage 
of the respective protonated-nucleosides. Thus, the unique MRM transitions obtained at m/z 
253.1>136.1, 244.1>127.1, 269.1>152.1, 229.1>112.1 and 242.1>126.1 were followed to detect 
and quantify dA, dG, dT, dC and 5mdC simultaneously as depicted in Figure 1A.  Under 
optimized elution and ESI conditions, we were able to resolve peaks corresponding to dA to A, 
dG to G, dT to T, dC to C and 5mdC to 5mC transitions with typical chromatogram shown in 
Figure 1B and D.  
Using equimolar mixture of dA, dG, dT and dC ranging from 10 to 100 pmoles prepared in 10 
mM Ammonium acetate, we were able to linearly detect these nucleosides simultaneously. The 
corresponding linear equations (representative) with coefficient of regression are shown in 
Figure 1C. Further, various concentrations of 5mdC were spiked in equimolar mixture of dA, 
dG, dT and dC (40 pmoles each) for quantification of 5mdC. We were able to detect 5mdC 
linearly in range of 1 to 20 pmoles as shown in Figure 1E by representative curve with 
correlation coefficient of 0.9925. The measured 5mdC levels using this external calibration curve 
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were found to be in proportion with nominal 5mdC levels as shown in Figure 1F. Further, limit 
of detection of 5mdC under the experimental conditions was found to be 25 fmoles as shown in 
Figure 1D. All these external calibration curves were included in every run for quality control.  
Linear digestion and quantification of nucleosides in oligodeoxynucleotides containing 
methylated and un-methylated cytosine 
Inefficient and variable digestion of DNA samples into nucleosides is a major limitation for 
accurate quantification of nucleosides from DNA samples using HPLC-MS/MS. Since we 
wanted to simulate the digestion conditions in real DNA samples, we used custom-made oligo-
deoxy-nucleotides either containing only dC or dC in combination 5mdC to investigate if we 
could obtain linear digestion of these oligo-deoxy-nucleotides and further quantify resulting 
nucleosides in linear manner. We obtained linear and proportional detection of dA, dG, dT and 
dC when un-methylated oligo-deoxy-nucleotide (ranging from 0.2 to 4 µg DNA in 100 µl of 
digestion mix) was digested and analyzed. The corresponding DNA amounts actually injected 
and analyzed ranged from 0.04 to 0.8 µg based on 20 µl injection volume. Representative curves, 
linear equations, and coefficient of regression along with nominal amount of respective 
nucleoside present in oligo-deoxy-nucleotide are shown in Figure 2A. Digestion was linear up to 
5 µg of DNA (in 100 µl of digestion mix) and was saturated beyond this amount of DNA for the 
given digestion conditions (data not shown). 5mdC was not detected in un-methylated oligo-
deoxy-nucleotide digested product confirming specificity of our method.  Similarly, oligo-deoxy-
nucleotide containing both dC and 5mdC (with similar range of DNA amounts as used for un-
methylated oligo-deoxy-nucleotide) was digested and analyzed. Linear and proportional 
detection of all the nucleosides (dA, dG, dT, dC and 5mdC) were obtained in the studied range 
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suggesting linear digestion of all nucleosides under optimized digestion conditions. 
Representative curves, linear equations, and coefficient of regression along with nominal amount 
of respective nucleoside present in oligo-deoxy-nucleotide samples are shown in Figures 2B and 
2C. Further, measured 5mdC levels using this oligo-deoxy-nucleotide calibration curve were 
found to be in proportion with nominal 5mdC levels as shown in Figure 2D. Calibration curves 
obtained by using digestion product of 5mdC containing oligo-deoxy-nucleotide  was used to 
calculate the amount of 5mdC in test  samples instead of using calibration curve obtained by 
analytical grade 5mdC in equimolar mixture of other nucleosides. This was done to account for 
any variability introduced during digestion process and is more comparable to conditions in test 
samples. Further, our calibration curves covered concentration range of each nucleoside expected 
to be present in test DNA samples. Both un-methylated and methylated oligo-deoxy-nucleotide 
standards were included in each run.   
Linear and proportional detection of nucleosides in SH-SY5Y mtDNA 
Since we wanted to measure methylation in mtDNA, we first investigated, using our digestion 
conditions for custom oligodeoxynucleotides, if we could obtain linear digestion of mtDNA and 
quantify resulting nucleosides. MtDNA was obtained from mitochondria isolated from SH-
SY5Y cells and digested (0.2 to 4 µg mtDNA was used for digestion in 100 µl of digestion mix) 
as described previously Figure 3A. MtDNA displayed a single band on 1% agarose gel which 
resulted into smear upon digestion as shown in Figure 3B. We obtained linear detection of dA, 
dG, dT, dC and 5mdC in SH-SY5Y mtDNA (DNA analyzed ranged from 0.04 to 0.8 µg based 
on 20 µl injection volume). Representative curves, linear equations, coefficient of regression 
along with calculated amount of respective nucleosides present in SH-SY5Y mtDNA are shown 
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in Figure 3C-G. Further, calculated amount of nucleosides increased in proportion to the amount 
of DNA analyzed. Similar to oligo-deoxy-nucleotide experiments, digestion was linear up to 5 
µg of DNA (in 100 µl of digestion mix) and was saturated beyond this concentration (data not 
shown). 2 µg of mtDNA (in 100 µl of digestion mix) was used for digestion in all the following 
experiments for analyses, which is within the linear range of digestion of mtDNA. 
Detection of 5mdC in mtDNA extracted from crude and gradient-purified mitochondria 
As we were able to linearly digest and quantitate all nucleosides including 5mdC in DNA 
obtained from isolated mitochondria, we wanted to quantitate and confirm presence of 5mdC in 
SH-SY5Y mitochondria isolated using different methodologies (which are conventionally used 
to get pure mitochondria) and prepared at different times over an extended time period of about a 
year (n=5-6). We determined absolute values of 5mdC (pmoles/µg DNA) in ‘Long PCR’, whole-
cell DNA, mtDNA isolated from crude and gradient-purified mitochondria as depicted in Figure 
4A. As the name suggests, ‘Long PCR’ denotes the PCR fragment generated from SH-SY5Y 
mtDNA of 15,745 base-pair in size, almost the size of human mtDNA as described previously 
(Binder, Dunn et al. 2005). As ‘Long –PCR’ of mtDNA has been generated by DNA Polymerase 
that does not copy the methylation like DNMT1, it is devoid of any methylation and thus serves 
as a negative-control for our HPLC-ESI-MS/MS assay. Indeed, no 5mdC was detected in ‘Long-
PCR’ of mtDNA, thus further confirming the specificity of our assay. Nuclear DNA methylation 
is well established (Bestor 2000, Jones 2012) and 5mdC was successfully detected in whole-cell 
DNA. Further, 5mdC was detected in mtDNA isolated from both crude mitochondria and 
gradient-purified mitochondria and moreover, were not significantly different from each other.  
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To account for inter-sample variation due to the possibility of differential enzymatic digestion, 
sample preparation and downstream analysis, the absolute values of 5mdC were normalized by 
the amount of dC and the sum of 5mdC and dC, and subsequently represented in terms of 
percentages as shown in Figure 4B-C. 5mdC percentages were found to be comparable between 
whole-cell DNA and mtDNA extracted from crude and gradient-purified mitochondria, 
approximately 3% in each of them. These results suggest that mtDNA has similar percentage 
methylation as the nuclear DNA in SH-SY5Y cells. Our results for percentage methylation are in 
agreement with that reported for both the nuclear DNA (Laurent, Wong et al. 2010) and mtDNA 
(Pollack, Kasir et al. 1984, Rebelo, Williams et al. 2009, Byun, Panni et al. 2013) in literature 
and remain quite consistent in all our other experiments conducted using SH-SY5Y cell line 
assuring our methodology to be reliable.  
Purity characterization of mtDNA extracted from crude and gradient-purified mitochondria 
Next, we characterized purity of our mitochondrial preparations in comparison to the whole-cell 
lysates. The purity of the preparation of mitochondria at protein level was determined by the 
presence of VDAC (mitochondrial-marker), HDAC1 (nuclear-marker) and ß-Tubulin (cytosolic-
marker) as shown in Figure 5A. Both the crude and gradient-purified preparations of 
mitochondria were highly enriched in mitochondrial content as observed by the remarkable 
increase of VDAC levels in them compared to whole cell lysate. Minimal nuclear contamination 
was found in the crude mitochondrial preparations, whereas gradient-purified mitochondria did 
not have any detectable nuclear contamination, as observed by the presence of HDAC1 in them. 
Further, cytosolic contamination was minimal in the crude preparation of mitochondria and not 
detectable in gradient-purified mitochondria in comparison to the whole-cell lysates. These 
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results indicate that the crude and gradient-purified mitochondria are free of nuclear 
contamination at protein level considerably.  
MtDNA extracted from crude-preparation of mitochondria was seen as a single band, with no 
apparent smear, thus suggesting the absence of nuclear DNA (Figure 3B). However, we wanted 
to assess nuclear DNA contamination in a quantitative way and not just qualitatively as studied 
previously (Infantino, Castegna et al. 2011). In order to address the possibility of nuclear DNA 
contamination in mtDNA isolated from crude and gradient-purified mitochondria, qPCR-based 
method was used to determine the levels of mtDNA and nuclear DNA by amplifying 18S rRNA 
and 16S rRNA. We report that 97.5% of nuclear DNA was excluded from mtDNA isolated from 
the crude preparation of mitochondria and mtDNA obtained in such a manner, was enriched by 
45 fold (as determined by measuring 16S/18S ratio) in comparison to the whole-cell DNA, 
whereas 99.1% of nuclear DNA was eliminated from mtDNA isolated from the gradient-purified 
preparation of mitochondria and was enriched by 115 fold in comparison to the whole-cell DNA 
as depicted in Figure 5B-C.  
Linear regression analysis of percentage methylation and percentage mtDNA in 
mitochondrial preparations suggests presence of mtDNA methylation 
Considering the substantial difference in the size between nuclear genome and mitochondrial 
genome (33138 bases in mtDNA and 1.28 X 10
10 
bases in nuclear DNA), the small fraction of 
nuclear DNA remaining in mitochondrial DNA preparations (0.88% in gradient purified 
mitochondria with respect to whole-cell), can potentially cause significant contribution to the 
detected 5-methyl cytosine and thus, confound our analysis. In contrary to the small size of 
mitochondrial genome with respect to that of the nuclear genome, mtDNA is present in 
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numerous copies (thousands) per copy of nuclear genome which should also be considered in 
analysis. Thus, we adopted a conservative approach to estimate fraction of bases of mtDNA 
present with respect to nuclear bases in each sample, from the percentage of nuclear DNA 
eliminated and the fold-enrichment of mtDNA. We have also accounted for the ratio of number 
of bases in the mtDNA to that of nuclear DNA as well as mtDNA copy number w.r.t the copy of 
nuclear DNA in each sample of DNA preparation (whole-cell DNA, crude and gradient-purified 
mtDNA). The estimated percentages of mtDNA obtained were found to be 0.6% ± 0.13, 21% ± 
4.06 and 41% ± 5.06 for whole-cell DNA, crude mtDNA and gradient-purified mtDNA, 
respectively.  
Next, a linear regression analysis of percentage of mtDNA in a sample of DNA (with increasing 
purity levels of mtDNA) with its respective percentage methylation was performed to determine 
whether mtDNA methylation contributes significantly to overall observed methylation levels. 
Analysis was performed using triplicates for whole-cell DNA, crude and gradient-purified 
mtDNA signifying levels of increasing purity. Assuming the arbitrary rates of methylation for 
mtDNA and nuclear DNA as M and N respectively, the four possible scenarios of regression 
models are depicted in Figure 6A-D. Figure 6A represents the scenario assuming M to be 0 (i.e. 
no mtDNA methylation) with a negative slope (β < 0). Figure 6B represents a similar scenario of 
negative slope but where mtDNA methylates at a level greater than 0 but lesser than that of 
nuclear DNA (i.e. M>0 and M<N). Figure 6C represents the scenario where mtDNA methylates 
at a rate equal to that of nuclear DNA (M=N). Figure 6D represents the scenario where the rate 
of mtDNA methylation is greater than that of the nuclear DNA and where β would be greater 
than zero (positive slope). Our simple linear regression analysis revealed a significant correlation 
between percentage mtDNA and percentage methylation levels corresponding to the scenario as 
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depicted in Figure 6D with a p value of 0.00879 and coefficient of regression β = 3.333, with 
95% confidence interval of (0.780, 5.885) which does not include 0, as shown in Figure 6E. 
This suggests that mtDNA methylation occurs at an observable level at least as much as 
methylation for nuclear DNA.   
MtDNA methylation observed by methylation-specific PCR at a site-specific level 
As we observed presence of methylation at global levels in DNA obtained from purified-
mitochondria of SH-SY5Y cells, we wanted to confirm our findings using an alternate strategy. 
Therefore, we investigated methylation in mtDNA at site-specific level using methylation-
specific PCR. MtDNA extracted from isolated mitochondria was treated with bisulfite leading to 
sulfonation of mtDNA which converts the unmodified cytosines to uracil whereas modified 
cytosines remain the same as bisulfite-treatment cannot de-aminate them by sulphonation. Thus, 
by using primers that specifically would amplify a region of mtDNA containing the unchanged 
cytosine in bisulfite-treated DNA (actually a modified C in the original DNA), presence of 
methylated cytosines can be detected by methylation-specific PCR as diagrammatically 
represented in Figure 7A. 
There are 435 CpG sites in the Cambridge reference sequence of human mtDNA. By using the 
MethPrimer software (Li and Dahiya 2002) for prediction of CpG islands according to the 
criteria:- Island size > 100 bp, GC Percent > 30.0, Observed/Expected > 0.6, 44 CpG islands 
were found in human mtDNA. We selected a CpG island in 12s rRNA for further site specific 
study. 12s rRNA has been previously studied by several groups where mtDNA methylation has 
been determined (Shock, Thakkar et al. 2011, Byun, Panni et al. 2013, Iacobazzi, Castegna et al. 
2013) and its functional association is shown (Byun, Panni et al. 2013). We designed 
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methylation-specific primers for a specific site in selected CpG island of 12s rRNA as per the 
recommendations published previously (Li 2007). A single band of PCR product indicated 
presence of methylation at this site as shown in Figure 7B. Additionally as negative-controls, we 
used ‘Long PCR of mtDNA’ as the template under the same PCR conditions that did not amplify 
a band, similar to the ‘no template’ PCR reaction indicating specificity of our primers and thus, 
our method.  
2.5 DISCUSSION 
The status of mtDNA methylation has remained questionable since 1970’s due to limitations of 
the approaches used (van der Wijst and Rots 2015). Nevertheless, involvement of mtDNA 
methylation in regulating transcription of mtDNA-encoded genes and subsequently 
mitochondrial function is being contemplated (Chestnut, Chang et al. 2011, Shock, Thakkar et al. 
2011, Bellizzi, D'Aquila et al. 2013, Iacobazzi, Castegna et al. 2013, Pirola, Gianotti et al. 2013, 
Wong, Gertz et al. 2013). In this study, a highly specific and direct method of HPLC-ESI-
MS/MS was established to determine the presence and quantify global mtDNA methylation in 
SH-SY5Y neuroblastoma cells, along with addressing the issues regarding nuclear DNA 
contamination and the possibility of differential enzymatic digestion of DNA. We have for the 
first time reported presence of methylation, at global level, in human mtDNA prepared from 
gradient-purified mitochondria. Further, our results about percentage methylation in SH-SY5Y 
mtDNA are consistent with that reported previously using different approaches other than 
HPLC-ESI-MS/MS (Pollack, Kasir et al. 1984, Rebelo, Williams et al. 2009, Byun, Panni et al. 
2013). Moreover, existence of methylation in SH-SY5Y mtDNA was further substantiated using 
methylation-specific PCR for a specific site in 12S rRNA. 
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Variability in DNA digestion efficiency and possibility of nuclear contamination are the two 
critical issues that should be addressed carefully for accurate quantification of mtDNA 
methylation by HPLC-MS (Dahl and Guldberg 2003). Unlike a previous study (Infantino, 
Castegna et al. 2011) that has determined mtDNA methylation levels by HPLC-MS/MS using 
external standard curves derived from analytical-grade nucleosides, our study utilized oligo-
deoxy-nucleotides with known amounts dC and 5mdC as calibrators, so that the possibility of 
differential digestion efficiency is accounted in the calibration curve. Thus, our methodology 
used for calibration is more similar and replicative of the actual process of DNA digestion. 
Further, previous studies have employed the Crain method for digestion of mtDNA (Crain 1990), 
which is  a three-step digestion process requiring prior denaturation of DNA and adjustments of 
pH/incubation temperature at different stages. Here we used a much simplified protocol where 
the nuclease was substituted by Benzonase requiring just one step digestion as described 
previously (Quinlivan and Gregory 2008), thus reducing the chances of variability introduced 
during digestion process. Furthermore in our study, we ensured linear and proportional digestion 
of oligo-deoxy-nucleotides as well as mtDNA and the used concentrations of the test samples 
were within this range for reliable measurements.  
In the current study, the possibility of nuclear DNA contamination was addressed critically and 
assessed both qualitatively and quantitatively compared to previous study where this issue was 
poorly reported and addressed only qualitatively using less sensitive approaches (Infantino, 
Castegna et al. 2011). The purity of our mitochondrial preparations, at protein level, was 
assessed by determining the presence of nuclear-marker and was found to be significantly free of 
nuclear contamination. Further, isolated mtDNA displayed a single band on agarose gel 
suggesting minimal levels of nuclear DNA contamination. Moreover, qPCR-assisted 
54 
  
measurements of nuclear contamination suggested that 99.12% of nuclear DNA was eliminated 
from mtDNA isolated from the gradient-purified preparation of mitochondria and our mtDNA 
preparations were highly enriched (up to 115 fold) for mtDNA compared to whole cell DNA. 
Although we found only 0.88% of nuclear DNA remaining in gradient purified mitochondria 
w.r.t. whole cell DNA, this can be substantial relative to the amount of mtDNA as mitochondrial 
DNA comprises only a small fraction (less than 1%) of total cellular DNA (because of its very 
small size, in spite of being present in numerous copies). The estimated percentages of mtDNA 
were found to be 0.6%, 21% and 41% for whole-cell DNA, crude mtDNA and gradient-purified 
mtDNA, respectively after accounting for difference in size of nuclear genome compared to 
mitochondrial genome and also accounting for the mitochondrial DNA copy number. Thus, the 
fraction of nuclear DNA contamination was estimated to be substantial relative to the mtDNA 
present in purified mitochondrial preparations and caution must be placed while interpreting our 
results. However, linear regression analysis performed between percentages of mtDNA in whole-
cell DNA and mtDNA extracted from mitochondrial preparations (with increasing purity levels) 
with its respective percentage methylation, suggested that mtDNA methylation does contribute 
significantly to overall methylation and mtDNA methylation occurs at least  at levels  similar to 
methylation for nuclear DNA. Although our results suggested significant presence of mtDNA 
methylation at global levels, additional studies will need to be conducted in future to achieve 
more purified mtDNA in order to substantiate our findings.  
Lack of methods to isolate completely pure mitochondrial DNA is a bottleneck in the field of 
mitochondrial DNA methylation. A recent study (Jayaprakash, Benson et al. 2015) established a 
method to isolate mtDNA from whole-cell DNA using repetitive treatments with Exonuclease V 
to achieve 98% pure mtDNA. As Exonuclease V selectively degrades single stranded DNA in 
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ATP-dependent manner, the rationale was to eliminate single stranded DNA fragments most 
likely derived from the nuclear genome, while keeping the circular mtDNA intact. Along similar 
lines, we attempted purifying mtDNA using repetitive treatments with Exonuclease V followed 
by column purification. In order to achieve higher purity, we used DNA extracted from isolated 
mitochondria for Exonuclease V-treatment, instead of just using whole cell DNA, as used in the 
above mentioned study. Our preliminary data (n =1) suggested unprecedented enrichment of 
about 1300 fold for mtDNA (compared to 115 fold enrichment in gradient purified mtDNA) 
using this combinatorial approach of mitochondrial isolation and Exonuclease V treatment. It 
should be mentioned that crude mitochondrial isolation technique was utilized for this study; 
thus, we speculate that using gradient purification of mitochondria along with Exonuclease V 
treatment can further improve the purity of mtDNA preparation. Further studies will need to be 
conducted in the future in order to examine the reproducibility of this approach followed by 
analysis of methylation level both at global levels using our established HPLC-MS assay and at 
specific site using methylation-specific PCR assays. 
Apart from studying mtDNA methylation at global levels using HPLC MS/MS, the presence of 
methylation in SH-SY5Y mtDNA was further substantiated using methylation-specific PCR for 
a specific site in 12S rRNA. Although, in our study we used long PCR of mtDNA (an un-
methylated amplicon of mtDNA) as negative control, the possibility of obtaining methylation 
from insertions of mitochondrial DNA in the nuclear genome (NUMT) needs to be ruled out by 
utilizing ρ0 cell lines that lack functional mtDNA, as a negative control in addition to un-
methylated amplicon of mtDNA. In a preliminary study, our methylation-specific primers 
amplified a product from SH-SY5Y ρ0 cell line raising potential concern about the specificity of 
primers for mitochondrial genome. However, this analysis requires further confirmatory studies  
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as amplification was also observed from un-methylated amplicon of mtDNA in this study (which 
was not observed in any of our previous studies) raising concern about possible reagent 
contamination  that needs to be resolved and carefully examined in future. Further, this analysis 
can also be confounded by the fact that, although ρ0 cell lines cannot form a functional 
respiratory chain, but they might have fragments of mtDNA from damaged mtDNA. 
Alternatively, to address specificity of methylation-specific primers, BLAST analysis was 
performed which revealed 100% match of primers only to the mitochondrial sequence. However, 
two nuclear hits in chromosome 11and 17 were also identified, but with less than 85% match and 
mismatches being in the reverse primer sequence suggesting less likely amplification from these 
sites. Further, it should be noted that the site-specific analysis was conducted using isolated 
mitochondria where majority of nuclear DNA contamination is eliminated. Also, in contrast to 
analysis of global nuclear contamination, where small residual nuclear DNA can be substantial 
compared to mtDNA at global levels due to difference in the size of two genomes, for the 
specific site studied using methylation specific primer, as mentioned above, only two potential 
sites of NUMT exist while copy number of mitochondrial 12S rRNA is in thousands. Although 
all these data suggests higher possibility of the amplification being obtained from SH-SY5Y 
mtDNA instead of the nuclear pseudogenes, further confirmatory studies should be conducted by 
sequencing the methylation specific PCR products and comparing the sequence to mitochondrial 
genome and potential pseudogene sites and also by following up studies conducted using SH-
SY5Y ρ0 cell line.  
A limitation of using HPLC-ESI-MS/MS to determine global mtDNA methylation levels is that 
the frequency of methylation at specific sites in mtDNA cannot be estimated. However, site-
specific studies of mtDNA methylation performed by methylated-DNA-IP and bisulfite- 
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sequencing have not considered the heteroplasmy that can be present in mtDNA. By studying 
global mtDNA methylation using HPLC-ESI-MS/MS, we have accounted for the possibility of 
heteroplasmy present in mtDNA. Further, the method of HPLC-MS/MS entails direct 
determination of methylated cytosines using the approach of analytical chemistry, making it 
more sensitive, specific and reproducible compared to other methods which are based on indirect 
measurements such as bisulphite-sequencing  (which requires bisulphite conversion that does not 
differentiate 5mdC and 5-hydroxy-methyl cytosine), Methylated-DNA-IP and 5-mC-ELISA 
(requires antibody-mediated- binding to 5mdC in DNA) (Dahl and Guldberg 2003). 
In conclusion, we established a direct and specific method to quantify global methylation in 
mtDNA using HPLC-MS/MS and addressed issues of variable DNA digestion and the possibility 
of nuclear DNA contamination.  Further, we reported for the first time, presence of methylated 
DNA in gradient-purified SH-SY5Y mitochondria suggesting presence of mtDNA methylation 









Figure 1 Characterization of dA, dG, dT, dC and 5mdC by HPLC-ESI-MS/MS: (A) 
Description of nucleosides including structure, molecular weight and the MRM transitions 
followed for quantification of respective nucleosides. (B) Typical chromatograms obtained from 
equimolar mixture of dA, dT, dG and dC showing peaks corresponding to MRM transitions 
followed for dA, dT, dG and dC. (C) Representative linear equations with coefficient of 
regression derived from calibration curve of each nucleoside which were obtained from 
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equimolar mixture of dA, dT, dG and dC (10 -100 pmoles). (D) Chromatogram obtained from 25 
fmol of 5mdC (LOD) in equimolar mixture of dA, dT, dG and dC showing peak corresponding 
to MRM transition followed for 5mdC quantification (E) Representative calibration curve for 
5mdC (1-20 pmoles) in equimolar mixture of  dA, dT, dG and dC (40 pmoles of each). (F) 
Measured 5mdC levels derived from calibration curve were plotted against nominal 5mdC levels 









For legend, see next page 
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Figure 2 Linear digestion and quantification of nucleosides in oligo-deoxy-nucleotides 
containing methylated and un-methylated cytosine: Representative calibration curves plotting 
nominal amounts against Area under curve (AUC) for dA, dT, dG, and dC derived from 
digestion products of custom-made (A) un-methylated oligo-deoxy-nucleotide and (B) 
methylated oligo-deoxy-nucleotide. (C) Representative calibration curve for 5mdC derived from 
digestion products of custom-made methylated oligo-deoxy-nucleotide showing linear digestion. 
Total DNA content for analyzed oligo-deoxy-nucleotide ranged from 0.04 to 0.8 µg and 
corresponding nominal levels of each nucleoside are shown on X-axis. (D) Measured 5mdC 
levels (derived from calibration curve) plotted vs. nominal 5mdC levels present in oligo-deoxy-





For legend, see next page 
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Figure 3 Linear and proportional detection of nucleosides in SH-SY5Y mtDNA: (A) 
Schematic representation of processing samples upstream of HPLC-MS/MS analysis including 
mtDNA isolation and digestion. (B) Representative image of 1% agarose gel showing the 
presence of single band for isolated mtDNA before digestion and the resulting smear after 
enzymatic digestion. (C) – (G) Measured levels of nucleosides (derived from methylated oligo-
deoxy-nucleotide calibration curves) plotted against the amount of DNA present in SH-SY5Y 
mtDNA samples before digestion showing linearity of digestion for each nucleoside. Total DNA 












Figure 4 Detection of 5mdC in mtDNA extracted from crude and gradient-purified 
mitochondria: 5mdC was quantitated using HPLC-ESI-MS/MS in ‘Long PCR of mtDNA’, 
whole-cell DNA and mtDNA extracted from crude and gradient-purified mitochondria, after they 
were digested into nucleosides. The 5mdC levels are represented as (A) absolute values 
(pmoles/µg DNA) and as percentages of (B) 5mdC/dC and (C) 5mdC/(dC + 5mdC). At level of 




For legend, see next page 
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Figure 5 Purity of the preparation of mitochondria and mtDNA extracted from crude and 
gradient-purified mitochondria: (A) Whole-cell lysates, mitochondrial lysates of crude and 
gradient-purified mitochondria of SH-SY5Y were checked for the presence of VDAC, ß-Tubulin 
and HDAC1 to determine purity of the isolated mitochondria using western blot analysis. Whole-
cell DNA and mtDNA from crude and gradient-purified mitochondria were extracted from equal 
number of SH-SY5Y cells. (B) Percentage of nuclear DNA eliminated in mtDNA extracted from 
crude and gradient-purified mitochondria were determined with respect to whole-cell DNA. (C) 
Fold-enrichment of mtDNA was determined in mtDNA extracted from crude and gradient-












Figure 6 Linear regression analysis of percentage methylation levels and percentage 
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 mtDNA in mitochondrial preparations: M and N are the arbitrary level of methylations for 
mitochondrial and nuclear DNA respectively. (A) to (D) shows scenarios representing 
relationship between percentage methylation levels and percentage mtDNA based on linear 
regression modeling when (A) M=0, (B) M > 0 and M < N, (C) M > 0 and M=N and (D) M>0 
and M>N. (E) Linear regression analysis based on experimental data set showing correlation 
between percentage methylation and percentage mtDNA using preparation of mitochondria with 












Figure 7 Detection of methylation in mtDNA at 12S rRNA by methylation-specific PCR 
following bisulfite treatment: (A) Flowchart depicting the isolation of mtDNA, its bisulfite-
conversion and amplification using methylation-specific primers and semi-quantitative 
assessment by agarose-gel electrophoresis. (B) Methylation-specific primers for specific site in 
12s rRNA were used to amplify from bisulfite-treated mtDNA and ‘Long- PCR’; subsequent 
PCR products were electrophoresed through 1% agarose-gel containing ethidium bromide and 














CHAPTER III: ALTERATIONS IN MTDNA METHYLATION BY DNMT1 
OVEREXPRESSION & 5-AZA-DC TREATMENT AND ITS ASSOCIATION WITH 
MITOCHONDRIAL TRANSCRIPTION AND MITOCHONDRIAL FUNCTION IN SH-
SY5Y NEUROBLASTOMA CELL LINE 
 
 
















Functional significance of mitochondrial DNA (mtDNA) methylation has largely remained 
unchartered in the past. However, recent discoveries regarding presence of DNA Methyl-
Transferases (DNMTs) in mitochondria, existence of mitochondrial isoform of DNMT1 and 
studies demonstrating the association of mtDNA methylation with various patho-physiological 
conditions have led to speculations about contribution of mtDNA methylation in regulating 
transcription of mtDNA-encoded genes and mitochondrial function, which remain untested. 
Further, any direct role of DNMTs in altering mtDNA methylation is yet to be established. In 
this study, we investigated if mtDNA methylation can be altered by different experimental 
approaches and whether this alteration in mtDNA methylation has any influence on 
mitochondrial transcription and mitochondrial function in SH-SY5Y neuroblastoma cell line. In 
order to investigate whether mtDNA methylation can be altered, DNMT1 overexpression and 
treatment with DNA methylation inhibitor (5-az-2’-deoxycytidine or 5-aza-dC) were 
implemented as experimental strategies. Global mtDNA methylation was assessed by HPLC-
ESI-MS/MS and site-specific methylation of 12S rRNA was examined by methylation-specific 
primer.  DNMT1 was found to be present in purified mitochondria extracted from SH-SY5Y 
cells. Interestingly, transient overexpression of DNMT1 in SH-SY5Y increased mtDNA 
methylation at global levels as well at a specific site in 12S rRNA. This corresponded with 
decreased transcription of mtDNA-encoded genes and reduced basal-mitochondrial oxygen 
consumption rate upon overexpression of DNMT1. In contrast, treatment of SH-SY5Y by DNA 
methylation inhibitor (5-aza-dC) reduced levels of mtDNA methylation, which corresponded 
with increased transcription of mtDNA-encoded genes. However, mitochondrial oxygen 
consumption rate was reduced after 5-aza-dC treatment, similar to DNMT1 overexpression. In 
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conclusion, we report that mtDNA methylation is an alterable phenomenon, which can be 
influenced by levels of DNMT1 and treatment with DNA methylation inhibitor and is associated 



















DNA methylation is known to play a key role in regulation of nuclear gene-expression (Bestor 
2000, Jones 2012). DNA methylation is catalyzed by a group of enzymes called DNA Methyl-
Transferases (DNMTs) that transfer a methyl group from S-Adenosine-Methionine (SAM) to the 
C5 position of cytosine residue to generate 5-methyl-cytosine (5mdC). DNMT family consists of 
the de novo DNA Methyl-Transferases (Okano, Bell et al. 1999), namely DNMT3A and 
DNMT3B and the maintenance DNA Methyl-Transferase -DNMT1 (Li, Bestor et al. 1992), 
which copies the methylation onto the nascent un-methylated strand of DNA formed during 
DNA replication.  
Mitochondria are bi-genomically encoded by two genomes - the nuclear and mitochondrial 
genome (mtDNA). Along with 24 rRNAs/tRNAs that are essential for mitochondrial translation, 
mtDNA encodes for 13 proteins required for mitochondrial function. Although nuclear DNA 
methylation and its role in gene expression are well established, mtDNA methylation and its role 
in regulating the expression of mtDNA-encoded genes were largely overlooked until some recent 
studies. Latest reports regarding existence of mitochondrial isoform of DNMT1 (mtDNMT1) 
(Shock, Thakkar et al. 2011) and localization of DNMTs (including DNMT1 (Chestnut, Chang et 
al. 2011, Shock, Thakkar et al. 2011, Bellizzi, D'Aquila et al. 2013), DNMT3A (Chestnut, Chang 
et al. 2011, Wong, Gertz et al. 2013) and DNMT3B (Bellizzi, D'Aquila et al. 2013)) in 
mitochondria, coupled with possible histone-like role of TFAM (Kanki, Nakayama et al. 2004, 
Shutt, Lodeiro et al. 2010, Lodeiro, Uchida et al. 2012), have revived interest in studying 
mtDNA methylation and its functional significance. Mitochondrial isoform of DNMT1 has been 
reported to be encoded from start sites upstream of the conventional open reading frame (ORF) 
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and its expression is regulated by NRF1 and PGC1-α, which are transcription factors that control 
expression of nuclear-encoded genes for mitochondrial biogenesis. Further, mtDNMT1 was 
found to interact with mtDNA at CpG sites (Shock, Thakkar et al. 2011). However, direct role of 
mtDNMT1 or any other DNMTs in mtDNA methylation is not yet known. 
Alterations in mtDNA methylation have been reported in samples obtained from human subjects 
with various pathological conditions (such as Non-Alcoholic Fatty Liver Disease (NAFLD) 
(Pirola, Gianotti et al. 2013), Down-Syndrome (Infantino, Castegna et al. 2011), colorectal 
cancer (Feng, Xiong et al. 2012), insulin-resistance (Zheng, Linarelli et al. 2015) and 
cardiovascular disease (Baccarelli and Byun 2015)),  during developmental-stages of brain 
(Ghosh, Sengupta et al. 2014) and upon exposure to air-borne heavy-metals in blood (Byun, 
Panni et al. 2013) and placenta (Janssen, Byun et al. 2015). Abnormalities of 16S rRNA 
methylation were found in mtDNA obtained from the skeletal muscle and spinal cord in a mice-
model for Amyolateral sclerosis (Wong, Gertz et al. 2013). In few of these reports, correlations 
of mtDNA methylation were observed with the expression of mtDNA-encoded genes (Feng, 
Xiong et al. 2012, Byun, Panni et al. 2013, Pirola, Gianotti et al. 2013, Wong, Gertz et al. 2013), 
thus raising the possibility that mtDNA methylation and transcription of mtDNA-encoded genes 
are connected. However, no studies have tested a direct link yet. Although, mitochondrial 
dysfunction is known to be present in the some of the above-mentioned pathological conditions, 
role of mtDNA methylation in altering mitochondrial function has not been explored either.   
In the current study, we investigated whether mtDNA methylation can be altered by 
overexpression of DNMT1 and treatment with DNA-methylation inhibitor (5-aza-deoxy-
Cytosine or 5-aza-dC) in SH-SY5Y cells and if changes in mtDNA methylation are linked with 
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mitochondrial transcription and mitochondrial function. We have found mtDNA methylation to 
be an alterable phenomenon, which can be affected by DNMT1 levels or 5-aza-dC treatment and 
is associated with changes in mtDNA transcription and mitochondrial function. 
3.3 MATERIALS AND METHODS 
Cell Culture and its harvest 
SH-SY5Y neuroblastoma cells were cultured in DMEM containing 25 mM glucose, 10% heat-
inactivated fetal bovine serum (FBS), 1% Pen-strep and maintained at 37°C, 5% CO2. Cell lines 
growing in the culture flasks or petri-dishes were rinsed with 1X Phosphate Buffered Saline 
(PBS), trypsinized and then harvested using the growth media. The harvested cells were then 
pelleted at 800g for 5 minutes at 4°C and subsequently washed with 1X PBS at 4°C for 
subsequent downstream procedure. 
Plasmid preparation and overexpression of DNMT1 
PcDNA3/Myc-DNMT1 (Plasmid #36939) and the vector–backbone pcDNA3 were purchased 
from Addgene in the form of their bacterial stock and grown in Lurea Broth containing 1 µg/mL 
ampicillin for selection as described previously (Wilkins, Marquardt et al. 2012). The respective 
plasmids were isolated from the cultures using Endo-Free Plasmid Maxi Kit from Qiagen.  SH-
SY5Y cells were seeded and lipofectamine-mediated-transient- transfection in optimem  medium 
was carried out at 16 hours as described previously (Wilkins, Marquardt et al. 2012) , 48 hours 
post-seeding, the transfected cells were harvested for various experimental purposes. Details of 














6- well plates 7 X 10
5
 5 µg 5 µL 
mtDNA isolation  10 cm dish 7 X 10
6








 0.5 µg 1 µL 
 
DNA methylation inhibitor treatment 
5-aza-2’deoxycytidine (catalogue # A3656) was purchased from Sigma. SH-SY5Y cells were 
cultured in the growth medium containing 0, 5, 10 and 15 µM 5-aza-2’deoxycytidine for 48 
hours and maintained at 37°C, 5% CO2. SH-SY5Y cells were seeded at 15 X 10
6
 in T180 flasks 
for isolation of mitochondria and subsequently mtDNA was extracted from them. SH-SY5Y 
cells were seeded at 7 X 10
5
 in 60 mm petri-dishes for extraction of RNA, cDNA synthesis and 
to determine the transcript levels of mtDNA-encoded genes. SH-SY5Y cells were seeded at 5 X 
10
5
 in XF seahorse culture plate for the study of oxygen consumption rate. 
Isolation of crude and percoll-gradient purified mitochondria    
Crude preparation of mitochondria: Mitochondria were isolated as described previously 
(Kristian, Hopkins et al. 2006) with some modifications. Briefly, cells growing in a confluent 
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T180 flask were harvested as described above. The washed cell pellets were then re-suspended in 
MSHE buffer, collected in a pre-cooled cavitation chamber (nitrogen bomb; Parr Instrument 
Company, Moline, IL) and subjected to 900 psi for 15 minutes. The cell suspension is collected 
by releasing the pressure instantaneously and centrifuged at 1000g for 5 minutes at 4°C to pellet 
the cell debris. The supernatant was collected and spun at high speed of 20000g for 10 minutes at 
4°C. The pellet obtained was re-suspended in MSHE and is the crude preparation of 
mitochondria. 
Percoll gradient-purified mitochondria: Gradient-purified mitochondria were isolated in a 
modified version as described previously (Kristian, Hopkins et al. 2006). Percoll was purchased 
from GE-Healthcare (catalogue # 28-9038-48) and 100% percoll was prepared by mixing 9 parts 
of Percoll with 1 part of 1.5M NaCl. The crude pellet of mitochondria obtained is re-suspended 
in 800 µL of 15% percoll and layered on to a gradient of 50% and 21% percoll. The resulting 
percoll-gradient underwent ultra-centrifugation in a swing-bucket rotor system (SW 28.1 rotor) 
at 30,700 g for 15 minutes at 4°C. The pure mitochondria separated between 50 and 21% percoll, 
was collected, diluted with MSHE and then washed at 20,000 g for 15 minutes at 4°C twice. The 
pellet obtained is the percoll-gradient purified mitochondria.  
Mitochondrial lysate of crude and gradient-purified mitochondria were prepared using M-PER 
Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA). Protein concentrations for 




DNA extraction was done by the method based on organic-solvent extraction of DNA as 
described previously (Guo, Jiang et al. 2009). Briefly, the sample in ice-cold lysis buffer 
underwent dounce homogenization, followed by Proteinase K digestion at 55°C for 3h in a water 
bath. The mixture was spun to remove the non-soluble fractions and the DNA in the supernatant 
was extracted by standard Phenol-Chloroform-Isoamyl alcohol method. DNA was precipitated 
using Sodium Acetate and isopropanol at -20°C. The DNA pellet was washed twice with 70% 
ethanol. Finally, the extracted DNA pellet is then air-dried, re-suspended in nuclease-free water 
and then quantitated using Infinite M200 (Tecan, San Jose, USA).  
SH-SY5Y mtDNA extraction: The mitochondrial DNA was extracted from both the crude 
mitochondria for determining the amount of mtDNA methylation. Twenty million cells in a T180 
flask were seeded and harvested 48 hours later for extraction of mitochondria as described 
above. The isolated mitochondria were suspended in ice-cold Lysis buffer for DNA extraction as 
described above.  
Digestion of DNA 
Oligo-deoxy-nucleotides with known amount of dC and 5mdC and mtDNA obtained from SH-
SY5Y cells that were treated with 5-az-dC and in which DNMT1 was overexpressed, were 
digested as described previously (Quinlivan and Gregory 2008).  Briefly, known amount of the 
DNA of interest (2 µg) was digested in 100 µL reaction volume, using the enzymes- 2.5 U 
Benzonase (Sigma E1014), 3 mU Phosphodieasterase I (Sigma P3243) and 2U Alkaline 
Phosphatase (Sigma P7923) in Tris-HCl (20 mM. pH 7.9) containing 1 mM NaCl and 0.2 mM 




Reagents: 5-Methyl-2'-deoxycytidine (5MdC) was purchased from Berry & Associates, Dexter, 
MI (Catalogue# PY7635). The four other deoxyribonucleosides- 2’-deoxycytosine (dC), 2’-
deoxyguanosine (dG), 2’-deoxyadenosine (dA), and 2’-deoxythymidine (dT), were purchased 
from Sigma Chemical Co. (St. Louis, MO).  
Apparatus: Waters Acquity “Classic” (Waters Corp. Milford, MA) UPLC system was used with 
an Altima C18 column that had internal diameter of 2.1 mm and length of 50 mm, with sorbent 
particles of size 3.5 µm (Grace, Columbia, MD). Triple quadrupole mass-spectrometer (Quattro 
Ultima Micromass Ltd. Manchester, UK) was coupled with the UPLC system through electron-
spray probe for detection and quantification of nucleosides.  
LC-ESI-MS/MS Procedure: Released nucleosides in the digestion buffer of a particular sample of 
interest were separated by UPLC for MS/MS detection, adapting a general strategy used for 
separating a complex mixture of nucleosides. The injection volume used was 20 µL. LC 
separation was performed at a flow rate of  300 µL/minute. Two buffers, A: 10 mM ammonium 
acetate (NH4OAc) and B: 10% Methanol comprised the mobile phase that was used for elution 
of the nucleosides using the following gradient:  
Time    A%  B% 
(min)    
0.0  99  1  
1  99  1  
2  90  10  
9  20  80  
11  99  1  
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The mobile phase effluent were passed through the electrospray probe (source block 
temperature: 110
○
C, desolvation temperature: 200
○
C and cone voltage: 50V) and tandem mass 
spectra was acquired on triple quadrupole in multiple reaction monitoring (MRM) mode. The 
first quadrupole (Q1) that acts as a mass-filter, allowed a parent ion of a specific mass-to-charge 
ratio to enter the second quadrupole. The second quadrupole (Q2) is the collision cell, where 
Argon gas at a pressure of 2e-3 mbar was used to fragment the ions through the process of 
collision-activated disassociation (collision energy: 15 eV). The resulting fragment ions were 
transmitted to the third quadrupole (Q3), where only the daughter ions of a desired mass-to-
charge ratio were allowed to pass and reach the detector for further quantification to compose the 
tandem mass spectra.   Selected ion recordings for 5-Methyl-2'-deoxycytidine methylated 
(5MdC) was 242.1 (parent ion) >126.1 (daughter ion) and for the other nucleosides were dC: 
229.1>112.1, dT: 244.1>127.1, dA: 253.1>136.1, dG: 269.1>152.1 with 0.1 sec dwell time. To 
monitor instrument performance, every batch of samples were punctuated with duplicate 
preparations of 5MdC standard curve, ranging from 1 to 20 pmoles in a mixture of 40 pmoles of 
each of the nucleosides dA, dT, dG and dC in 10 mM NH4OAc as well as  only 10mM NH4OAc 
as the blank. Further, custom-made oligo-deoxy-nucleotide containing known amount of dC and 
5mdC were digested as described above and digestion products was used for generating  standard 
curve to calculate the amount of 5mdC in test  samples.   
Long PCR of human mtDNA 
SH-SY5Y mtDNA was extracted and used as template to generate a PCR product of 15.745Kb 
long  to represent the un-methylated version of human mtDNA as described previously (Binder, 
Dunn et al. 2005) using Expand Long Range, dNTPack (Roche Diagnostics) that served as a 
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negative control for methylation in methylation-specific primer assay.  The PCR product thus 
obtained was purified using Qiaquick PCR purification kit (Qiagen) before using it for HPLC-
ESI-MS/MS assay, following digestion and for methylation-specific PCR assay, following 
bisulfite-conversion.  
Bisulfite conversion and Methylation-specific PCR assay  
Bisulfite conversion: The extracted mtDNA of interest and ‘Long PCR’ was treated with bisulfite 
using EZ DNA methylation-Gold kit (Zymoresearch, Irvine, CA, USA). Bisulfite sulphonates 
and then deaminates the un-methylated Cytosine to produce uracil in DNA. Thus methylated 
cytosines are protected from the conversion to uracil, allowing the use of site-specfic PCR 
amplification i.e. methylation-specific PCR. Briefly, 350 ng of mtDNA in 20 µL nuclease-free 
water was mixed with 130 µL of CT Conversion reagent and was placed in the thermal cycler 
where the program consisted of initial denaturation at 98°C for 10 minutes, followed by 
conversion at 64°C for 2.5 hours. The converted solution of mtDNA was mixed with binding 
buffer to allow its binding to the column. A high speed spin was followed by washes, 
desulphonation for 20 minutes at room temperature and then finally eluted using the Elution 
buffer to obtain the bisulfite-treated DNA.  
After obtaining the converted mtDNA, the following primers were used to amplify a region of 
12S rRNA using the following PCR program. The primers were designed using the bisulfite 






PCR set up: .4 µM of the forward and reverse primer was used to amplify to obtain a 320 bp 
amplicon using ZymoTaq Premix (Zymoresearch, Irvine, CA, USA).  
PCR program: Initial denaturation of 10 mins at 95°C was followed by 30 cycles of denaturation 
at 95 °C for 30 secs, annealing at 51.5°C for 45 secs and synthesis at 72°C at 45 secs, with a final 
elongation step of 7 mins at 72°C. 
Agarose-gel-electrophoresis: The subsequent PCR products obtained were electrophoresed 
through 1% agarose gel containing 0.5 µg/ml ethidium-bromide and visualized under ultraviolet 
light using a Bio-Rad ChemiDoc Imager.  
RNA extraction 
RNA extraction was performed using TRI Reagent solution (Life technologies AM9738). 
Briefly, supernatant was removed and TRI was added to harvest the cells. The homogenate was 
incubated at room temperature to allow dis-association of the nucleoprotein complexes. 
Chloroform was used to separate the protein from the nucleic acids. RNA was precipitated using 
isopropanol; the pellet obtained was washed with 70% ethanol and then air-dried before re-
suspending in nuclease-free water. The extracted RNA is then further quantitated using Infinite 
M200 (Tecan, San Jose, USA) and ran on gel to assess its quality.  
cDNA synthesis 
1 µg of RNA was used to synthesize cDNA using iScript Reverse transcription 5X super-mix in 
a 20 µL reaction as per the recommendations in the protocol (Biorad 170-8840). The 20 µL 
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reaction was then diluted 5 times by adding 80 µL nuclease-free water. 2 µL of the diluted 
cDNA solution was used for every qPCR reaction.  
Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was performed using the TaqMan Universal PCR Master 
Mix (Applied Biosystems, Foster City, CA) and ready-to-use TaqMan Gene Expression Assays 
(Applied Biosystems). We quantified mRNA levels deriving from the following genes:  
DNMT1, MT-12S rRNA, MT-16S rRNA, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND5, 
MT-ND6, MT-COX1, MT-COX2, MT-CytB and MT-ATP6. GAPDH or β-Actin was used as an 
internal loading control.  
Quantitative real-time PCR (qPCR) was performed using the Sybr Green Universal PCR Master 
Mix (Applied Biosystems, Foster City, CA) for quantifying mRNA levels of  MT-DNMT1 using 
primers as used in (Dzitoyeva, Chen et al. 2012) and HPRT was used as an internal loading 
control.  
qPCR amplification was determined utilizing an Applied Biosystems StepOnePlus Real-Time 
PCR System (Applied Biosystems). 
Protein lysates from mitochondrial and cytosolic fractions 
Upon overexpression of DNMT1, protein lysates of mitochondrial and cytosolic fractions were 
prepared as described previously (Wilkins, Marquardt et al. 2012) using the 
Mitochondrial/Cytosol Fractionation kit from Biovision. Briefly, cells were harvested and re-
suspended in 1X Cytosolic extraction buffer, incubated on ice for 10 minutes and homogenized 
by dounce-homogenization. The homogenate was spun at 700 g for 10 minutes at 4°C and the 
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pellet obtained is the nuclear compartment.  The supernatant was collected and spun again at 
10000g for 30 minutes at 4°C. The pellet obtained is the mitochondria whereas the supernatant is 
the cytosolic fraction. Protein concentrations for all the lysates were determined using a BCA 
Protein Assay kit (BioRad). 
Immunoblotting 
Whole cell lysates were prepared by M-PER Mammalian Protein Extraction Reagent (Pierce, 
Rockford, IL, USA). Protein concentrations for all the lysates were determined using a BCA 
Protein Assay kit (BioRad).  
Equal amount of proteins from the protein lysates were resolved by electrophoresis in pre-cast 4–
12% gels (BioRad), and then transferred to polyvinyl di-fluoride (PVDF) membranes. Non-
specific binding was blocked by gently agitating the membranes in 5% non-fat milk and 0.1% 
Tween in PBS (PBST) for 1 hour at room temperature. Blots were subsequently incubated in 5% 
bovine serum albumin (BSA) containing 0.1% Tween with the designated primary antibody 
overnight at 4°C with gentle agitation. After PBST washes, the blot was then incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature with gentle agitation. After PBST washes, the blots were incubated with 
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Chemiluminescence signals 
were detected using a Bio-Rad ChemiDoc Imager.  
Primary antibodies for DNMT1, VDAC, ß-Tubulin, GAPDH were purchased from Cell 
Signaling Technology (Beverly, MA, USA) and that of HDAC1 was purchased from Pierce 
(Thermo Scientific, Eugene, OR, USA). All of the antibodies were used at a 1:1000 dilution.   
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Oxygen consumption rate (OCR) studies 
Approximately 50,000 cells of SH-SY5Y cells were seeded in the wells of Seahorse XF cell 
culture microplates (Seahorse Bioscience, Billerica, MA) and standard two-step seeding 
procedure was performed as per the manufacturer’s recommendations.  The XF cell culture 
microplates were placed in a 37
o
, 5% CO2 incubator for the cells to proliferate. The assays were 
done 48 hours post seeding. Twenty four hours post seeding, the cells were starved off FBS into 
a buffered DMEM medium containing 5mM glucose. On the assay day (48 hours post seeding),  
before placing culture microplates in the Seahorse Analyzer, the cells were washed with un-
buffered DMEM containing 5mM glucose and 2 mM pyruvate and then placed in the same 
medium for an hour in an incubator without CO2 at 37°C for degassing.  OCR respiration 
measurements were collected after every cycle of 3 minutes of mixing, 2 minutes of wait time, 
followed by measurements for 3 minutes by the Seahorse Analyzer and the entire assay was 
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The non-mitochondrial OCR was subtracted from the total OCR to yield the mitochondrial OCR.  
The proton-leak OCR was obtained by subtracting the non-mitochondrial OCR from the post-
oligomycin OCR whereas the maximal OCR was calculated by subtracting the non-
mitochondrial OCR from the post-FCCP OCR.  After OCR measurements were completed, the 
cell mass in each well was estimated by measuring the total protein in each well (DC Protein 
Assay, BioRad). OCR values from each well were normalized to the amount of protein in that 
well to yield a final corrected OCR in pMol O2/minute/µg protein.  
Data analysis 
Data are expressed as means ± standard error of the means (SEM).To compare means between 
two groups we used two-way, unpaired Student’s t-tests, with p-values of <0.05 considered 
significant.   
3.4 RESULTS 
Presence of DNMT1 in SH-SY5Y mitochondria and its overexpression 
DNMT1 is one of the members of the family of DNA methyl transferases that transfer methyl 
group to the cytosine in DNA to yield 5-methyl-cytosine (5mdC). Recently, DNMT1 localization 
in mitochondria was reported for several cell lines (Chestnut, Chang et al. 2011, Shock, Thakkar 
et al. 2011, Bellizzi, D'Aquila et al. 2013). Additionally, existence of mitochondrial isoform of 
DNMT1 (mtDNMT1) was also reported recently, which was found to bind mtDNA at CpG sites 
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(Shock, Thakkar et al. 2011). However, role of DNMT1 in mtDNA methylation is not yet 
established which was investigated in the current study. To begin with, we isolated crude 
fractions of mitochondria from SH-SY5Y cells and found DNMT1 to be present in them. In 
order to rule out the possibility of contamination of nuclear DNMT1 in our crude fractions of 
mitochondria, we extracted gradient-purified mitochondria by a percoll-gradient.  DNMT1 was 
also found to be present in gradient-purified mitochondria isolated from SH-SY5Y cells (Figure 
1A). Further, the purity of the preparation of each mitochondrial fraction (crude and gradient-
purified mitochondria) was determined by the presence of VDAC (mitochondrial-marker) and 
HDAC1 (nuclear-marker). These results indicate the presence of DNMT1 in the mitochondria of 
SH-SY5Y cells. 
Next, we transiently overexpressed DNMT1 in SH-SY5Y cells in order to study its effects on 
mtDNA methylation and subsequently mitochondrial transcription and mitochondrial function. 
Relative mRNA levels of DNMT1 (Figure 1B) as well as mtDNMT1 (Figure 1C) were 
significantly elevated in cells transfected with the plasmid DNA containing DNMT1 gene in 
comparison to the cells transfected with the empty vector- backbone. DNMT1 protein was found 
to be increased in the cytosolic, mitochondrial, nuclear fractions as well as whole-cell lysates of 
the cells transfected with the plasmid DNA containing DNMT1 gene in comparison to the cells 
transfected with the empty vector-backbone as depicted in Figure 1D. The purity of the 
preparation of each fraction was determined by the presence of VDAC (mitochondrial-marker), 
HDAC1 (nuclear-marker) and GAPDH (cytosolic-marker). Cells transfected with the empty 
vector backbone will be referred to as “control” whereas the cells that were transfected with the 
vector backbone containing DNMT1 gene will be referred to as “oDNMT1”. 
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Overexpression of DNMT1 increases mtDNA methylation 
Next, we investigated whether mtDNA methylation was affected by overexpression of DNMT1 
in SH-SY5Y cells. Using HPLC-ESI-MS/MS, total mtDNA methylation was measured in 
‘control’ and ‘oDNMT1’ cells. Absolute 5mdC levels were found to be significantly increased 
(about 2.5 fold) in mtDNA from ‘oDNMT1 cells’ compared to ‘control cells’ as shown in Figure 
2A. Absolute 5mdC levels were further normalized by the amount of dC and the sum of dC and 
5mdC. Both the percentages were significantly higher in the mtDNA from ‘oDNMT1 cells’ than 
‘control cells’ as shown in Figure 2B-C. We also examined methylation at a specific site in 12S 
rRNA in bisulfite-treated mtDNA from both the ‘oDNMT1’ and ‘control’ cells using 
methylation specific primers. A single band of PCR product with remarkably higher density was 
amplified from bisulfite-treated mtDNA of ‘oDNMT1 cells’ compared to ‘control cells’ as 
shown in Figure 2D. No band was detected in the lane that was loaded with PCR product 
obtained by using the un-methylated “Long PCR” as a template (negative-control) with the 
methylation specific primers. These results indicate that overexpression of DNMT1 in SH-SY5Y 
cell line increases mtDNA methylation. Also, this suggests that mtDNA methylation is an 
ongoing process in the mitochondria that can be further stimulated by overexpression of 
DNMT1.  
Overexpression of DNMT1 decreases mtDNA transcription 
MtDNA encodes for 2 ribosomal RNAs, 22 tRNAs and 13 mRNAs which contribute to the 
formation of the apparatus essential for oxidative phosphorylation, a prime function of 
mitochondria (Scarpulla 2008). We examined if the increased methylation of mtDNA by 
DNMT1 overexpression had any correlation with transcription levels of mtDNA-encoded genes. 
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Relative expression levels of mitochondrial ribosomal genes -12S rRNA and 16S rRNA were 
examined and found to be significantly decreased in ‘oDNMT1 cells’ as shown in Figure 3A 
and 3B, respectively. Relative mRNA levels of several Complex I encoding genes such as MT-
ND1, MT-ND2, MT-ND3, MT-ND5 and MT-ND6 were also significantly reduced in ‘oDNMT1 
cells’ compared to ‘control cells’ as represented in Figure 3C-E, G-H, however that of MT-ND4 
(Figure 3F) were not significantly different between the two groups. Further, relative mRNA 
levels of MT-CytB, which is a single gene present in mtDNA that codes for Complex III, was 
significantly reduced in ‘oDNMT1 cells’ than ‘control cells’ as shown in Figure 3I. Similarly, 
relative mRNA levels of MT-COX2 (Figure 3K) and MT-ATP6 (Figure 3M) that encode for 
Complex IV and ATP synthase, were assayed and found to be significantly reduced as well in 
‘oDNMT1 cells’ compared to ‘control cells’. However, relative mRNA levels of MT-COX1 
(Figure 3J) and MT-COX3 (Figure 3L) encoding for Complex IV were found to be comparable 
between ‘control cells’ and ‘oDNMT1 cells’. These results indicate that overexpression of 
DNMT1 in SH-SY5Y cells reduces the levels of mtDNA transcription in general; suggesting that 
increase in mtDNA methylation upon overexpression of DNMT1 is associated with decreased 
mitochondrial transcription.  
Overexpression of DNMT1 affects mitochondrial oxygen consumption rate (OCR) 
As proteins that form the mitochondria are encoded by both nuclear as well as mitochondrial 
genes, alteration in mitochondrial transcription can affect mitochondrial function. Since, we 
observed an overall decrease in transcription of mtDNA-encoded genes after overexpression of 
DNMT1; we investigated if mitochondrial function is also affected. We used Seahorse XF 
Analyzer to determine oxygen consumption rates (OCR) (a measure of mitochondrial function) 
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in the ‘control’ and ‘oDNMT1’ cells in unstressed assay conditions. At the end of the assay, 
rotenone (a Complex I inhibitor) and Antimycin (a Complex III inhibitor) was injected that 
blocked the mitochondrial respiration, and thus provide the non-mitochondrial OCR. The basal 
mitochondrial OCR was obtained by subtracting the non-mitochondrial OCR from the total 
OCR. Under unstressed assay conditions, ‘oDNMT1 cells’ had significantly lower total OCR 
than the ‘control cells’ (34% decrease) (Figure 4A). Further, the basal-mitochondrial OCR was 
significantly decreased in the ‘oDNMT1 cells’ when compared to the ‘control cells’ (36% 
decrease) (Figure 4B). However, the non-mitochondrial OCR was similar between the 
‘oDNMT1 cells’ and ‘control cells’ (Figure 4C). These results indicate that overexpression of 
DNMT1 reduces basal-mitochondrial oxygen consumption rate, suggesting that increase in 
mtDNA methylation is associated with mtDNA transcription and might be responsible for 
affecting mitochondrial oxygen consumption.  
DNA methylation inhibitor decreases mtDNA methylation 
Decitabine or 5-Aza-2′-deoxycytidine (5-aza-dC) is a modified cytosine that cannot be 
methylated at C5 position (site where cytosine is methylated), gets incorporated in nascent DNA 
during replication and thus, leads to demethylation or hypo-methylation. 5-aza-dC is commonly 
used as a tool to inhibit nuclear DNA methylation (Momparler, Cote et al. 1997, Momparler 
2005) but whether it can inhibit mtDNA methylation is not known. We examined if 5-aza-dC 
treatment of SH-SY5Y cells decreased mtDNA methylation. Using HPLC-ESI-MS/MS, total 
mtDNA methylation was found to be significantly decreased (36% reduction) in mtDNA isolated 
from SH-SY5Y cells treated with 5-aza-dC (5-15 µM) compared to the vehicle-treated (0 µM) 
cells as shown in Figure 5A. Absolute 5mdC levels were further normalized by the amount of 
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dC and the sum of dC and 5mdC. Both the percentages were significantly reduced (50% 
reduction) in the mtDNA isolated from 5-15 µM 5-aza-dC treated cells compared to vehicle-
treated cells as shown in Figure 5B-C. 5µM 5-aza-dC was sufficient to produce maximal 
decrease in global mtDNA methylation levels such that increase in 5-aza-dC concentration did 
not decrease methylation levels further. We also examined methylation at a specific site in 12S 
rRNA in bisulfite-treated mtDNA from 5-aza-dC treated cells using methylation-specific 
primers. A single band of PCR product with dose dependent decrease in band intensity  were 
obtained from mtDNA of 5-aza-dC treated cells compared to vehicle treated cells as shown in 
Figure 5D. No band was detected in the lane that was loaded with PCR product obtained while 
using the un-methylated “Long PCR” as a template (negative control) with the methylation-
specific primers. These results indicate that 5-aza-dC treatment in SH-SY5Y cell line decreases 
mtDNA methylation. Also, this suggests that mtDNA methylation is an ongoing process in the 
mitochondria that can be inhibited by 5-aza-dC treatment.  
DNA methylation inhibitor increases mtDNA transcription and affects mitochondrial oxygen 
consumption rate (OCR) 
Next, we examined if the decreased methylation of mtDNA by 5-aza-dC treatment had any 
correlation with mtDNA transcription and mitochondrial function. Relative expression levels of 
mitochondrial ribosomal genes - 12S rRNA (Figure 6A) and 16S rRNA (Figure 6B) were 
significantly elevated after 5-aza-dC treatment. Further, relative mRNA levels of genes that code 
for Complex I such as MT-ND1,MT-ND3 and MT-ND4 (Figure 6C-E) increased significantly 
after treatment with 5-aza-dC , but were not significantly different for MT-ND5 and MTND6 
(Figure 6F-G). Additionally, after 5-aza-dC treatment, relative mRNA levels of  all three 
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mtDNA genes that encode Complex IV ( namely, MT-COX1, MT-COX2 and MT-COX3) were  
found to be significantly elevated (Figure 6H-J).  Further, mRNA levels of MT-CytB and MT-
ATP6 that code for Complex III and ATP synthase, respectively increased significantly after 5-
azadC treatment (Figure 6K-L). These results indicate that treatment with DNA methylation 
inhibitor 5-aza-dC in SH-SY5Y cells increases the levels of transcription for mtDNA-encoded 
genes in general; suggesting that decrease in mtDNA methylation upon 5-aza-dC treatment is 
associated with increased mitochondrial transcription.  
Further, mitochondrial function was investigated using Seahorse XF Analyzer by determining 
oxygen consumption rates (OCR) upon 5-aza-dC treatment (5-15 µM). Under unstressed assay 
conditions, 5-aza-dC treatment significantly decreased total OCR (40% reduction) (Figure 7A). 
Further, the basal-mitochondrial OCR was significantly decreased upon 5-aza-dC treatment 
when compared to the vehicle-treated cells (42% reduction) (Figure 7B). The non-mitochondrial 
OCR was found to be comparable for 5 and 10 µM 5-aza-dC treated cells with respect to the 
vehicle-treated, but was significantly lower in the 15 µM treated cells (Figure 7C). These results 
indicate that 5-aza-dC treatment reduces mitochondrial oxygen consumption rate, suggesting that 
decrease in mtDNA methylation by 5-aza-dC treatment is associated with increased mtDNA 
transcription and might have a role to play in altering mitochondrial function.  
3.5 DISCUSSION 
Involvement of mtDNA methylation in regulating transcription of mtDNA-encoded genes and 
subsequently mitochondrial function is being contemplated, ever since DNA Methyl -
Transferases were reported to be present in mitochondria (Shock, Thakkar et al. 2011). In this 
study, we investigated whether mtDNA methylation is alterable by overexpression of DNMT1 
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and 5-aza-dC treatment in SH-SY5Y cells and if there are any associated changes in 
mitochondrial transcription and function. MtDNA methylation was found to increase after 
overexpression of DNMT1 and decrease after 5-aza-dC treatment at both global and site-specific 
levels. Further, alteration of mtDNA methylation was accompanied with changes in transcription 
of mtDNA-encoded genes and mitochondrial-oxygen consumption rate. 
Previous studies have reported DNMT1 localization in mitochondria of human cell lines such as 
HCT116 (Shock, Thakkar et al. 2011), HEK293 (Chestnut, Chang et al. 2011), HeLa (Bellizzi, 
D'Aquila et al. 2013) and mouse cell lines such as MEF (Shock, Thakkar et al. 2011), 3T3-L1 
(Bellizzi, D'Aquila et al. 2013) and NSC34 (Chestnut, Chang et al. 2011). Recently, existence of 
mitochondrial isoform of DNMT1 also known as the mtDNMT1 was reported, which was also 
found to interact with mtDNA at CpG sites (Shock, Thakkar et al. 2011). However, any direct 
role of DNMT1 or its mitochondrial isoform in methylation of mtDNA is yet to be determined.  
To the best of our knowledge, we report for the first time that DNMT1 is present in SH-SY5Y 
mitochondria and that its overexpression increases methylation of mtDNA at global levels as 
well as at 12S rRNA. Concomitant increases of DNMT1 levels in mitochondria and mtDNA 
methylation, suggests that DNMT1 might be responsible for mtDNA methylation. However, this 
does not refute the possibility of presence of other DNA methyl transferases that could be 
involved in methylating SH-SY5Y mtDNA. We also report a significant decrease in mtDNA 
methylation upon treatment with DNA-methylation inhibitor (5-aza-dC) at global levels and at 
12S rRNA.  Both of these observations put together suggest that mtDNA methylation is an 
alterable and on-going phenomenon that can be both stimulated as well as inhibited. As HPLC-
ESI-MS/MS assay used in our study cannot differentiate nucleosides obtained from mtDNA or 
nuclear DNA and even though the mtDNA has been extracted from isolated mitochondria, 
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chances of nuclear DNA contamination cannot be excluded completely. However, we have 
observed that the mtDNA prepared in this manner is enriched by 50 fold for mtDNA with respect 
to total DNA and 99.71 % of the nuclear DNA is eliminated. Moreover, changes in mtDNA 
methylation globally by HPLC-ESI-MS/MS were corroborated by similar changes at specific site 
in mtDNA as detected by methylation-specific PCR assay, suggesting that confounding presence 
of nuclear DNA contamination would not have affected the interpretation of our results. 
Additionally, bisulfite-sequencing of mtDNA following overexpression of DNMT1 as well as 5-
aza-dC treatment might provide an in-depth insight on about sites where methylation was altered, 
which was not pursued in the current study.  
Previous studies have only correlated the expression of mtDNA-encoded genes with levels of 
mtDNA methylation in various pathological conditions such as colorectal cancer (Feng, Xiong et 
al. 2012) and non-alcoholic fatty liver disease (Pirola, Gianotti et al. 2013), but direct evidence 
supporting the role of mtDNA methylation in controlling the mitochondrial transcription is 
lacking. We found for the first time that increasing global mtDNA methylation by 
overexpressing DNMT1 decreased the transcript levels of mtDNA-encoded genes, whereas 
decreasing mtDNA methylation upon treatment with DNA-methylation inhibitor increased the 
transcript levels of mtDNA-encoded genes. Moreover, we found that relative expression levels of 
12S rRNA inversely correlated with the levels of mtDNA methylation in 12S rRNA as studied 
by methylation-specific PCR assay. Our observations about the association of altered transcript 
levels of MT-ND6 with DNMT1 levels are coincident with other correlative findings (Shock, 
Thakkar et al. 2011, Pirola, Gianotti et al. 2013). Thus, our results support the hypothesis that 
mtDNA methylation can regulate the expression of mtDNA-encoded genes.  
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Several pathological conditions (Infantino, Castegna et al. 2011, Feng, Xiong et al. 2012, Pirola, 
Gianotti et al. 2013, Wong, Gertz et al. 2013, Zheng, Linarelli et al. 2015) and even 
physiological states (Ghosh, Sengupta et al. 2014) have been correlated with pattern of mtDNA 
methylation. However, evidences supporting such a causal relationship of mtDNA methylation 
are still lacking. Moreover, any association of mtDNA methylation with mitochondrial function 
is completely unexplored. We explored whether mitochondrial function is affected by alteration 
of mtDNA methylation by overexpression of DNMT1 and treatment with the DNA methylation 
inhibitor (5-aza-dC). Interestingly, it was found that both basal-mitochondrial oxygen 
consumption and total oxygen consumption decreased, irrespective of the trend (an increase or 
decrease) in mtDNA methylation and transcription of mtDNA-encoded genes. This tempted us to 
speculate that there may be a steady-state level of mtDNA methylation, which is required to 
maintain normal mitochondrial function and that deviation from such a steady-state may result in 
mitochondrial dysfunction. However, further mechanistic studies such as enzymes activity of the 
Electron Transport Chain (ETC), mtDNA-driven retrograde signaling along with determination 
of mitochondrial mass, are required to understand why a decrease in total and basal-
mitochondrial oxygen consumption was observed in both the scenarios and how mitochondrial 
function is related to mtDNA methylation.  
A limitation of our approach is that the overexpression of DNMT1 and 5-aza-dC treatment will 
affect the methylation levels in both the nuclear (Momparler, Cote et al. 1997, Biniszkiewicz, 
Gribnau et al. 2002, Momparler 2005) as well as the mitochondrial genome.  An alternative for 
overexpression of DNMT1 could have been the overexpression of mitochondria-targeted 
DNMT1, but it is very difficult to control the level of overexpression and limit the non-specific 
localization of mitochondria-targeted-gene. Hence, we chose to overexpress DNMT1 instead of 
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the mitochondria-targeted-isoform, which is relatively a simpler approach. With regards to 
inhibiting DNA methylation, a technology to specifically inhibit methylation in mitochondria is 
lacking, which might have also hindered the field from pursuing mechanistic studies on mtDNA 
methylation. Irrespective of these limitations, since ours is one of the first studies to  investigate 
role of mtDNA methylation in controlling transcription of mtDNA-encoded genes and 
subsequently mitochondrial function by attempting to alter mtDNA methylation, our results will 
pave foundation for further studies in this direction to get more valuable insights on functional 
relevance of mtDNA methylation. 
In conclusion, our results strongly suggest mtDNA methylation to be an ongoing and alterable 
phenomenon. Along with alterations in mtDNA methylation by DNMT1 overexpression and 5-
aza-dC treatment, concomitant changes in mitochondrial transcription and mitochondrial 
function were seen. Our results support the hypothesis that mtDNA methylation can regulate the 





For legend, see next page. 
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Figure 1 Presence of DNMT1 in SH-SY5Y mitochondria and its global overexpression in 
SH-SY5Y neuroblastoma cell line: (A) Presence of DNMT1was determined in the crude and 
gradient-purified mitochondria along with purity markers: mitochondrial marker (VDAC) and 
nuclear marker (HDAC1) with respect to the whole-cell lysate using western blot analysis. 
DNMT1 was overexpressed in SH-SY5Y cells and was confirmed by determining (B) its relative 
mRNA expression, (C) relative mRNA expression of mtDNMT1 and (D) the protein levels of 
DNMT1 in whole-cell, nuclear, mitochondrial and cytosolic fractions in cells that were 
transfected with the empty vector and the vector containing DNMT1. ** indicates a significant 





Figure 2 Overexpression of global DNMT1 increases mtDNA methylation: 5mdC was 
quantitated using HPLC-ESI-MS/MS in mtDNA extracted from cells that were transfected with 
the empty vector ‘control cells’ and the vector containing DNMT1 ‘oDNMT1 cells’, after they 
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were digested into nucleosides. 5mdC levels are represented as (A) absolute values (pmoles/µg 
DNA) and as percentages of (B) 5mdC/dC and (C) 5mdC/ (dC + 5mdC). (D) Methylation-
specific primers for specific site in 12s rRNA were used to amplify from bisulfite-treated 
mtDNA prepared from ‘control cells’ and ‘oDNMT1 cells’; subsequent PCR products were 
electrophoresed through 1% agarose-gel containing ethidium bromide and visualized by UV as 















Figure 3 Overexpression of global DNMT1 decreases mtDNA transcription: Transcript 
levels of mtDNA-encoded genes were assayed for ‘control cells’ and ‘oDNMT1 cells’ by 
determining the relative expression levels of (A) MT-12S rRNA, (B) MT-16S rRNA, (C) MT-
ND1, (D) MT-ND2, (E) MT-ND3, (F) MT-ND4, (G) MT-ND5, (H) MT-ND6, (I) MT-CytB , 
(J) MT-COX1, (K) MT-COX2, (L) MT-COX3 and (M) MT-ATP6. * indicates a significant 
difference between groups at p<0.05. ** indicates a significant difference between groups at 










For legend, see next page 
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Figure 4 Overexpression of global DNMT1 affects mitochondrial OCR: (A) Total OCR, (B) 
Basal- Mitochondrial OCR and (C) Non-Mitochondrial OCR were determined for ‘control cells’ 
and ‘oDNMT1 cells’.  The units for all OCR (A-C) are pMoles/O2/min/µg protein. *** indicates 




     
For legend, see next page 
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Figure 5 DNA methylation inhibitor decreases mtDNA methylation: 5mdC was quantitated 
using HPLC-ESI-MS/MS in mtDNA extracted from cells that were treated with different 
concentrations of 5-aza-dC – 0 µM, 5 µM, 10 µM and 15 µM, after they were digested into 
nucleosides.  5mdC levels are represented as (A) absolute values (pmoles/µg DNA) and as 
percentages of (B) 5mdC/dC and (C) 5mdC/(dC + 5mdC). (D) Methylation-specific primers for 
specific site in 12s rRNA were used to amplify from bisulfite-treated mtDNA prepared from 
cells treated with different concentrations of 5-aza-dC – 0 µM, 5 µM and 10 µM; subsequent 
PCR products were electrophoresed through 1% agarose-gel containing ethidium bromide and 














Figure 6 DNA methylation inhibitor increases mtDNA transcription: Transcript levels of 
mtDNA-encoded genes were assayed for cells that were treated with different concentrations of 
5-aza-dC – 0 µM, 5 µM, 10 µM and 15 µM by determining the relative expression levels of (A) 
MT-12S rRNA, (B) MT-16S rRNA, (C) MT-ND1, (D) MT-ND3, (E) MT-ND4, (F) MT-ND5, 




For legend, see next page 
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Figure 7 DNA methylation inhibitor affects mitochondrial OCR: (A) Total OCR, (B) Basal- 
Mitochondrial OCR and (C) Non-Mitochondrial OCR were determined for cells that were treated 
with different concentrations of 5-aza-dC – 0 µM, 5 µM, 10 µM and 15 µM.  The units for all 
OCR (A-C) are pMoles/O2/min/µg protein. *** indicates a significant difference with respect to 
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Mitochondrial dysfunction is a hallmark of aging and age-related disorders. As mitochondria are 
bi-genomically encoded, mitochondrial function is governed by both the nuclear and 
mitochondrial genome (mtDNA). Although, alterations in mtDNA have been positively 
correlated with mitochondrial dysfunction during aging, direct role of mtDNA in aging-
associated mitochondrial dysfunction has not been established. To investigate the role of human 
mtDNA in aging, we created cytoplasmic hybrid cell lines by transferring mitochondria from 
platelets of healthy young and aged human subjects to mtDNA-depleted SH-SY5Y cells. 
Bioenergetic fluxes, their regulators and DNA methylation-associated parameters were 
characterized in the resulting cytoplasmic hybrids. Relative to the cybrids generated from young 
donors, total oxygen consumption and basal-mitochondrial oxygen consumption were reduced in 
the cybrids made from aged subjects. Furthermore, COX activity was remarkably decreased in 
the cybrids created from aged subjects.  Interestingly, there was a compensatory increase of 
Complex I activity in the cybrids generated from aged subjects.  However, no alterations were 
found in ATP levels, redox states and glycolysis fluxes. Although the mitochondrial mass was 
not different, mRNA levels of some of the mtDNA-encoded OXPHOS genes and nuclear-
encoded genes that promote mitochondrial biogenesis were induced in the cybrids created from 
aged subjects. As DNA methylation can regulate gene expression and also known to change in 
an age-dependent manner, DNA-methylation associated parameters were studied. Although total 
DNA methylation remained unaltered, DNMT1 protein, mRNA levels of mitochondrial DNMT1 
and methylation in the mtDNA were higher in the cybrids generated from aged subjects, 
suggesting their role in age-related changes in bioenergetics. We conclude that age-dependent 
117 
  
changes in mtDNA have a direct role in determining bioenergetic flux, ETC function and 



















Mitochondrial dysfunction is known to occur during aging (Bratic and Larsson 2013), age-
related diseases such as diabetes (Janssen, Maassen et al. 1999, van den Ouweland, Maechler et 
al. 1999), cardiovascular diseases (Tanaka, Konno et al. 1992), cancer (Chandra and Singh 
2011)and neurodegenerative diseases such as Alzheimer’s disease (Swerdlow 2011, Selfridge, E 
et al. 2013), Parkinson’s disease (Cooper, Mann et al. 1992), Amyolateral sclerosis (Fujita, 
Yamauchi et al. 1996, Browne, Bowling et al. 1998) and encephalomyopathies (Holt, Harding et 
al. 1988, Wallace, Zheng et al. 1988, Holt, Harding et al. 1989). However, the mechanisms 
behind aging are poorly understood. 
The primary function of mitochondria is to generate ATP through the process of oxidative 
phosphorylation (OXPHOS), performed by the Electron Transport Chain (ETC) consisting of 
Complex I-IV and ATP synthase (Complex V). Mitochondria contain their own genetic 
information in form of a circular double-stranded DNA called the mitochondrial DNA (mtDNA), 
which exists in multiple copies in a tissue-dependent manner. Mitochondrial proteins are 
encoded by both the nuclear genome as well as the mitochondrial genome. Along with 24 
rRNAs/tRNAs that are required for mitochondrial translation, mtDNA encodes for 13 proteins 
required for ETC (except Complex II) and ATP synthase.  
Aging-associated mitochondrial dysfunction and alterations in mtDNA have been observed in 
various organs in animal models (Vermulst, Wanagat et al. 2008) and clinical samples (Short, 
Bigelow et al. 2005). During aging, mtDNA mutations are known to accumulate (Trifunovic 
2006), which are attributed to oxidative damage caused by elevated levels of reactive oxygen 
species (ROS) (Harman 1956, Harman 1981), the poor proof-reading efficiency of polymerase-ɤ 
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(Kaguni 2004, Trifunovic, Wredenberg et al. 2004, Pursell, McDonald et al. 2008, Vermulst, 
Wanagat et al. 2008) and also to the limited efficiency of the mtDNA repair machinery 
(Druzhyna, Wilson et al. 2008, Santos, Correia et al. 2013). Several studies have reported strong 
correlation of mtDNA mutations with decline in oxygen consumption and tissue-dependent 
decrease in enzymatic activities of ETC.  However, there is lack of evidence for a direct role of 
mtDNA in aging-associated mitochondrial dysfunction (Bratic and Larsson 2013) due to 
concomitant  control of mitochondrial function by both mtDNA as well nuclear DNA. This 
problem can be circumvented by using cytoplasmic hybrid (cybrid) system    (Khan, Smigrodzki 
et al. 2007, Swerdlow 2007, Wilkins, Carl et al. 2014). Cytoplasmic hybrid (cybrid) cell lines 
can incorporate human subject’s mitochondria and perpetuate mitochondrial DNA (mtDNA)-
encoded components of the human subject. Since the nuclear background of different cybrid 
lines can be kept constant, this technique allows investigators to study the influence of mtDNA 
on various cellular functions. Prior usage of cybrids has elucidated the contribution of mtDNA to 
various parameters associated with mitochondrial function such as electron transport chain 
activities, bioenergetic fluxes, free radical production and mitophagy (Esteves, Domingues et al. 
2008, Esteves, Lu et al. 2010, Swerdlow 2012, Silva, Selfridge et al. 2013).  
Very few studies have addressed the direct role of mtDNA in aging-associated mitochondrial 
dysfunction using cybrid model. Mouse cybrid cell lines of different ages were created by fusing 
mitochondria from skeletal muscle, neurons and synaptosomes with mtDNA-depleted cell line 
and displayed age-related mitochondrial dysfunction (Li, Li et al. 2010, Li, Kumar Sharma et al. 
2013). However, concerns have been raised previously, regarding the ability of mouse mtDNA to 
mimic human aging physiology (Demetrius 2006, Kazachkova, Ramos et al. 2013, Kowald and 
Kirkwood 2013).  Moreover, very few studies have interrogated the direct role of human mtDNA 
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in aging-associated mitochondrial dysfunction and have arrived at conclusions contradictory to 
each other (Hayashi, Ohta et al. 1994, Laderman, Penny et al. 1996, Isobe, Ito et al. 1998). All 
these studies used human mtDNA from skin fibroblasts, but used different mtDNA-depleted cell 
lines and different model systems, namely – cytoplasmic hybrid  (Hayashi, Ohta et al. 1994, 
Laderman, Penny et al. 1996) and nuclear hybrid (Isobe, Ito et al. 1998). While one group 
concluded that damage in the mtDNA was responsible for the observed differences in aging-
dependent functional alterations of mitochondria (Laderman, Penny et al. 1996), the other group 
inferred that the nuclear genome is responsible for age-related respiration deficiency (Hayashi, 
Ohta et al. 1994, Isobe, Ito et al. 1998). Thus, a direct role of human mtDNA in age-associated 
mitochondrial dysfunction has not been established yet and further comprehensive studies are 
required in this regard.  
Therefore, we wanted to determine if human mtDNA has a role in mitochondrial dysfunction 
observed during aging. We have created cybrid cell lines by fusing platelets from young and old 
human donors with mtDNA-depleted SH-SY5Y ρ
0
cells. We have found that age-dependent 
changes in mtDNA have a direct role in determining bioenergetic flux, ETC function and 
expression of genes controlling mitochondrial biogenesis.  
4.3 MATERIALS AND METHODS 
Human subjects  
After obtaining informed consent, young (n = 9) and aged (n = 7) human subjects, who were 
healthy and without any neurodegenerative disease, underwent a 10 mL phlebotomy using tubes 
containing acid-citrate-dextrose as an anticoagulant. The average age of the young subjects who 
participated in this study was 29.1 ± 0.9 years, and that of the aged subjects was 75.1 ± 3.0 years 
121 
  
as represented in Figure 1B. The cybrids generated from young donors will be referred to as 
“Young Donors Cybrid or YDC” whereas the cybrids generated from aged donors will be 
referred to as “Aged Donors Cybrid or ADC”.  
Creation of cybrid lines and the culture media  
We used platelet mitochondria to generate cybrid cell lines from young and old subjects as 
demonstrated pictographically in Figure 1A and as described previously (Swerdlow, Parks et al. 
1997). Briefly, warm histopaque was used to fractionate whole blood of the human donor for 
isolating platelets. Isolated platelets were washed with   S-minimum essential medium (SMEM) 
and briefly triturated with SH-SY5Y ρ0 cells in polyethylene glycol diluted with SMEM 
(Swerdlow, Parks et al. 1997). The products of this trituration were plated on T75 flasks, 
maintained for 1 week in ρ0 growth medium, and then switched to cybrid selection medium for 6 
weeks. SH-SY5Y ρ0 cells lack intact mtDNA, do not possess a functional ETC, and are 
auxotrophic for pyruvate and uridine. Maintaining cells in the cybrid selection medium devoid of 
pyruvate and uridine, removes ρ0 cells that have not acquired platelet mtDNA during trituration. 
Along with the true fusions, ‘mock fusions’ in which SH-SY5Y ρ0 cells not triturated with 
platelets were plated and maintained in selection medium, and during the selection period all 
cells from the mock fusions died. After selection was complete, the resultant cybrid cells were 
changed to ρ0 growth medium. Flasks were maintained in this medium at 37°C, 5% CO2 for 24 
h prior to harvesting. Thus, cybrid cell lines were made from 9 young donors and 7 aged healthy 
donors for this study.  
Composition of the ρ0 growth-media is DMEM containing 25 mM glucose, 10% FBS, 1% 
Penstrep, 100ug/mL pyruvate, 50ug/mL uridine whereas that of the cybrid selection-medium is 
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DMEM containing 25 mM glucose, 10% heat-inactivated-dialyzed FBS, 1% Penstrep, no 
pyruvate and no uridine.  
Harvesting of cells 
Cybrid cell lines growing in the culture flasks or petri-dishes were rinsed with 1X Phosphate 
Buffered Saline (PBS), trypsinized and then harvested using the ρ0 growth media. The harvested 
cells were then pelleted at 800g for 5 minutes at 4°C and subsequently washed with 1X PBS at 
4°C for subsequent downstream procedure. 
Oxygen consumption rate (OCR) & Extra-cellular acidification rate (ECAR) studies 
Approximately 50,000 cells from each cybrid line were seeded in the wells of Seahorse XF cell 
culture microplates (Seahorse Bioscience, Billerica, MA) and standard two-step seeding 
procedure was performed as per the manufacturer’s recommendations.  The XF cell culture 
microplates were placed in a 37
o
, 5% CO2 incubator for the cells to proliferate. The assays were 
done 48 hours post seeding. 
OCR studies: Twenty four hours post seeding, the cells were starved off FBS into a buffered 
DMEM medium containing 5mM glucose. On the assay day (48 hours post seeding),  before 
placing culture microplates in the Seahorse Analyzer the cells were washed with un-buffered 
DMEM containing 5mM glucose and 2 mM pyruvate and then placed in the same medium for an 
hour in an incubator without CO2 at 37°C for degassing.  OCR respiration measurements were 
collected after every cycle of 3 minutes of mixing, 2 minutes of wait time, followed by 
measurements for 3 minutes by the Seahorse Analyzer and the entire assay was completed in 
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0.3 μM FCCP was injected after the 6
th
 cycle. The post-FCCP OCR was 
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Mixture of 0.1 μM Rotenone and 0.2 μM Antimycin A was injected after 
the 9
th
 cycle. Non-mitochondrial OCR was measured and 12
th
 cycle 
reading was used for analysis. 
The non-mitochondrial OCR was subtracted from the total OCR to yield the mitochondrial OCR.  
The proton-leak OCR was obtained by subtracting the non-mitochondrial OCR from the post-
oligomycin OCR whereas the maximal OCR was calculated by subtracting the non-
mitochondrial OCR from the post-FCCP OCR.   
ECAR studies: Twenty four hours post seeding, the cells were starved off FBS into a buffered 
DMEM medium containing no glucose. On the assay day (48 hours post seeding), before placing 
culture microplates in the Seahorse Analyzer, the cells were washed with un-buffered DMEM 
containing L-Glutamine and were placed in the same medium for an hour in an incubator without 
CO2 at 37°C for degassing.  The wells were read for ECAR after every cycle of 3 minutes of 
mixing, 2 minutes of wait period, followed by measurements for 3 minutes by the Seahorse 




















20 mM glucose was injected after the 3
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100 mM 2-deoxy-glucose was injected after the 9
th
 cycle. Non-
Glycolytic ECAR was measured and 12
th
 cycle reading was used for 
analysis.  
The non-glycolytic ECAR was subtracted from the post-glucose ECAR to provide the glycolysis 
ECAR.  Next, the non-glycolytic ECAR was subtracted from the post-oligomycin ECAR to 
provide the glycolysis capacity ECAR.  Subtracting the glycolysis ECAR from the glycolysis 
capacity ECAR yielded the glycolysis spare reserve capacity.    
Both OCR and ECAR studies were repeated at least three times. The readings obtained for the 
particular day were normalized by the mean of ADC for a particular parameter and averaged 
across multiple days before statistical analysis to yield the relative values of each parameter.  
Isolation of mitochondria   
 Mitochondria were isolated as described previously (Kristian, Hopkins et al. 2006) with some 
modifications. Briefly, cells growing in a confluent T180 flask of each cybrid cell line were 
harvested as described above. The washed cell pellets were then re-suspended in MSHE buffer, 
collected in a pre-cooled cavitation chamber (nitrogen bomb; Parr Instrument Company, Moline, 
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IL) and subjected to 900 psi for 15 minutes. The cell suspension is collected by releasing the 
pressure instantaneously and centrifuged at 1000g for 5 minutes at 4°C to pellet the cell debris. 
The supernatant was collected and spun at high speed of 20000g for 10 minutes at 4°C. The 
pellet obtained was re-suspended in MSHE and is the crude preparation of mitochondria and 
used for COX assay. 
Mitochondria were also isolated using Mitochondria Isolation Kit for Cultured Cells (Abcam 
110170) for Complex I assay and isolation of mitochondrial DNA. Briefly, cells growing in a 
confluent T180 flask of each cybrid cell line were harvested as described above. The cell pellet 
was then freeze-thawed to weaken the cell membranes, suspended in Reagent A and kept on ice 
for 10 minutes. The suspension was then homogenized and spun at 1000 g for 10 minutes at 4°C, 
to pellet the cellular debris and collect the supernatant that contains the mitochondria. The 
cellular debris were re-suspended in Reagent B, incubated on ice for 10 minutes again, dounce 
homogenized and spun again to collect the supernatant that contains the mitochondria. Both the 
supernatants were combined and centrifuged at 12000 g for 15 minutes at 4°C to pellet the 
mitochondria. 
Cytochrome c oxidase (COX) assay and Citrate Synthase assay 
COX assays were performed on isolated mitochondria and whole cell pellets whereas citrate 
synthase assays were performed on whole cell pellets only as described previously (Ghosh, Patel 
et al. 2007). After the assay was performed, protein concentration was determined by DC Protein 
Assay (Biorad, Hercules, California, USA). The rate obtained was then corrected for the amount 
of protein in the cuvette.  
Complex I activity-ELISA based assay ` 
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Complex I activity was assayed using Complex I Enzyme Activity Microplate Assay Kit (Abcam 
109721). Briefly, the isolated mitochondria were permeabilized using the detergent and the 
enzyme Complex I, is immuno-captured within the wells of the microplate and its activity is 
determined by following the oxidation of NADH to NAD
+
 and the simultaneous reduction of a 
dye which leads to increased absorbance at 450 nm. Thus, the rate constant (Vmax) in min
-1
 was 
spectrophotometrically determined. Each cybrids line’s rate was then normalized to the amount 
of protein in the mitochondrial preparation and divided by the extinction coefficient of the dye, 




ADP levels, ATP levels and the ADP/ATP ratios were determined using the EnzyLight
TM
 
ADP/ATP Ratio Assay Kit (Bioassay Systems, CA, USA). Briefly, 6x10
5
 cells per well were 
seeded in 96 well plates and 48 hours later the assay was performed. In the first step, cells were 
lysed to release ATP and ADP. ATP reacts with the substrate D-Luciferin in presence of the 
enzyme luciferase, and the subsequent fluorescence reaction provides a direct indication of the 
ATP concentration. Next, the change in fluorescence reaction was followed as ADP was 





Cells were harvested and assayed for NAD
+
/NADH levels using the Fluorescent NAD/NADH 
Detection Kit (Cell Technology, Inc., CA, USA). Briefly, 2x10
6
 cells were seeded in 60 mm 
dish, harvested after 48 hours and divided into two different vials, one for NAD
+
 and another for 
NADH. Cells were then re-suspended in the appropriate extraction and lysis buffers. Cell 
suspensions were then vortexed for homogenization and the lysates were incubated at 60ºC for 
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15 minutes. These lysates were cooled immediately and reaction buffer, along with the opposite 
buffer for neutralization was added. Samples were centrifuged at 8000 g for 5 minutes to clarify 
the supernatants. The supernatants obtained were then assayed for NAD+/NADH with the 
following fluorescence measurements - excitation 530 nm and emission 590 nm.  
DNA extraction 
DNA extraction was done by the method based on organic-solvent extraction of DNA as 
described previously (Guo, Jiang et al. 2009). Briefly, the sample in ice-cold lysis buffer 
underwent dounce homogenization, followed by Proteinase K digestion at 55°C for 3h in a water 
bath. The mixture was spun to remove the non-soluble fractions and the DNA in the supernatant 
was extracted by standard Phenol-Chloroform-Isoamyl alcohol method. DNA was precipitated 
using Sodium Acetate and isopropanol at -20°C. The DNA pellet was washed twice with 70% 
ethanol. Finally, the extracted DNA pellet is then air-dried, re-suspended in nuclease-free water 
and then quantitated using Infinite M200 (Tecan, San Jose, USA).  
Total DNA was extracted for mtDNA copy number assay and to determine the amount of global 
methylation. Two million cells from each cybrid line were seeded in 60 mm dish and harvested 
48 hours later as described above and the washed cell pellets were suspended in ice-cold Lysis 
buffer for DNA extraction as described above.  
The mitochondrial DNA was extracted for determining the amount of mtDNA methylation for 
every cybrid line. Twenty million cells of every cybrid cell line were seeded in a T180 flask and 
harvested 48 hours later. Cells were harvested and the mitochondria were isolated from every 
cybrid line as described above. The isolated mitochondria were suspended in ice-cold Lysis 




Two million cells from each cybrid line were seeded in 60 mm dish and harvested 48 hours later. 
RNA extraction was performed using TRI Reagent solution (Life technologies AM9738). 
Briefly, supernatant was removed and TRI was added to harvest the cells. The homogenate was 
incubated at room temperature to allow disassociation of the nucleoprotein complexes. 
Chloroform was used to separate the protein from the nucleic acids. RNA was precipitated using 
isopropanol; the pellet obtained was washed with 70% ethanol and then air-dried before re-
suspending in nuclease-free water. The extracted RNA is then further quantitated using Infinite 
M200 (Tecan, San Jose, USA).  
cDNA synthesis 
1 µg of RNA was used from every cybrid line to synthesize cDNA using iScript Reverse 
transcription 5X super-mix in a 20 µL reaction as per the recommendations in the protocol 
(Biorad 170-8840). The 20 µL reaction was then diluted 5 times by adding 80 uL nuclease-free 
water. 2 µL of the diluted cDNA solution was used for every qPCR reaction.  
Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was performed using the TaqMan Universal PCR Master 
Mix (Applied Biosystems, Foster City, CA) and ready-to-use TaqMan Gene Expression Assays 
(Applied Biosystems). We quantified mRNA levels deriving from the following genes:  PGC1a, 
PGC1ß, PRC, NRF1, NRF2, TFAM, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND5, MT-
ND6, MT-COX1, MT-COX2, MT-COX4Ii, MT-CytB and MT-ATP6. GAPDH was used as an 
internal loading control. qPCR amplification was determined utilizing an Applied Biosystems 
StepOnePlus Real-Time PCR System (Applied Biosystems). 
To quantify mtDNA by mtDNA copy number assay, we used the TaqMan Gene Expression 
Assay Kit (Applied Biosystems) and primers for three mtDNA-encoded genes, 16S RNA gene, 
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NADH dehydrogenase subunit 2 (MT-ND2) and Cytochrome c oxidase 1 (MT-COX1), as well 
as to the nuclear 18s rRNA gene. The primers were used to amplify from 5 ng of total DNA in 
every PCR reaction. Relative ratios of mtDNA to nuclear DNA is called the mtDNA copy 
number and was determined using the comparative ∆∆CT method, and thus 16S/18S, MT-
ND2/18S and MT-COX1/18S ratios were calculated. 
Immunoblotting 
To check for total protein levels, whole cell lysates were prepared by M-PER Mammalian 
Protein Extraction Reagent (Pierce, Rockford, IL, USA). Protein concentrations for all the 
lysates were determined using a BCA Protein Assay kit (BioRad). Equal amount of proteins 
from the protein lysates of every cybrid line were resolved by electrophoresis in pre-cast 4–12% 
gels (BioRad), and then transferred to polyvinyl di-fluoride (PVDF) membranes. Non-specific 
binding was blocked by gently agitating the membranes in 5% non-fat milk and 0.1% Tween in 
PBS for 1 hour at room temperature. Blots were subsequently incubated in 5% bovine serum 
albumin (BSA) containing 0.1% Tween with the designated primary antibody overnight at 4°C 
with gentle agitation. Blots were washed thrice for 10 minutes with PBS containing 0.1% Tween 
three times and then incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibody for 1 hour at room temperature with gentle agitation. After three washes, the blots were 
incubated with SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). 
Chemiluminescence signals were detected using a Bio-Rad ChemiDoc Imager and band densities 
determined using Quantity One Software. Primary antibody for DNMT1 was purchased from 
Cell Signaling Technology (Beverly, MA, USA) and that of PGC1α was purchased from 
Molecular Probes (Molecular Probes, Eugene, OR, USA). Both of them were used at a 1:1000 
dilution.   
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HPLC-ESI-MS/MS assay  
MtDNA was extracted followed by isolation of mitochondria from every cybrid line as described 
above. 1 µg of mtDNA in 50 µL of digestion buffer was incubated at 37°C overnight as 
described previously (Quinlivan and Gregory 2008) and the digestion products for every cybrid 
line was quantitated by HPLC-ESI-MS/MS. The digestion buffer consists of 2.5U benzonase, 3 
mU of alkaline-phosphatase and 2 U phosphodiesterase-I in 20 mM Tris-HCl pH 7.9 containing 
100mM NaCl  and 20mM MgCl2, which digests the mtDNA into nucleosides. Pmoles of 5-
methyl-deoxy-cytidine (5mdC) present per ug of mtDNA were compared. To account for inter-
sample variability in digestion, 5mdC (pmoles/ug DNA) were normalized by with the amount of 
deoxy-Cytidine (dC) and sum of dC and 5mdC (dC + 5mdC), to yield percentages and then 
compared between the group of cybrids.  
Data analysis 
Data are expressed as means ± standard error of the means (SEM).To compare means between 
two groups we used two-way, unpaired Student’s t-tests, with p-values of <0.05 considered 
significant.  
4.4 RESULTS 
Reduced Total and Mitochondrial Oxygen Consumption Rate (OCR) in the cybrids created 
from aged donors  
We used Seahorse XF Analyzer to determine oxygen consumption rates (OCR) in the cybrids 
generated from young and aged donors in unstressed assay conditions of 5mM glucose and 2 
mM pyruvate. At the end of the assay, rotenone (a Complex I inhibitor) and Antimycin (a 
Complex III inhibitor) was injected that blocked the mitochondrial respiration, and thus provide 
the non-mitochondrial OCR. The basal mitochondrial OCR was obtained by subtracting the non-
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mitochondrial OCR from the total OCR. Under unstressed conditions, cybrids made from aged 
donors had significantly lower total OCR (37% decrease) than the cybrids made from young 
donors (Figure 2A). Further, the basal-mitochondrial OCR was significantly decreased (45% 
decrease) in the cybrids made from aged donors when compared to the cybrids made from young 
donors (Figure 2B). However, the non-mitochondrial OCR were similar between the cybrids 
made from young and aged donors (Figure 2C), suggesting that changes in total OCR were due 
to alteration in basal-mitochondrial OCR only. These results indicate that age-dependent 
alterations in mtDNA play a role in decreasing oxygen consumption observed during aging-
associated mitochondrial dysfunction.  
Oligomycin is an inhibitor of ATP synthase. Oxygen consumption rates due to ATP production 
and proton-leak were measured post-oligomycin injection of 1 µM and estimated after 
subtracting the non-mitochondrial OCR, but were found to be comparable between the cybrids 
made from young and aged donors (data not shown). FCCP is a protonophore (H+ ionophore) 
and can thus change the location of protons across inner-mitochondrial membrane. By bringing 
all the protons to the matrix, FCCP can force the mitochondria to consume oxygen at the highest 
rate possible, also called the maximal OCR.  Maximal oxygen consumption capacity rates were 
measured post-FCCP injection of 0.3 µM and estimated after subtracting the non-mitochondrial 
oxygen consumption rate, but were found to be not different between the cybrids made from 
young and aged donors (data not shown).  
No alteration in Glycolysis in the cybrids created from aged donors when compared to cybrids 
made from young donors 
XF Seahorse Analyzers can also measure pH of the medium and thus can determine the rate at 
which cells acidify their surrounding medium.  Since lactic acid excretion by the cultured cells is 
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primarily responsible for acidification of the medium, and lactic acid is produced by anaerobic 
glycolysis, Extra-Cellular Acidification Rate (ECAR) can be used to estimate glycolysis fluxes. 
Cells from each of our cybrid lines were placed in a glucose-free medium so that the initial 
ECAR values were not only quite low but also equivalent between the groups. 2-Deoxy-D-
glucose is a modified glucose molecule in which the 2-hydroxyl group is replaced by hydrogen 
and thus inhibits further glycolysis. At the end of the experiment, 2-Deoxy-D-glucose was added 
to every well, and this revealed that the baseline ECAR measurements were stable throughout. 
The post-2-deoxyglucose ECARs were used to provide non-glycolysis acidification rates. Next, 
cells were subjected to glucose, with a final concentration of 20 mM.  The non-glycolysis 
acidification rate for each line was subtracted from the rate in 20 mM glucose to yield the true 
glycolysis-dependent ECAR or the glycolysis rate. No significant difference was found in 
glycolysis rate (Figure 2D) between the cybrids made from young and aged donors. The glucose 
injection was followed by an injection of oligomycin with a final concentration of 1 mM that 
eliminates mitochondrial ATP production by inhibiting the mitochondrial ATP synthase and 
forces a compensatory increase in glycolysis-related ATP production. On subtracting the non-
glycolysis acidification rate from the post-oligomycin ECAR, glycolysis capacity was obtained. 
We found that the glycolysis capacity was similar between the cybrids made from young and 
aged donors (Figure 2E).  The post-glucose, pre-oligomycin ECAR was subtracted from post-
oligomycin ECAR, to provide the glycolysis spare reserve capacity, which was again found to be 
not different between two groups (Figure 2F).  
Reduction in Cytochrome c oxidase (COX or Complex IV) activity in the cybrids created from 
aged donors  
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Complex IV activity is known to decrease upon aging (Boffoli, Scacco et al. 1994, Ojaimi, 
Masters et al. 1999). Since we found a significant reduction in basal-mitochondrial OCR in the 
cybrids generated from aged donors, we investigated if the COX activity is altered. The isolated 
mitochondria and whole cells from each of the cybrid lines were assayed for the Cytochrome c 
oxidase activity. The Mito-prep COX activities were derived by normalizing the Vmax activities 
obtained from the isolated mitochondria by the amount of mitochondrial protein for each cybrid 
line. It was found that the Mito-prep COX activity was significantly reduced in the cybrids made 
from aged donors (Figure 3A). Similarly, the Whole-Cell COX activities were derived by 
normalizing the Vmax activities obtained from the whole cells by the amount of total protein in 
whole-cells extract for each cybrid line. The whole-cell COX activity was also found to be 
significantly reduced (by 32%) in the cybrids made from aged donors (Figure 3B). The whole-
cell COX activities were further normalized for the amount of mitochondrial protein by assaying 
the activity of citrate synthase, an enzyme located in the mitochondrial-matrix, for every cybrid 
line. The resultant COX activity/CS activity was also found to be significantly reduced (by 26%) 
in cybrids made from aged donors (Figure 3C). These results clearly indicate that in comparison 
to the cybrids made from young donors, cytochrome c oxidase activity was impaired in the 
cybrids made from aged donors and was influenced by age-dependent alterations in mtDNA.  
Increase of Complex I activity in the cybrids created from aged donors  
Next, we investigated if the Complex I activity is altered between cybrids made from young and 
aged donors. Isolated mitochondria from each of the cybrid lines were assayed for the Complex I 
activity. The Complex I activity were normalized for the amount of protein in the isolated 
mitochondria for each cybrid line. Although the Complex I activity trended to be higher (p value: 
0.0517) in the cybrids made from aged donors than that of the young donors, the difference was 
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not statistically significant (Figure 3D). However, when the Complex I activity of each cybrid 
line were further normalized using  their respective citrate synthase activity, the cybrids made 
from aged donors were found to have significantly higher ratio of Complex I activity/Citrate 
Synthase activity (Figure 3E).  
Similar levels of mitochondrial mass markers in the cybrids created from young and aged 
donors  
As we observed differences in basal-mitochondrial OCR, complex IV activity and complex I 
activity, it was important to determine if differences in mitochondrial mass were responsible for 
these changes. To evaluate the mitochondrial mass, mtDNA copy number and citrate synthase 
activity assays were performed for every cybrid line.  
For mtDNA copy number assay, we determined the relative mtDNA to nuclear DNA ratios in 
our cybrid lines. The copy number of the mtDNA-encoded genes were normalized to the copy 
number of nuclear gene 18S rRNA. No significant differences were found in the ratios of 16S 
rRNA: 18S rRNA (Figure 4A), MT-ND2:18S rRNA (Figure 4B) and MT-COX1: 18S rRNA 
(Figure 4C) between the cybrids created from young and aged donors.  
As a mitochondrial enzyme, the citrate synthase can be used as a normalization factor for 
mitochondrial protein as well as a biomarker for mitochondrial content of a cell. Even the citrate 
synthase activity was found to be comparable between the two groups of cybrids (Figure 4D). 
These results indicate that the observed differences between the young and old group of cybrids 
were not due to differences in mitochondrial content or mass.  




Levels of ATP (Figure 5A) and the ratio of ADP: ATP (Figure 5B) were determined for every 
cybrid line from both the groups of cybrids, but no significant alteration was found between the 
cybrids made from young and aged donors.  Levels of NAD
+ 
(Figure 5C) and NADH (Figure 
5D) were determined for every cybrid line from both the groups of cybrids and were also found 
to be comparable between the two groups of cybrids.  The levels of NAD
+
 were normalized for 
the levels of NADH for every cybrid line to yield the NAD
+
: NADH ratios, which again were 
found to be similar between cybrids made from young and aged donors (Figure 5E).  
Induction of transcriptional co-activators and transcription factors that promote 
mitochondrial biogenesis in the cybrids created from aged donors 
PPARɤ co-activator-1 (PGC-1) family of transcriptional co-activators consists of PGC-1α, PGC-
1ß and PGC-related coactivator (PRC); plays a critical role in the regulation of mitochondrial 
oxidative metabolism and maintenance of glucose, lipid and energy homeostasis. PGC-1α is 
vastly studied and its protein levels are known to decrease upon aging. Hence total PGC-1α 
protein levels were checked, but were found to be similar between the cybrids made from young 
and aged donors (Figure 6A-B). Relative mRNA levels of PGC-1α were not different either 
between the two groups of cybrids (Figure 6C). However, relative mRNA levels of other 
members of PGC-1 family, PGC-1ß and PRC were assayed and PGC-1ß  trended to be higher in 
the cybrids made from aged donors whereas PRC was found to be significantly higher in the 
cybrids made from aged donors than that of young donors (Figure 6D-E).        
PGC-1 family promotes mitochondrial biogenesis by activating the transcription factors that 
regulate the expression of nuclear-DNA-encoded mitochondrial proteins. These transcription 
factors include NRF1 and NRF2. Relative mRNA levels of NRF1 (Figure 6F) and NRF2 
(Figure 6G) were assayed and were found to be significantly elevated in the cybrids made from 
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aged donors. The activation of these transcription factors increases the expression of many 
mitochondrial proteins, including mitochondrial transcription factor A (TFAM). TFAM 
stimulates transcription of mtDNA by binding to the promoters in mtDNA. Thus, by regulating 
TFAM levels, PGC-1 coactivators can influence the expression of proteins encoded by mtDNA. 
TFAM mRNA levels were investigated and found to be induced  2.8 fold times in cybrids made 
from aged donors when compared to cybrids made from young donors (Figure 6H).  
These results indicate that age-associated differences in mtDNA can alter the expression of 
nuclear-encoded genes involved in mitochondrial biogenesis, which can be a compensatory 
phenomenon to mitigate the reduced mitochondrial function in the cybrids created from aged 
donors.  
Alteration of mRNA levels of mtDNA-encoded OXPHOS genes in the cybrids created from 
young and aged donors  
The process by which the proton-gradient is created across the inner-mitochondrial membrane 
and utilized for synthesis of ATP is called oxidative phosphorylation (OXPHOS). The OXPHOS 
apparatus located in the mitochondria is bi-genomically encoded, i.e. it is encoded by two 
genomes- the nuclear genome and the mitochondrial genome (mtDNA). MtDNA encodes for 2 
rRNAs, 22 tRNAs and 13 mRNAs and all these 37 genes need to be transcribed for the 
mitochondria to function. The translation products of 13 mRNAs from the mtDNA, along with 
the nuclear-encoded OXPHOS proteins, form the functional subunits of different complexes 
(Complex-I and Complex-III-V) in the OXPHOS apparatus. As mRNA levels of transcriptional 
co-activators (Figure 6D-E) and transcription factors (Figure 6F-H) that promote mitochondrial 
biogenesis, especially TFAM were elevated in the cybrids created from aged donors, we studied 
if transcription of mtDNA-encoded OXPHOS genes was different, which can be an important 
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determinant of mitochondrial function. Relative mRNA levels of MT-ND1 (Figure 7A) and MT-
ND5 (Figure 7E) that encode for Complex I components were found to be significantly higher 
in the cybrids  made from aged donors. Relative mRNA levels of other mtDNA-encoded genes 
(Figure 7B-D, F-J) were slightly higher in the cybrids created from aged donors than that of 
young donors, but failed to attain statistical significance.  
Increased Dnmt1 and mtDNA methylation in the cybrids created from aged donors 
Global hypo-methylation and local hyper-methylation is known to occur upon aging in the 
nuclear genome (Terry, Delgado-Cruzata et al. 2011, Jin, Jiang et al. 2014, Reynolds, Taylor et 
al. 2014, Bacalini, Boattini et al. 2015, Jung and Pfeifer 2015, Yuan, Jiao et al. 2015, Zampieri, 
Ciccarone et al. 2015). Also, few studies found total DNA methylation to be different in cybrids 
created from different haplogroups of human mtDNA, thus implying that mtDNA-specific 
interactions between mitochondria and the nucleus can regulate epigenetic changes (Bellizzi, 
D'Aquila et al. 2012, Atilano, Malik et al. 2015). Moreover as we have observed differences in 
mRNA levels of nuclear-encoded genes (Figure 6D-H), we wanted to investigate if age-
dependent changes in mtDNA affects the global DNA methylation in our cybrids.  
To determine the global DNA methylation levels, total cellular DNA was extracted, digested and 
HPLC-ESI-MS/MS assay was performed. Global DNA methylation did not decrease in the 
cybrids made from aged donors (Figure 8A). Global DNA methylation levels for each cybrid 
line were further normalized for the total levels of de-oxy-cytidine and the sum of de-oxy-
cytidine and 5-methyl- de-oxy-cytidine present in the respective cybrid line’s total DNA and 




Multiple studies have reported significant alteration of mtDNA methylation in pathologic 
conditions such as Down’s Syndrome(Infantino, Castegna et al. 2011), Amyolateral sclerosis 
(Wong, Gertz et al. 2013), non-alcoholic fatty liver disease (Pirola, Gianotti et al. 2013) and also 
during development in the brain (Ghosh, Sengupta et al. 2014). Limited data is available about 
age-dependent changes in the mtDNA methylation. While one group has reported that mtDNA 
methylation does not change (Dzitoyeva, Chen et al. 2012), another group reported that mtDNA 
methylation changes in an age-dependent manner (Iacobazzi, Castegna et al. 2013). As we found 
a significant alteration in few of the mtDNA-encoded genes (Figure 7A, E) and considering a 
potential role of mtDNA methylation in regulating mitochondrial transcription (Shock, Thakkar 
et al. 2011), we investigated mtDNA methylation in our model of aging cybrids by HPLC-ESI-
MS/MS assay. Absolute levels of mtDNA methylation did not differ significantly between the 
cybrids created from young and aged donors but appear to be higher in aged donor group 
(Figure 8D). It should be mentioned that the high intra-group variation in the mtDNA 
methylation levels in the cybrids lines could have masked any significant difference. Thus, the 
mtDNA methylation levels for each cybrid line were normalized for the amount of de-oxy-
cytidine and also for the sum of de-oxy-cytidine and 5methyl-deoxy-cytidine as internal controls 
to account for inter-sample variation in digestion. The resulting percentages of mtDNA 
methylation were found to be significantly elevated (by 40%) in the cybrids generated from aged 
donors (Figure 8E-F).  
DNA Methyl transferases (DNMTs) transfer methyl groups to the 5’ position of deoxycytidine in 
DNA and the resulting 5-methyl cytosine are known to regulate gene expression. Presence of 
mitochondrial isoform of DNMT1 (mtDNMT1) was recently reported, interacting with mtDNA 
at the CpG sites (Shock, Thakkar et al. 2011). As we found that the percentage of mtDNA 
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methylation had altered significantly, mRNA levels of mtDNMT1 and total DNMT1 protein 
levels were examined. We found that relative mRNA levels of mtDNMT1 were significantly 
increased (2.75 times) in the cybrids generated from the aged donors than the young donors by 
more than two fold (Figure 8G). Subsequently, we found that the cybrids created from aged 
donors had significantly higher levels of DNMT1 protein (Figure 8H and I) in concordance 
with the increased percentage of mtDNA methylation found in this group. 
4.5 DISCUSSION 
Alterations in mtDNA have been strongly correlated with age-associated mitochondrial 
dysfunction. However, there is a lack of evidence that support a direct role of mtDNA in the 
mitochondrial dysfunction which is known to occur during aging and age-related disorders. In 
our study, cybrid cell lines created through transfer of platelet-mitochondria from young and old 
subjects, show altered bioenergetic function. Age-associated mitochondrial dysfunction, in terms 
of decreased COX holoenzyme function and basal-mitochondrial oxygen consumption were 
found in the cybrids created from aged donors. Thus, we have demonstrated a direct role for 
human mtDNA in causing mitochondrial dysfunction during aging. Additionally, increase in 
mRNA levels of some of the mtDNA-encoded and nuclear-encoded genes that promote 
mitochondrial biogenesis, mRNA levels of mitochondrial isoform of DNMT1, total protein 
levels of DNMT1 and mtDNA methylation were observed in the cybrids made from aged 
donors.  
Majority of the aging studies have only established correlations between mtDNA alterations and 
mitochondrial dysfunction using skin fibroblasts, organs of animal models and clinical samples. 
Limited studies have addressed the direct role of mtDNA in aging. Our results regarding direct 
role of age-associated alterations in the mtDNA in causing mitochondrial dysfunction are 
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supported by previous mouse cybrid studies, which have used mitochondria from skeleton 
muscle and synaptosomes from mice of different ages (Li, Li et al. 2010, Li, Kumar Sharma et 
al. 2013). Very few studies have examined the direct role of mtDNA from human subjects in 
age-dependent mitochondrial dysfunction, and have arrived at contradictory conclusions 
(Hayashi, Ohta et al. 1994, Laderman, Penny et al. 1996, Isobe, Ito et al. 1998).  All these studies 
have used skin fibroblast as the source of mtDNA, but used different approaches (nuclear hybrid 
or cytoplasmic hybrids) or used different nuclear background (i.e. different ρ
0 
cells). Study 
outcomes in cybrid models are influenced by the nuclear background of the ρ
0
 cell line that has 
been used to generate the cybrid cell lines (Khan, Smigrodzki et al. 2007, Wilkins, Carl et al. 
2014).  Even if mitochondria used to generate the cybrid cell lines are obtained from a common 
source, they might not function similarly in the context of different nuclear backgrounds. Thus, 
variations in cybrid technology coupled with difference in approaches might have resulted in 
conflicting findings. All these studies have based their conclusions by using the clones obtained 
after generating the transformed cybrid cell line (Hayashi, Ohta et al. 1994, Laderman, Penny et 
al. 1996). On one hand, Laderman et al. found that only 5% of the clones obtained from the old-
transformants were respiration-deficient (Laderman, Penny et al. 1996) whereas Hayashi et al. 
and Isobe et. al. worked with clones of a very small group of  individuals (Hayashi, Ohta et al. 
1994, Isobe, Ito et al. 1998). Our studies were conducted in the transformed cybrid cell line 
itself, which not only is more analogous to the heteroplasmy that is observed in physiology, but 
also with a larger sample set of transformed cell lines generated from 9 young and 7 aged human 
donors making our study more relevant. Moreover, we have explored bioenergetic fluxes and 
associated parameters in more detailed manner compared to previous human studies (Hayashi, 
Ohta et al. 1994, Laderman, Penny et al. 1996, Isobe, Ito et al. 1998) and shown for the first time 
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that age-dependent alterations of human mtDNA determines reduced COX activity during aging, 
which is consistent with various correlative studies in animal and bio-specimens. Further our 
data suggest that decreased COX activity may be responsible for reduced mitochondrial oxygen 
consumption observed in the cybrids generated from aged donors.  
In our model of aging using cybrids, we did not observe age-dependent alteration of energy 
(ATP levels, ADP/ATP), redox states (NAD
+
/NADH), glycolysis and decrease in Complex I 
activity, as observed in some other aging studies. In our model, cybrids were created with a 
common nuclear background of the SH-SY5Y ρ0 cells and the only variable factor was the 
platelet-mitochondria that were obtained from different aged subjects. This suggests the 
possibility of predominant control of the nuclear genome over these bioenergetic parameters, 
which failed to alter in an age-dependent manner. Other studies indicating regulation of 
mitochondrial dysfunction by nuclear genome during aging support such a possibility (Hayashi, 
Ohta et al. 1994, Isobe, Ito et al. 1998). Paradoxically, we observed an increase in Complex I 
activity in the cybrids generated from aged donors, suggesting a compensatory response to 
decreased mitochondrial OCR and COX activity. This may be another reason why some of the 
bioenergetic parameters remained unaltered. Overall, induction of mRNA levels of nuclear-
encoded genes that promote mitochondrial biogenesis (PRC, NRF1, NRF2 and TFAM) and some 
of the mtDNA-encoded OXPHOS genes (MT-ND1 and MT-ND5), further support a potential 
compensatory phenomenon in the cybrids created by transfer of platelets from aged human 
donors. 
Similar to Laderman et.al (Laderman, Penny et al. 1996), we have found that age-dependent 
changes in mtDNA do not have an effect on mtDNA copy number, suggesting possibility of 
nuclear dominance over controlling mtDNA copy number during aging. However,  it needs to be 
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mentioned that inconsistency exists with regards to age-dependency of the mtDNA copy number 
in the literature; while some reports suggested that there is no alteration in mtDNA copy number 
(Laderman, Penny et al. 1996, Miller, Rosenfeldt et al. 2003, Frahm, Mohamed et al. 2005, 
Mohamed, Hanke et al. 2006), others reported it to be  decreased (Welle, Bhatt et al. 2003, Short, 
Bigelow et al. 2005, Cree, Patel et al. 2008) or even increased (Lee, Pang et al. 1994, Barrientos, 
Casademont et al. 1997, Pesce, Cormio et al. 2001) upon aging. Considering that mtDNA copy 
number is a tissue-specific characteristic, even reports about mtDNA copy number from a single 
tissue such as skeletal muscle are inconsistent. Few studies have reported mtDNA copy number 
in the aging muscle to be unaltered (Miller, Rosenfeldt et al. 2003, Frahm, Mohamed et al. 2005)  
whereas others concluded an increase (Barrientos, Casademont et al. 1997, Pesce, Cormio et al. 
2001) or decrease (Welle, Bhatt et al. 2003, Short, Bigelow et al. 2005) in mtDNA copy number. 
Irrespective of these inconsistencies, our studies indicate that age-dependent changes in mtDNA 
are not a determining factor for controlling mtDNA copy number.  
DNA methylation can regulate gene-expression and also known to change in an age-dependent 
manner (Terry, Delgado-Cruzata et al. 2011, Jin, Jiang et al. 2014, Reynolds, Taylor et al. 2014, 
Bacalini, Boattini et al. 2015, Jung and Pfeifer 2015, Yuan, Jiao et al. 2015, Zampieri, Ciccarone 
et al. 2015). As significant alteration in mRNA levels of nuclear-encoded genes that promote 
mitochondrial biogenesis and some of the mtDNA-encoded genes were observed, we explored 
total DNA methylation and mtDNA methylation in the cybrids created from young and aged 
donors. We did not find a significant difference in total DNA methylation in our cybrid model; 
suggesting that age-dependent changes in mtDNA does not have a role in global DNA 
methylation. However, this does not negate the possibility of gene-specific changes in 
methylation in the nuclear genome that might occur during age-associated mitochondrial 
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dysfunction and that they can be regulated by mtDNA alterations, which have not been pursued 
in this study. Limited data is available regarding mtDNA methylation or its alteration during 
aging. Our study, for the first time reported that total levels of DNMT1 protein, relative mRNA 
levels of mitochondrial isoform of DNMT1 and percentage methylation in the mtDNA were 
significantly elevated in the cybrids created from aged donors. As HPLC-ESI-MS/MS assay used 
in our study cannot differentiate nucleosides obtained from mtDNA or nuclear DNA and even 
though the mtDNA has been extracted from isolated mitochondria, chances of nuclear DNA 
contamination cannot be excluded completely. However, we have observed that the mtDNA 
prepared in this manner is enriched by 50 fold for mtDNA with respect to total DNA and 99.71 
% of the nuclear DNA is eliminated. Moreover, our data indicated that the total DNA 
methylation did not change (or trended to be decreased) whereas the mtDNA methylation was 
increased in cybrids from aged donors, suggesting that confounding presence of  nuclear DNA 
contamination would not affect interpretation of our results that mtDNA methylation is increased 
in cybrids from aged donors. Our results suggest the possibility that age-dependent alterations in 
mtDNA may play a role in determining DNA methylation-associated parameters. An alternative 
explanation could be that the age-dependent differences in mtDNA methylation existed in the 
source mtDNA itself (i.e. the platelet-mtDNA), even before the cybrids were made. However, 
irrespective of both the scenarios, concomitant age-dependent variation in expression levels of 
genes that promote mitochondrial biogenesis, DNMT1 protein and mtDNA methylation 
illustrates the possibility that mtDNA methylation, DNMT1 and cellular-bioenergetics could be 
related in an age-dependent manner, but the mechanism behind remains unclear and needs to be 




In conclusion, using cybrid cell lines created through transfer of platelet-mitochondria from 
young and aged human subjects, we demonstrated that age-dependent changes in mtDNA have a 
direct role in determining bioenergetic flux, electron transport chain function and expression of 
genes that control mitochondrial biogenesis. Further, we found that mtDNA methylation is 
altered in age-dependent manner in cybrid model. Furthermore, our study indicates that age-
dependent alterations in mtDNA may not be the sole determinant of mitochondrial dysfunction 
observed during aging, but simultaneous effects of dysregulation via nuclear genome may have a 


















Figure 1. Schematic representation of preparation of human cybrids: (A) Platelets isolated 
from blood of 9 young donors (mean age=29.1 ± 0.9 years) and 7 aged donors (mean age=75.1 ± 
3.01 years) were fused with mtDNA depleted SH-SY5Y ρ
0
 cells by Poly-Ethylene-Glycol 
(PEG). After a week of expansion, mtDNA-less cells were removed by culturing them in 
selection medium for 6 weeks thus resulting in 9 and 7 cybrid lines generated from young and 
aged human donors respectively, that have a common nuclear background but different 
mitochondrial DNA. (B) Tabular representation of the sex and age for the young and aged 









Figure 2. Oxygen Consumption Rate (OCR) and Extra-Cellular Acidification Rate (ECAR) 
parameters in the cybrids created from young and aged donors: (A) Total OCR, (B) Basal- 
Mitochondrial OCR, (C) Non-Mitochondrial OCR, (D) Glycolysis rate, (E) Glycolysis capacity 
and (F) Glycolysis reserve were determined for each cybrid line, compared between the two 
groups and then shown. * indicates a significant difference between groups at p<0.05; ** 







For legend, see next page 
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Figure 3. Cytochrome c oxidase (COX) assay and Complex I assay in the cybrids created 
from young and aged donors: For COX assay, isolated mitochondria and whole-cell were used 
to determine the rate constant (Vmax) spectrophotometrically by following the conversion of 
reduced cytochrome c to oxidized cytochrome c. Each cybrid line’s rate constant was normalized 
to the amount of protein in (A) the mitochondrial preparation or (B) lysed whole cell in its assay 
cuvette to provide a rate in sec
-1
/mg protein. Citrate synthase assay was performed for each 
cybrid line and was used to normalize the respective COX Vmax obtained in (B) and then 
compared in (C) Relative COX activity/Citrate synthase activity. For Complex I assay, the rate 
constant (Vmax) was spectrophotometrically determined by following the oxidation of NADH to 
NAD
+
. Each cybrids line’s rate was then normalized to the amount of protein in the 
mitochondrial preparation and divided by the extinction coefficient of the dye in both the groups 
to provide (D) Complex I activity.  The complex I activity was then further normalized by the 
citrate synthase to provide (E) Complex I activity/Citrate Synthase activity for both the group of 
cybrids. * indicates a significant difference between groups at p<0.05; ** indicates a significant 











Figure 4. Mitochondrial mass markers in the cybrids created from young and aged donors: 
MtDNA levels relative to the nuclear DNA (18S rRNA) was estimated for each cybrid line by 
using primers to amplify (A) 16S rRNA, (B) MT-ND2 and (C) MT-COX1 from total DNA in 
both the groups of cybrids. For Citrate synthase assay, linear formation of 5-mercapto-2-
nitrobenzoic acid is followed spectrophotometrically at 412 nm to provide the rate, whose 




.  The rate was then normalized for the amount of 














For legend, see next page 
154 
  
Figure 5. Energy and redox intermediates in the cybrids created from young and aged 
donors : (A) ATP levels (µM), (B) ADP/ATP ratio, (C) NAD
+
 levels (nM), (D) NADH levels 





For legend, see sext page 
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Figure 6. Transcriptional co-activators and transcription factors that promote 
mitochondrial biogenesis in the cybrids created from young and aged donors: Relative 
levels of PGC1α protein (A and B) and (C) mRNA are shown. Relative mRNA levels of (D) 
PGC1ß, (E) PRC, (F) NRF1, (G) NRF2 and (H) TFAM are shown. * indicates a significant 













Figure 7. Relative mRNA expression of OXPHOS genes in the cybrids created from young 
and aged donors: Relative mRNA levels of (A) MT-ND1, (B) MT-ND2, (C) MT-ND3, (D) 
MT-ND4, (E) MT-ND5, (F) MT-ND6, (G) MT-COX1, (H) MT-COX2, (I) MT-CytB and (J) 
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Figure 8.  Global DNA methylation, mtDNA methylation and DNMT1 expression in the 
cybrids created from young and aged donors : Global DNA methylation was estimated from 
the total DNA for each cybrid line in pmoles/µg DNA (A) and normalized by the amount of dC 
and the sum of dC and 5mdC in every cybrid line’s total DNA and represented as percentage in 
(B) and (C) respectively.  Mitochondrial DNA methylation was estimated in the mitochondrial 
DNA for each cybrid line in pmoles/µg mtDNA as represented in (D) and normalized by the 
amount of dC in (E) and also the sum of dC and 5mdC in (F) for every cybrid line’s 
mitochondrial DNA and represented as percentages. Relative mRNA levels of mtDNMT1 is 
compared and shown in (G). Relative levels of DNMT1 protein in whole cell lysates are shown 
in (H and I). * indicates a significant difference between groups at p<0.05; ** indicates a 
significant difference between groups at p<0.01; *** indicates a significant difference between 













































5.1 STATE OF THE FIELD AT THE ONSET OF THIS DISSERTATION WORK AND 
ITS PROGRESS 
MtDNA methylation has remained ignored for four decades until the recent resurgence in the 
field. When this dissertation work was proposed, mtDNA methylation was controversial with 
only eight studies that claimed it to be present (Vanyushin, Kiryanov et al. 1971, Nass 1973, 
Vanyushin and Kirnos 1977, Shmookler Reis and Goldstein 1983, Pollack, Kasir et al. 1984, 
Chestnut, Chang et al. 2011, Infantino, Castegna et al. 2011, Shock, Thakkar et al. 2011), 
whereas three other studies asserted its absence (Dawid 1974, Groot and Kroon 1979, Maekawa, 
Taniguchi et al. 2004). As most of these studies had used methods with poor sensitivity for 
detecting mtDNA methylation, reproducibility issues and possibilities of artifacts could not be 
refuted. After discovery of mitochondrial isoform of DNMT1 (mtDNMT1) in 2011 (Shock, 
Thakkar et al. 2011), there was resurgence in the field with several studies reporting presence of 
mtDNA methylation in different model systems (Dzitoyeva, Chen et al. 2012, Kelly, Mahmud et 
al. 2012, Bellizzi, D'Aquila et al. 2013, Byun, Panni et al. 2013, Jia, Li et al. 2013, Pirola, 
Gianotti et al. 2013, Wong, Gertz et al. 2013, Ghosh, Sengupta et al. 2014, Janssen, Byun et al. 
2014, Baccarelli and Byun 2015, Ferreira, Serafim et al. 2015, Janssen, Byun et al. 2015, Zheng, 
Linarelli et al. 2015)and a single study reported its absence (Hong, Okitsu et al. 2013). However, 
debate revolving presence of mtDNA methylation still has not ended, as concerns with regards to 
the limitations of utilized methods have been raised (van der Wijst and Rots 2015). Moreover, 
the likely prospects for presence of nuclear DNA contamination in the preparation of mtDNA 
have not been so far critically addressed and most of the studies have not used purified mtDNA 
for determining mtDNA methylation.  
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At the onset of this dissertation work, only two studies had reported changes in mtDNA 
methylation in pathological conditions using samples from patients inflicted with Down’s 
syndrome and ALS (Chestnut, Chang et al. 2011, Infantino, Castegna et al. 2011). With the 
renewed interest in the field after discovery of mtDNMT1, multiple other studies reported 
changes in mtDNA methylation in bio-specimens obtained from several physiological states and 
pathophysiological conditions (Dzitoyeva, Chen et al. 2012, Feng, Xiong et al. 2012, Kelly, 
Mahmud et al. 2012, Byun, Panni et al. 2013, Jia, Li et al. 2013, Pirola, Gianotti et al. 2013, 
Wong, Gertz et al. 2013, Ghosh, Sengupta et al. 2014, Janssen, Byun et al. 2014, Baccarelli and 
Byun 2015, Ferreira, Serafim et al. 2015, Janssen, Byun et al. 2015, Zheng, Linarelli et al. 2015). 
A few of these studies have also reported concomitant changes in expression levels of some of 
the mtDNA-encoded genes (Shock, Thakkar et al. 2011, Feng, Xiong et al. 2012, Pirola, Gianotti 
et al. 2013). However, any role of mtDNA methylation in controlling gene expression of 
mtDNA-encoded genes and mitochondrial function still remains completely unexplored. Further, 
how mtDNA gets methylated and whether DNMTs can methylate mtDNA is not yet known. 
Besides, the field of mtDNA methylation is still at such an incipient state that it has not yet been 
tested whether mtDNA methylation can be altered experimentally in the first place and whether 
any such alterations in mtDNA methylation have an association with expression of mtDNA-
encoded genes and mitochondrial function. 
Nuclear genome is known to undergo global hypo-methylation and gene-specific hyper-
methylation during aging (Terry, Delgado-Cruzata et al. 2011, Jin, Jiang et al. 2014, Reynolds, 
Taylor et al. 2014, Bacalini, Boattini et al. 2015, Jung and Pfeifer 2015, Yuan, Jiao et al. 2015, 
Zampieri, Ciccarone et al. 2015). Unlike nuclear DNA, whether mtDNA methylation is altered 
upon aging is not known. Mitochondrial dysfunction is known to occur during aging (Boffoli, 
164 
  
Scacco et al. 1994, Fujita, Yamauchi et al. 1996, Ojaimi, Masters et al. 1999, Short, Bigelow et 
al. 2005) and positive correlations have been drawn between alterations in mtDNA and the 
mitochondrial dysfunction that occurs during aging (Vermulst, Wanagat et al. 2008)  . However, 
very few studies have investigated the direct role of aging-associated alterations of mtDNA in 
causing mitochondrial dysfunction and have arrived at contradictory conclusions (Hayashi, Ohta 
et al. 1994, Laderman, Penny et al. 1996, Isobe, Ito et al. 1998). Thus, a direct role of mtDNA in 
aging-associated mitochondrial dysfunction is not yet established and neither it is clear if 
mtDNA methylation is altered during aging.                        
5.2 SUMMARY OF FINDINGS 
5.2.1 SUMMARY OF FINDINGS: CHAPTER II – DETECTION OF METHYLATION IN 
MITOCHONDRIAL DNA USING HPLC-MS/MS IN SH-SY5Y NEUROBLASTOMA 
CELL LINE 
To quantitate global levels of 5-mC in SH-SY5Y mtDNA accurately, a highly specific and direct 
assay was established using HPLC-ESI-MS/MS. It is known that differential or incomplete DNA 
digestion is the pitfall for quantifying 5-mC using HPLC-ESI-MS/MS that can lead to inaccurate 
quantification of 5-mC (van der Wijst and Rots 2015). This limitation was not addressed by the 
single study that has studied mtDNA methylation using HPLC-MS/MS (Infantino, Castegna et 
al. 2011). In our study, a single-step method for digesting mtDNA was used to minimize 
variabilities in digestion. Also, a novel approach of utilizing oligonucleotides containing known 
amounts of 5-mC and cytosine as reference standards was adopted for quantification of 5mC to 
account for differential digestion. Another limitation for studying mtDNA methylation is the 
chances of nuclear DNA contamination, which was addressed by determining 5-mC in gradient 
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purified SH-SY5Y mitochondria. Additionally, the purity of our mtDNA preparations was 
characterized at both protein and DNA levels. 
Initial mass-spectrophotometric characterization of the nucleosides using mixture of analytical 
standards was carried out where each nucleoside resolved distinctly and was detected in a linear 
manner. Further, linear and proportional detection of all nucleosides in the digestion products of 
our reference standards (oligonucleotides containing known amounts of 5-mC and Cytosine) was 
observed. No 5-mC was detected in the digestion mixture of oligonucleotides that did not contain 
the nucleoside 5-mC, thus indicating that our assay is specifically detecting 5-mC.  
Next, the range of linear and proportional digestion for SH-SY5Y mtDNA was established. 5-
mC levels were quantitated and compared between whole-cell DNA, crude and gradient-purified 
mtDNA and were found to be comparable (~3% methylation) in all these preparations, which is 
consistent with the literature. Further, purity characterization at DNA level suggested that more 
than 99% of nuclear DNA contamination was removed in mtDNA prepared from both crude and 
gradient-purified mitochondria. Further, linear regression analysis between estimated percentage 
of mtDNA in various mitochondrial preparations and the corresponding percentage methylation 
revealed that mtDNA methylation occurs at levels at least as much as that of the nucleus. 






5.2.2 SUMMARY OF FINDINGS: CHAPTER III – ALTERATIONS IN MTDNA 
METHYLATION BY DNMT1 OVEREXPRESSION AND 5-AZA-DC TREATMENT 
AND ITS ASSOCIATION WITH MITOCHONDRIAL TRANSCRIPTION AND 
MITOCHONDRIAL FUNCTION IN SH-SY5Y NEUROBLASTOMA CELL LINE 
To investigate whether mtDNA methylation can be altered and if there are any associated 
changes in mtDNA-encoded gene expression and mitochondrial function, two distinct 
experimental approaches were utilized. DNMT1 was overexpressed in SH-SY5Y cells or cells 
were treated with DNA methylation inhibitor (Decitabine (5-aza-dC)). DNMT1 is previously 
known to localize in mitochondria (Chestnut, Chang et al. 2011, Shock, Thakkar et al. 2011, 
Bellizzi, D'Aquila et al. 2013) but whether it can cause mtDNA methylation is not yet known. 
Further, whether DNA methylation inhibitor can alter mtDNA methylation was not explored 
previously. Overexpression of DNMT1 increased global mtDNA methylation by 2.5 fold 
whereas 5-aza-dC treatment decreased it by half in SH-SY5Y mtDNA as studied using HPLC-
ESI-MS/MS. Similar results were obtained when methylation-specific PCR was used to study 
mtDNA methylation at a specific site in 12S rRNA. Thus, our data suggested that mtDNA 
methylation is an alterable phenomenon which can be affected by DNMT1 levels and DNA 
methylation inhibitor treatment. As we found that overexpression of DNMT1 resulted in increase 
in mtDNA methylation, DNMT1 might have a role in methylating mtDNA.  
Nuclear DNA methylation controls gene expression but very few studies have correlated 
mtDNA-encoded gene expression levels with changes in mtDNA methylation (Shock, Thakkar 
et al. 2011, Feng, Xiong et al. 2012, Pirola, Gianotti et al. 2013). As mtDNA methylation was 
found to be altered by both our experimental approaches, we determined if there were any 
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associated changes in mtDNA gene expression. Overexpression of DNMT1 led to an overall 
decrease in transcription of mtDNA-encoded genes, whereas 5-aza-dC increased the expression 
of most of the mtDNA-encoded genes.  Although alteration in mtDNA methylation inversely 
corresponded with expression of mtDNA-encoded genes, mitochondrial oxygen consumption 
rate were found to be decreased significantly after both the experimental interventions. 
5.2.3 SUMMARY OF FINDINGS: CHAPTER IV – AGING-ASSOCIATED 
BIOENERGETICS, ITS REGULATORS AND DNA METHYLATION IN A 
CYTOPLASMIC HYBRID MODEL CREATED FROM PLATELETS OF YOUNG AND 
OLD HUMAN SUBJECTS 
To investigate the direct role of mtDNA in aging-associated mitochondrial dysfunction, cybrids 
were created from platelets of healthy young and elderly donors; various bio-energetic 
parameters, factors that control mitochondrial biogenesis and multiple aspects of DNA 
methylation were studied.  
As the nuclear background was kept constant, the only difference across each cybrid was the 
source of mtDNA in the cybrid model. Our data suggests that mtDNA has a direct role in some 
of the aging-associated parameters of mitochondrial dysfunction as we found significant 
reduction in total oxygen consumption rate, basal mitochondrial oxygen consumption rate and 
complex IV activity (in the isolated mitochondria and whole-cell preparations) in the cybrids 
generated from elderly donors compared to young donors. 
However, no alteration in certain age-dependent bio-energetic parameters such as energy levels 
(ATP, ADP: ATP ratio) and redox states (levels of NAD
+
 and NADH, NAD
+
: NADH ratio) were 
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found. Paradoxically, we found that complex I activity was significantly elevated in cybrids that 
were generated from elderly donors. These results suggest the possibility of predominant control 
by nuclear genome over these bioenergetic parameters, which failed to alter in an age-dependent 
manner in our model.  
Additionally, we found significantly higher mRNA levels of the transcriptional coactivator PRC, 
transcription factors   - NRF1, NRF2 and TFAM (which are known to promote mitochondrial 
biogenesis) and mtDNA genes coding for Complex I – MTND1 and MTND5 in the cybrids 
created from aged donors. These results suggest the possibility of nuclear genome- driven 
compensatory mechanisms in the cybrids created from aged donors, which is further supported 
by paradoxical increase in complex I activity in cybrids generated from elderly donors.  
As we found differences in gene expression levels of both nuclear and mtDNA-encoded genes, 
multiple aspects of DNA methylation were studied. Although no alteration was found in total 
DNA methylation, significant increase in mtDNA methylation, mtDNMT1 mRNA levels and 
DNMT1 protein levels were found in the cybrids made from elderly donors. These results 
suggest that mtDNA methylation, mtDNMT1 and cellular bioenergetics could be related in an 
age-dependent manner supporting the rationale to explore the field of mitochondrial-epigenetics.  
5.3 STRENGTHS, LIMITATIONS AND FUTURE DIRECTIONS  
5.3.1. STUDYING GLOBAL LEVELS OF MTDNA METHYLATION 
For approaches that have currently been used for studying global methylation in mtDNA, the 
presence of nuclear DNA contamination in preparations of mtDNA has not been critically 
addressed yet. Most of these studies have not characterized purity comprehensively or 
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considered isolating pure mitochondria (van der Wijst and Rots 2015). We have addressed these 
issues by isolating gradient purified-mtDNA and then characterizing purity of our mtDNA 
preparations using qPCR-based methods. Although we found only 0.88% of nuclear DNA 
remaining in gradient purified mitochondria w.r.t. whole cell DNA, this can be substantial 
relative to the amount of mtDNA as mitochondrial DNA comprises only a small fraction (less 
than 1%) of total cellular DNA (because of its very small size, in spite of being present in 
numerous copies). The estimated percentages of mtDNA were found to be 0.6%, 21% and 41% 
for whole-cell DNA, crude mtDNA and gradient-purified mtDNA, respectively after accounting 
for difference in size of nuclear genome compared to mitochondrial genome and also accounting 
for the mitochondrial DNA copy number. Thus, the fraction of nuclear DNA contamination was 
estimated to be substantial relative to the mtDNA present in purified mitochondrial preparations 
and caution must be placed while interpreting our results. However, regression analysis between 
percentage of mtDNA present in a DNA sample (with increasing levels of mtDNA in DNA 
extracted from crude and gradient-purified mitochondria w.r.t. whole-cell DNA) and the 
corresponding percentage methylation, suggested that mtDNA methylation does contribute 
significantly to overall methylation and mtDNA methylation occurs at least  at levels  similar to 
methylation for nuclear DNA. Further in our cybrid studies, where we found a significant 
increase solely in the DNA methylation from mitochondrial preparations but not from whole cell 
upon aging, also suggest the presence of mtDNA methylation at significant levels which was not 
masked by the extent of nuclear DNA contamination. Although our results suggested significant 
presence of mtDNA methylation at global levels, additional studies will need to be conducted in 
future to achieve more purified mtDNA in order to substantiate our finding.  
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Lack of methods to isolate completely pure mitochondrial DNA is a bottleneck in the field of 
mitochondrial DNA methylation (van der Wijst and Rots 2015). A recent study (Jayaprakash, 
Benson et al. 2015) established a method to isolate mtDNA from whole-cell DNA using 
repetitive treatments with Exonuclease V to achieve 98% pure mtDNA. As Exonuclease V 
selectively degrades single stranded DNA in ATP-dependent manner, the rationale was to 
eliminate single stranded DNA fragments most likely derived from the nuclear genome, while 
keeping the circular mtDNA intact. Along similar lines, we attempted purifying mtDNA using 
repetitive treatments with Exonuclease V followed by column purification. In order to achieve 
higher purity, we used DNA extracted from isolated mitochondria for Exonuclease V-treatment, 
instead of just using whole cell DNA, as used in the above mentioned study. Our preliminary 
data (n =1) suggested unprecedented enrichment of about 1300 fold for mtDNA (compared to 
115 fold enrichment in gradient purified mtDNA) using this combinatorial approach of 
mitochondrial isolation and Exonuclease V treatment. It should be mentioned that crude 
mitochondrial isolation technique was utilized for this study; thus, we speculate that using 
gradient purification of mitochondria along with Exonuclease V treatment can further improve 
the purity of mtDNA preparation. Further studies will need to be conducted in the future in order 
to examine the reproducibility of this approach followed by analysis of methylation level both at 
global levels using our established HPLC-MS assay and at specific site using methylation-
specific PCR assays. 
Further, for our purity characterization using qPCR-based methods, an underlying assumption 
was that the analysis of tested nuclear and mtDNA-encoded genes (which is miniscule in size 
compared to whole genome) is representative of overall genomic contamination, which needs to 
be considered for interpretation of our results. In future, deep-next generation sequencing of 
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mtDNA-samples needs to be performed to determine the absolute levels of nuclear and 
mitochondrial DNA present at whole genomic level, for a more accurate analysis.  
5.3.2 STUDYING SITE-SPECIFIC LEVELS OF MTDNA METHYLATION 
Apart from studying mtDNA methylation at global levels using HPLC MS/MS, the presence of 
methylation in SH-SY5Y mtDNA was further substantiated using methylation-specific PCR for 
a specific site in 12S rRNA. We found similar trends of alterations in methylation using both the 
experimental approaches (oDNMT1 and 5-aza-dC treatment) at both global levels as well as site-
specific levels supporting our interpretations. Although, in our study we have used long PCR of 
mtDNA (an un-methylated amplicon of mtDNA) as negative control, the possibility of obtaining 
methylation from insertions of mitochondrial DNA in the nuclear genome (NUMT) needs to be 
ruled out. One of the ways to address this is by utilization of ρ0 cell lines that lack functional 
mtDNA, as a negative control in addition to un-methylated amplicon of mtDNA. In a 
preliminary study, our methylation-specific primers amplified a product from SH-SY5Y ρ0 cell 
line raising potential concern about the specificity of primers for mitochondrial genome. 
However, this analysis requires further confirmatory studies  as amplification was also observed 
from un-methylated amplicon of mtDNA in this study (which was not observed in any of our 
previous studies) raising concern about possible reagent contamination  that needs to be resolved 
and carefully examined in future. Further, this analysis can also be confounded by the fact that, 
although ρ0 cell lines cannot form a functional respiratory chain, but they might have fragments 
of mtDNA from damaged mtDNA. Alternatively, to address specificity of methylation-specific 
primers, BLAST analysis was performed which revealed 100% match of primers only to the 
mitochondrial sequence. However, two nuclear hits in chromosome 11 and 17 were also 
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identified, but with less than 85% match and mismatches being in the reverse primer sequence 
suggesting less likely amplification from these sites. Further, it should be noted that the site-
specific analysis was conducted using isolated mitochondria where majority of nuclear DNA 
contamination is eliminated. In contrast to analysis of nuclear contamination at global levels for 
mtDNA methylation, where small residual nuclear DNA can be substantial compared to mtDNA 
due to difference in the size of two genomes; for site-specific analysis using methylation specific 
primer, only two potential sites of NUMT exist for studied region, while copy number of 
mitochondrial 12S rRNA is much higher (in thousands). Although all these data suggests higher 
possibility of the amplification being obtained from SH-SY5Y mtDNA instead of the nuclear 
pseudogenes, further confirmatory studies should be conducted by sequencing the products after 
methylation specific PCR and then comparing the sequence to mitochondrial genome and 
potential pseudogene sites and also by following up studies conducted using SH-SY5Y ρ0 cell 
line.  
In all the research work for this dissertation, we have determined global levels of mtDNA 
methylation using HPLC-ESI-MS/MS and mtDNA methylation at a particular site in 12S rRNA 
using methylation-specific PCR assay. Hence, we are not aware of the status of modified 
cytosines at other specific sites in the mtDNA genome, which can be addressed by bisulfite- next 
generation sequencing. One of the future experiments will be to determine the specific sites 
where mtDNA modifications have occurred after both the experimental interventions (i.e. 
DNMT1 overexpression and 5-aza-dC treatment) and in the cybrid model using bisulfite-next 
generation sequencing and methylation-specific PCR for other regions in mtDNA. This will 
provide us an in-depth view of the altered sites of methylation in mtDNA. One of the limitations 
of bisulfite-based methods that are used to study site-specific mtDNA methylation is that the 
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modified cytosines such as 5mC and 5hmC cannot be distinguished. Single molecule Real Time 
(SMRT) sequencing can also be used for future investigations to resolve this issue. SMRT 
sequencing can distinguish between modified cytosines due a difference in the time of 
incorporation of cytosine during synthesis for sequencing (Davis, Chao et al. 2013, Chavez, 
Huang et al. 2014, Yu, Ji et al. 2015). 
5.3.3 MECHANISM AND FUNCTIONAL RELEVANCE OF MTDNA METHYLATION 
In chapter III, a limitation of our experimental approach is that the overexpression of DNMT1 
and 5-aza-dC treatment could have affected the methylation levels in both the nuclear as well as 
the mitochondrial genome. As mitochondrial transcription is also regulated by nuclear-encoded 
genes, thus, the effects observed on mtDNA transcription by overexpression of DNMT1 and 5-
aza-dC treatment can be indirect consequence of alteration in nuclear DNA methylation and 
transcription. Interestingly, the mRNA levels of TFAM were not altered by both the 
experimental approaches and TFAM being the major nuclear-encoded regulator of mitochondrial 
transcription suggests that there is a possibility that it’s the differences in mtDNA methylation 
which are responsible for changes in transcription of mtDNA-encoded genes. However, the 
causal role of altered mtDNA methylation exclusively in affecting mitochondrial transcription 
cannot be confirmed definitively and needs to be addressed in future. Nonetheless, how mtDNA 
methylation can be selectively altered is not yet known, which has also hindered the field from 
pursuing mechanistic studies on mtDNA methylation. Irrespective of this limitation, ours is the 
first study to demonstrate that mtDNA methylation can be altered experimentally, which was 
previously not known. Further, we are the first to demonstrate that changing DNMT1 levels 
alters mtDNA methylation. Furthermore, previous studies only observed changes in mtDNA 
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methylation in bio-specimens from various pathological conditions and a few of these studies 
concomitantly observed changes in transcription of some of the mtDNA-encoded genes (Shock, 
Thakkar et al. 2011, Feng, Xiong et al. 2012, Pirola, Gianotti et al. 2013). The arena of 
functional significance of mtDNA methylation in the context of regulating mitochondrial 
transcription and function was completely unexplored. Our study provided the first significant 
experimental evidence in the direction that alteration of mtDNA methylation can associate with 
mitochondrial transcription and function. This will provide a platform for future studies in this 
direction to get more valuable insights on the functional relevance of mtDNA methylation.   
Although our work provided novel insights on several aspects of mtDNA methylation, our 
studies did not investigate mechanisms how mtDNA methylation can be affecting mitochondrial 
transcription and function. Future studies focused on site-specific methylation in mtDNA and 
studies investigating effects of alteration of mtDNA methylation at specific sites on binding of 
different proteins (that comprise the transcription machinery - TFAM, POLRMT and TFB2M) to 
mtDNA, especially in the D-loop region, will allow us to investigate how these sites of mtDNA 
methylation are linked to altered mitochondrial transcription. What determines synthesis of 
mitochondrial isoform of DNMT1 along with triggering its translocation to mitochondria needs 
to be studied. A histone-like role of TFAM is emerging, and few studies also reported that post-
translational modifications of TFAM can affect compaction or loosening of mtDNA and 
ultimately affecting transcription of mtDNA-encoded genes. Thus, an intriguing possibility is 
that mtDNA methylation may be regulating post-translational modifications of TFAM and thus 
affecting transcription by mtDNA methylation, which will be studied in future. All of these 
experiments might provide some mechanistic insight into how the transcription of mtDNA gets 
altered after experimental manipulations used in this study.  
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In chapter IV, we have found an age-dependent alteration in mtDNA methylation in the cybrid 
model. However, further studies are required to delineate role of mtDNA methylation as a cause 
or an effect in age-associated mitochondrial dysfunction.   Further, experiments need to be 
carried out in order to reverse the age-dependent alteration in mtDNA methylation in the cybrid 
model, and investigate if this reversal in mtDNA methylation altered mitochondrial function. But 
direct role of mtDNA methylation in aging-associated mitochondrial dysfunction will be difficult 
to establish, considering that how to exclusively alter mtDNA methylation is still not known. 
5.4 CONCLUSION 
The purpose of this dissertation was to establish a method to quantitate mtDNA methylation 
globally and evaluate the presence of mtDNA methylation in SH-SY5Y neuroblastoma cells; 
further, to examine whether mtDNA methylation can be altered experimentally and also if there 
are any associated changes in mitochondrial transcription and function; and finally, to investigate 
if mtDNA plays a role in mitochondrial dysfunction during aging using cybrid model and if 
mtDNA methylation is also altered in this model. 
We have established a direct method to quantify global methylation in mtDNA using HPLC-ESI-
MS/MS along with addressing issues of variable DNA digestion and the possible chances of 
nuclear DNA contamination. Also, we have found that global mtDNA methylation occurs at a 
level of 3% in SH-SY5Y gradient-purified mtDNA. Existence of mtDNA methylation was also 
confirmed by studying methylation at a particular site (12S rRNA) in mtDNA. Further, we found 
that mtDNA methylation is an alterable phenomenon, which can be influenced by levels of 
DNMT1 and treatment with DNA methylation inhibitor (5-aza-dC). Overexpression of DNMT1 
increased whereas 5-aza-dC treatment decreased mtDNA methylation, with concomitant inverse 
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changes in mtDNA transcription. Our data suggests that alterations in mtDNA methylation are 
associated with changes in expression of mtDNA-encoded genes and mitochondrial function. 
Finally, using cybrid model created from platelets of young and aged donors, we established a 
direct role of mtDNA in aging-associated mitochondrial dysfunction and found mtDNA 
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